id	sid	tid	token	lemma	pos
dpc-2912	1	1	dermatology	dermatology	NOUN
dpc-2912	1	2	:	:	PUNCT
dpc-2912	1	3	practical	practical	ADJ
dpc-2912	1	4	and	and	CCONJ
dpc-2912	1	5	conceptual	conceptual	ADJ
dpc-2912	1	6	original	original	ADJ
dpc-2912	1	7	article	article	NOUN
dpc-2912	1	8	|	|	ADV
dpc-2912	1	9	dermatol	dermatol	ADJ
dpc-2912	1	10	pract	pract	NOUN
dpc-2912	1	11	concept	concept	NOUN
dpc-2912	1	12	.	.	PUNCT
dpc-2912	2	1	2023;13(3):e2023145	2023;13(3):e2023145	NUM
dpc-2912	2	2	1	1	NUM
dpc-2912	2	3	long	long	ADJ
dpc-2912	2	4	-	-	PUNCT
dpc-2912	2	5	term	term	NOUN
dpc-2912	2	6	omalizumab	omalizumab	NOUN
dpc-2912	2	7	therapy	therapy	NOUN
dpc-2912	2	8	in	in	ADP
dpc-2912	2	9	patients	patient	NOUN
dpc-2912	2	10	with	with	ADP
dpc-2912	2	11	chronic	chronic	ADJ
dpc-2912	2	12	spontaneous	spontaneous	ADJ
dpc-2912	2	13	urticaria	urticaria	NOUN
dpc-2912	2	14	:	:	PUNCT
dpc-2912	2	15	does	do	AUX
dpc-2912	2	16	it	it	PRON
dpc-2912	2	17	increase	increase	VERB
dpc-2912	2	18	the	the	DET
dpc-2912	2	19	 	 	SPACE
dpc-2912	2	20	risk	risk	NOUN
dpc-2912	2	21	of	of	ADP
dpc-2912	2	22	covid-19	covid-19	PROPN
dpc-2912	2	23	?	?	PUNCT
dpc-2912	3	1	özge	özge	PROPN
dpc-2912	3	2	kaya1	kaya1	PROPN
dpc-2912	3	3	,	,	PUNCT
dpc-2912	3	4	zeynep	zeynep	NOUN
dpc-2912	3	5	keskinkaya1	keskinkaya1	PROPN
dpc-2912	3	6	,	,	PUNCT
dpc-2912	3	7	selda	selda	ADJ
dpc-2912	3	8	işık	işık	NOUN
dpc-2912	3	9	mermutlu1	mermutlu1	NOUN
dpc-2912	3	10	,	,	PUNCT
dpc-2912	3	11	sevilay	sevilay	VERB
dpc-2912	3	12	oğuz	oğuz	PROPN
dpc-2912	3	13	kılıç1	kılıç1	PROPN
dpc-2912	3	14	,	,	PUNCT
dpc-2912	3	15	sevgi	sevgi	PROPN
dpc-2912	3	16	öztürk1	öztürk1	PROPN
dpc-2912	3	17	1	1	NUM
dpc-2912	3	18	department	department	NOUN
dpc-2912	3	19	of	of	ADP
dpc-2912	3	20	dermatology	dermatology	NOUN
dpc-2912	3	21	and	and	CCONJ
dpc-2912	3	22	venereology	venereology	NOUN
dpc-2912	3	23	,	,	PUNCT
dpc-2912	3	24	çanakkale	çanakkale	NOUN
dpc-2912	3	25	onsekiz	onsekiz	PROPN
dpc-2912	3	26	mart	mart	PROPN
dpc-2912	3	27	university	university	PROPN
dpc-2912	3	28	faculty	faculty	NOUN
dpc-2912	3	29	of	of	ADP
dpc-2912	3	30	medicine	medicine	NOUN
dpc-2912	3	31	,	,	PUNCT
dpc-2912	3	32	çanakkale	çanakkale	NOUN
dpc-2912	3	33	,	,	PUNCT
dpc-2912	3	34	turkey	turkey	NOUN
dpc-2912	3	35	key	key	ADJ
dpc-2912	3	36	words	word	NOUN
dpc-2912	3	37	:	:	PUNCT
dpc-2912	3	38	angiotensin	angiotensin	NOUN
dpc-2912	3	39	-	-	PUNCT
dpc-2912	3	40	converting	convert	VERB
dpc-2912	3	41	enzyme	enzyme	NOUN
dpc-2912	3	42	2	2	NUM
dpc-2912	3	43	,	,	PUNCT
dpc-2912	3	44	chronic	chronic	ADJ
dpc-2912	3	45	spontaneous	spontaneous	ADJ
dpc-2912	3	46	urticaria	urticaria	NOUN
dpc-2912	3	47	,	,	PUNCT
dpc-2912	3	48	covid-19	covid-19	PROPN
dpc-2912	3	49	,	,	PUNCT
dpc-2912	3	50	omalizumab	omalizumab	NOUN
dpc-2912	3	51	,	,	PUNCT
dpc-2912	3	52	activation	activation	NOUN
dpc-2912	3	53	citation	citation	NOUN
dpc-2912	3	54	:	:	PUNCT
dpc-2912	4	1	kaya	kaya	PROPN
dpc-2912	4	2	ö	ö	PROPN
dpc-2912	4	3	,	,	PUNCT
dpc-2912	4	4	keskinkaya	keskinkaya	PROPN
dpc-2912	4	5	z	z	PROPN
dpc-2912	4	6	,	,	PUNCT
dpc-2912	4	7	işık	işık	ADJ
dpc-2912	4	8	mermutlu	mermutlu	PROPN
dpc-2912	4	9	s	s	PART
dpc-2912	4	10	,	,	PUNCT
dpc-2912	4	11	oğuz	oğuz	PROPN
dpc-2912	4	12	kılıç	kılıç	PROPN
dpc-2912	4	13	s	s	PROPN
dpc-2912	4	14	,	,	PUNCT
dpc-2912	4	15	öztürk	öztürk	PROPN
dpc-2912	4	16	s.	s.	PROPN
dpc-2912	4	17	long	long	ADJ
dpc-2912	4	18	-	-	PUNCT
dpc-2912	4	19	term	term	NOUN
dpc-2912	4	20	omalizumab	omalizumab	NOUN
dpc-2912	4	21	therapy	therapy	NOUN
dpc-2912	4	22	in	in	ADP
dpc-2912	4	23	patients	patient	NOUN
dpc-2912	4	24	with	with	ADP
dpc-2912	4	25	chronic	chronic	ADJ
dpc-2912	4	26	spontaneous	spontaneous	ADJ
dpc-2912	4	27	urticaria	urticaria	NOUN
dpc-2912	4	28	:	:	PUNCT
dpc-2912	4	29	does	do	AUX
dpc-2912	4	30	it	it	PRON
dpc-2912	4	31	increase	increase	VERB
dpc-2912	4	32	the	the	DET
dpc-2912	4	33	risk	risk	NOUN
dpc-2912	4	34	of	of	ADP
dpc-2912	4	35	covid-19	covid-19	PROPN
dpc-2912	4	36	?	?	PUNCT
dpc-2912	4	37	.	.	PUNCT
dpc-2912	5	1	dermatol	dermatol	NOUN
dpc-2912	5	2	pract	pract	PROPN
dpc-2912	5	3	concept	concept	NOUN
dpc-2912	5	4	.	.	PUNCT
dpc-2912	6	1	2023;13(3):e2023145	2023;13(3):e2023145	NUM
dpc-2912	6	2	.	.	PUNCT
dpc-2912	7	1	doi	doi	NOUN
dpc-2912	7	2	:	:	PUNCT
dpc-2912	7	3	https://doi.org/10.5826/dpc.1303a145	https://doi.org/10.5826/dpc.1303a145	PROPN
dpc-2912	7	4	accepted	accept	VERB
dpc-2912	7	5	:	:	PUNCT
dpc-2912	7	6	december	december	PROPN
dpc-2912	7	7	2	2	NUM
dpc-2912	7	8	,	,	PUNCT
dpc-2912	7	9	2022	2022	NUM
dpc-2912	7	10	;	;	PUNCT
dpc-2912	7	11	published	publish	VERB
dpc-2912	7	12	:	:	PUNCT
dpc-2912	8	1	july	july	PROPN
dpc-2912	8	2	2023	2023	NUM
dpc-2912	8	3	copyright	copyright	NOUN
dpc-2912	8	4	:	:	PUNCT
dpc-2912	8	5	©	©	PROPN
dpc-2912	8	6	2023	2023	NUM
dpc-2912	8	7	kaya	kaya	PROPN
dpc-2912	8	8	et	et	PROPN
dpc-2912	8	9	al	al	PROPN
dpc-2912	8	10	.	.	PUNCT
dpc-2912	9	1	this	this	PRON
dpc-2912	9	2	is	be	AUX
dpc-2912	9	3	an	an	DET
dpc-2912	9	4	open	open	ADJ
dpc-2912	9	5	-	-	PUNCT
dpc-2912	9	6	access	access	NOUN
dpc-2912	9	7	article	article	NOUN
dpc-2912	9	8	distributed	distribute	VERB
dpc-2912	9	9	under	under	ADP
dpc-2912	9	10	the	the	DET
dpc-2912	9	11	terms	term	NOUN
dpc-2912	9	12	of	of	ADP
dpc-2912	9	13	the	the	DET
dpc-2912	9	14	creative	creative	ADJ
dpc-2912	9	15	commons	common	NOUN
dpc-2912	9	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-2912	9	17	license	license	NOUN
dpc-2912	9	18	(	(	PUNCT
dpc-2912	9	19	by	by	ADP
dpc-2912	9	20	-	-	PUNCT
dpc-2912	9	21	nc-4.0	nc-4.0	NOUN
dpc-2912	9	22	)	)	PUNCT
dpc-2912	9	23	,	,	PUNCT
dpc-2912	9	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2912	9	25	,	,	PUNCT
dpc-2912	9	26	which	which	PRON
dpc-2912	9	27	permits	permit	VERB
dpc-2912	9	28	unrestricted	unrestricted	ADJ
dpc-2912	9	29	noncommercial	noncommercial	ADJ
dpc-2912	9	30	use	use	NOUN
dpc-2912	9	31	,	,	PUNCT
dpc-2912	9	32	distribution	distribution	NOUN
dpc-2912	9	33	,	,	PUNCT
dpc-2912	9	34	and	and	CCONJ
dpc-2912	9	35	reproduction	reproduction	NOUN
dpc-2912	9	36	in	in	ADP
dpc-2912	9	37	any	any	DET
dpc-2912	9	38	medium	medium	NOUN
dpc-2912	9	39	,	,	PUNCT
dpc-2912	9	40	provided	provide	VERB
dpc-2912	9	41	the	the	DET
dpc-2912	9	42	original	original	ADJ
dpc-2912	9	43	authors	author	NOUN
dpc-2912	9	44	and	and	CCONJ
dpc-2912	9	45	source	source	NOUN
dpc-2912	9	46	are	be	AUX
dpc-2912	9	47	credited	credit	VERB
dpc-2912	9	48	.	.	PUNCT
dpc-2912	10	1	funding	funding	NOUN
dpc-2912	10	2	:	:	PUNCT
dpc-2912	10	3	none	none	NOUN
dpc-2912	10	4	.	.	PUNCT
dpc-2912	11	1	competing	compete	VERB
dpc-2912	11	2	interests	interest	NOUN
dpc-2912	11	3	:	:	PUNCT
dpc-2912	11	4	none	none	NOUN
dpc-2912	11	5	.	.	PUNCT
dpc-2912	12	1	authorship	authorship	NOUN
dpc-2912	12	2	:	:	PUNCT
dpc-2912	12	3	all	all	DET
dpc-2912	12	4	authors	author	NOUN
dpc-2912	12	5	have	have	AUX
dpc-2912	12	6	contributed	contribute	VERB
dpc-2912	12	7	significantly	significantly	ADV
dpc-2912	12	8	to	to	ADP
dpc-2912	12	9	this	this	DET
dpc-2912	12	10	publication	publication	NOUN
dpc-2912	12	11	.	.	PUNCT
dpc-2912	13	1	corresponding	correspond	VERB
dpc-2912	13	2	author	author	NOUN
dpc-2912	13	3	:	:	PUNCT
dpc-2912	13	4	özge	özge	PROPN
dpc-2912	13	5	kaya	kaya	PROPN
dpc-2912	13	6	,	,	PUNCT
dpc-2912	13	7	md	md	PROPN
dpc-2912	13	8	,	,	PUNCT
dpc-2912	13	9	çanakkale	çanakkale	VERB
dpc-2912	13	10	onsekiz	onsekiz	PROPN
dpc-2912	13	11	mart	mart	PROPN
dpc-2912	13	12	üniversitesi	üniversitesi	PROPN
dpc-2912	13	13	tıp	tıp	PROPN
dpc-2912	13	14	fakültesi	fakültesi	PROPN
dpc-2912	13	15	deri	deri	PROPN
dpc-2912	13	16	ve	ve	AUX
dpc-2912	13	17	zührevi	zührevi	ADJ
dpc-2912	13	18	hastalıklar	hastalıklar	ADJ
dpc-2912	13	19	anabilim	anabilim	NOUN
dpc-2912	13	20	dalı	dalı	NOUN
dpc-2912	13	21	,	,	PUNCT
dpc-2912	13	22	17110	17110	NUM
dpc-2912	13	23	,	,	PUNCT
dpc-2912	13	24	çanakkale	çanakkale	NOUN
dpc-2912	13	25	,	,	PUNCT
dpc-2912	13	26	türkiye	türkiye	PROPN
dpc-2912	13	27	tel	tel	PROPN
dpc-2912	13	28	:	:	PUNCT
dpc-2912	13	29	+0902862635950	+0902862635950	PROPN
dpc-2912	13	30	fax	fax	NOUN
dpc-2912	13	31	:	:	PUNCT
dpc-2912	13	32	+0902862635956	+0902862635956	NUM
dpc-2912	13	33	e	e	NOUN
dpc-2912	13	34	-	-	NOUN
dpc-2912	13	35	mail	mail	NOUN
dpc-2912	13	36	:	:	PUNCT
dpc-2912	13	37	ozgetrkz@hotmail.com	ozgetrkz@hotmail.com	X
dpc-2912	14	1	introduction	introduction	NOUN
dpc-2912	14	2	:	:	PUNCT
dpc-2912	14	3	based	base	VERB
dpc-2912	14	4	on	on	ADP
dpc-2912	14	5	the	the	DET
dpc-2912	14	6	existing	exist	VERB
dpc-2912	14	7	literature	literature	NOUN
dpc-2912	14	8	,	,	PUNCT
dpc-2912	14	9	omalizumab	omalizumab	NOUN
dpc-2912	14	10	(	(	PUNCT
dpc-2912	14	11	omz	omz	PROPN
dpc-2912	14	12	)	)	PUNCT
dpc-2912	14	13	is	be	AUX
dpc-2912	14	14	considered	consider	VERB
dpc-2912	14	15	a	a	DET
dpc-2912	14	16	safe	safe	ADJ
dpc-2912	14	17	treatment	treatment	NOUN
dpc-2912	14	18	modality	modality	NOUN
dpc-2912	14	19	in	in	ADP
dpc-2912	14	20	chronic	chronic	ADJ
dpc-2912	14	21	spontaneous	spontaneous	ADJ
dpc-2912	14	22	urticaria	urticaria	NOUN
dpc-2912	14	23	(	(	PUNCT
dpc-2912	14	24	csu	csu	PROPN
dpc-2912	14	25	)	)	PUNCT
dpc-2912	14	26	during	during	ADP
dpc-2912	14	27	the	the	DET
dpc-2912	14	28	coronavirus	coronavirus	NOUN
dpc-2912	14	29	disease	disease	NOUN
dpc-2912	14	30	19	19	NUM
dpc-2912	14	31	(	(	PUNCT
dpc-2912	14	32	covid-19	covid-19	PROPN
dpc-2912	14	33	)	)	PUNCT
dpc-2912	14	34	era	era	NOUN
dpc-2912	14	35	.	.	PUNCT
dpc-2912	15	1	objectives	objective	NOUN
dpc-2912	15	2	:	:	PUNCT
dpc-2912	15	3	  	  	SPACE
dpc-2912	15	4	the	the	DET
dpc-2912	15	5	aim	aim	NOUN
dpc-2912	15	6	of	of	ADP
dpc-2912	15	7	this	this	DET
dpc-2912	15	8	study	study	NOUN
dpc-2912	15	9	is	be	AUX
dpc-2912	15	10	to	to	PART
dpc-2912	15	11	evaluate	evaluate	VERB
dpc-2912	15	12	the	the	DET
dpc-2912	15	13	effects	effect	NOUN
dpc-2912	15	14	of	of	ADP
dpc-2912	15	15	omz	omz	NOUN
dpc-2912	15	16	on	on	ADP
dpc-2912	15	17	csu	csu	PROPN
dpc-2912	15	18	patients	patient	NOUN
dpc-2912	15	19	regarding	regard	VERB
dpc-2912	15	20	covid-19	covid-19	PROPN
dpc-2912	15	21	infection	infection	NOUN
dpc-2912	15	22	.	.	PUNCT
dpc-2912	16	1	methods	method	NOUN
dpc-2912	16	2	:	:	PUNCT
dpc-2912	16	3	 	 	SPACE
dpc-2912	16	4	in	in	ADP
dpc-2912	16	5	this	this	DET
dpc-2912	16	6	retrospective	retrospective	ADJ
dpc-2912	16	7	study	study	NOUN
dpc-2912	16	8	,	,	PUNCT
dpc-2912	16	9	files	file	NOUN
dpc-2912	16	10	of	of	ADP
dpc-2912	16	11	csu	csu	NOUN
dpc-2912	16	12	patients	patient	NOUN
dpc-2912	16	13	using	use	VERB
dpc-2912	16	14	omz	omz	NOUN
dpc-2912	16	15	during	during	ADP
dpc-2912	16	16	the	the	DET
dpc-2912	16	17	covid-19	covid-19	PROPN
dpc-2912	16	18	pandemic	pandemic	NOUN
dpc-2912	16	19	were	be	AUX
dpc-2912	16	20	reviewed	review	VERB
dpc-2912	16	21	in	in	ADP
dpc-2912	16	22	terms	term	NOUN
dpc-2912	16	23	of	of	ADP
dpc-2912	16	24	demographic	demographic	ADJ
dpc-2912	16	25	features	feature	NOUN
dpc-2912	16	26	,	,	PUNCT
dpc-2912	16	27	medical	medical	ADJ
dpc-2912	16	28	history	history	NOUN
dpc-2912	16	29	including	include	VERB
dpc-2912	16	30	covid-19	covid-19	PROPN
dpc-2912	16	31	vaccination	vaccination	NOUN
dpc-2912	16	32	status	status	NOUN
dpc-2912	16	33	,	,	PUNCT
dpc-2912	16	34	clinical	clinical	ADJ
dpc-2912	16	35	characteristics	characteristic	NOUN
dpc-2912	16	36	,	,	PUNCT
dpc-2912	16	37	pretreatment	pretreatment	NOUN
dpc-2912	16	38	laboratory	laboratory	NOUN
dpc-2912	16	39	parameters	parameter	NOUN
dpc-2912	16	40	,	,	PUNCT
dpc-2912	16	41	duration	duration	NOUN
dpc-2912	16	42	,	,	PUNCT
dpc-2912	16	43	and	and	CCONJ
dpc-2912	16	44	dosing	dose	VERB
dpc-2912	16	45	regimen	regiman	NOUN
dpc-2912	16	46	of	of	ADP
dpc-2912	16	47	omz	omz	ADJ
dpc-2912	16	48	treatment	treatment	NOUN
dpc-2912	16	49	.	.	PUNCT
dpc-2912	17	1	patients	patient	NOUN
dpc-2912	17	2	with	with	ADP
dpc-2912	17	3	a	a	DET
dpc-2912	17	4	history	history	NOUN
dpc-2912	17	5	of	of	ADP
dpc-2912	17	6	covid-19	covid-19	PROPN
dpc-2912	17	7	infection	infection	NOUN
dpc-2912	17	8	while	while	SCONJ
dpc-2912	17	9	on	on	ADP
dpc-2912	17	10	omz	omz	ADJ
dpc-2912	17	11	therapy	therapy	NOUN
dpc-2912	17	12	and	and	CCONJ
dpc-2912	17	13	patients	patient	NOUN
dpc-2912	17	14	without	without	ADP
dpc-2912	17	15	covid-19	covid-19	PROPN
dpc-2912	17	16	history	history	NOUN
dpc-2912	17	17	were	be	AUX
dpc-2912	17	18	compared	compare	VERB
dpc-2912	17	19	with	with	ADP
dpc-2912	17	20	respect	respect	NOUN
dpc-2912	17	21	to	to	ADP
dpc-2912	17	22	these	these	DET
dpc-2912	17	23	parameters	parameter	NOUN
dpc-2912	17	24	.	.	PUNCT
dpc-2912	18	1	the	the	DET
dpc-2912	18	2	urticaria	urticaria	NOUN
dpc-2912	18	3	activations	activation	NOUN
dpc-2912	18	4	following	follow	VERB
dpc-2912	18	5	covid-19	covid-19	PROPN
dpc-2912	18	6	infection	infection	NOUN
dpc-2912	18	7	or	or	CCONJ
dpc-2912	18	8	vaccination	vaccination	NOUN
dpc-2912	18	9	were	be	AUX
dpc-2912	18	10	also	also	ADV
dpc-2912	18	11	recorded	record	VERB
dpc-2912	18	12	.	.	PUNCT
dpc-2912	19	1	results	result	NOUN
dpc-2912	19	2	:	:	PUNCT
dpc-2912	19	3	sixty	sixty	NUM
dpc-2912	19	4	-	-	PUNCT
dpc-2912	19	5	eight	eight	NUM
dpc-2912	19	6	patients	patient	NOUN
dpc-2912	19	7	with	with	ADP
dpc-2912	19	8	csu	csu	PROPN
dpc-2912	19	9	(	(	PUNCT
dpc-2912	19	10	female	female	NOUN
dpc-2912	19	11	:	:	PUNCT
dpc-2912	19	12	male	male	ADJ
dpc-2912	19	13	ratio	ratio	NOUN
dpc-2912	19	14	=	=	SYM
dpc-2912	19	15	1.8:1	1.8:1	NUM
dpc-2912	19	16	;	;	PUNCT
dpc-2912	19	17	mean	mean	ADJ
dpc-2912	19	18	age	age	NOUN
dpc-2912	19	19	=	=	SYM
dpc-2912	19	20	47.2	47.2	NUM
dpc-2912	19	21	±	±	NUM
dpc-2912	19	22	15.1	15.1	NUM
dpc-2912	19	23	years	year	NOUN
dpc-2912	19	24	)	)	PUNCT
dpc-2912	19	25	continued	continue	VERB
dpc-2912	19	26	to	to	PART
dpc-2912	19	27	receive	receive	VERB
dpc-2912	19	28	omz	omz	ADJ
dpc-2912	19	29	treatment	treatment	NOUN
dpc-2912	19	30	.	.	PUNCT
dpc-2912	20	1	the	the	DET
dpc-2912	20	2	median	median	ADJ
dpc-2912	20	3	duration	duration	NOUN
dpc-2912	20	4	of	of	ADP
dpc-2912	20	5	omz	omz	ADJ
dpc-2912	20	6	treatment	treatment	NOUN
dpc-2912	20	7	was	be	AUX
dpc-2912	20	8	12	12	NUM
dpc-2912	20	9	months	month	NOUN
dpc-2912	20	10	(	(	PUNCT
dpc-2912	20	11	range	range	NOUN
dpc-2912	20	12	:	:	PUNCT
dpc-2912	20	13	6	6	NUM
dpc-2912	20	14	-	-	SYM
dpc-2912	20	15	60	60	NUM
dpc-2912	20	16	)	)	PUNCT
dpc-2912	20	17	.	.	PUNCT
dpc-2912	21	1	twelve	twelve	NUM
dpc-2912	21	2	patients	patient	NOUN
dpc-2912	21	3	(	(	PUNCT
dpc-2912	21	4	17.6	17.6	NUM
dpc-2912	21	5	%	%	NOUN
dpc-2912	21	6	)	)	PUNCT
dpc-2912	21	7	were	be	AUX
dpc-2912	21	8	diagnosed	diagnose	VERB
dpc-2912	21	9	with	with	ADP
dpc-2912	21	10	covid-19	covid-19	PROPN
dpc-2912	21	11	showing	show	VERB
dpc-2912	21	12	no	no	DET
dpc-2912	21	13	exacerbation	exacerbation	NOUN
dpc-2912	21	14	in	in	ADP
dpc-2912	21	15	urticaria	urticaria	NOUN
dpc-2912	21	16	.	.	PUNCT
dpc-2912	22	1	the	the	DET
dpc-2912	22	2	duration	duration	NOUN
dpc-2912	22	3	of	of	ADP
dpc-2912	22	4	omz	omz	ADJ
dpc-2912	22	5	treatment	treatment	NOUN
dpc-2912	22	6	was	be	AUX
dpc-2912	22	7	significantly	significantly	ADV
dpc-2912	22	8	higher	high	ADJ
dpc-2912	22	9	in	in	ADP
dpc-2912	22	10	the	the	DET
dpc-2912	22	11	group	group	NOUN
dpc-2912	22	12	with	with	ADP
dpc-2912	22	13	covid-19	covid-19	PROPN
dpc-2912	22	14	infection	infection	NOUN
dpc-2912	22	15	history	history	NOUN
dpc-2912	22	16	compared	compare	VERB
dpc-2912	22	17	to	to	ADP
dpc-2912	22	18	patients	patient	NOUN
dpc-2912	22	19	with	with	ADP
dpc-2912	22	20	no	no	DET
dpc-2912	22	21	history	history	NOUN
dpc-2912	22	22	of	of	ADP
dpc-2912	22	23	covid-19	covid-19	PROPN
dpc-2912	22	24	(	(	PUNCT
dpc-2912	22	25	p	p	NOUN
dpc-2912	22	26	=	=	NOUN
dpc-2912	22	27	0.01	0.01	NUM
dpc-2912	22	28	)	)	PUNCT
dpc-2912	22	29	.	.	PUNCT
dpc-2912	23	1	among	among	ADP
dpc-2912	23	2	51	51	NUM
dpc-2912	23	3	patients	patient	NOUN
dpc-2912	23	4	(	(	PUNCT
dpc-2912	23	5	75	75	NUM
dpc-2912	23	6	%	%	NOUN
dpc-2912	23	7	)	)	PUNCT
dpc-2912	23	8	vaccinated	vaccinate	VERB
dpc-2912	23	9	against	against	ADP
dpc-2912	23	10	covid-19	covid-19	PROPN
dpc-2912	23	11	,	,	PUNCT
dpc-2912	23	12	urticaria	urticaria	ADJ
dpc-2912	23	13	activation	activation	NOUN
dpc-2912	23	14	occurred	occur	VERB
dpc-2912	23	15	in	in	ADP
dpc-2912	23	16	4	4	NUM
dpc-2912	23	17	patients	patient	NOUN
dpc-2912	23	18	without	without	ADP
dpc-2912	23	19	any	any	DET
dpc-2912	23	20	recurrence	recurrence	NOUN
dpc-2912	23	21	following	follow	VERB
dpc-2912	23	22	booster	booster	NOUN
dpc-2912	23	23	vaccinations	vaccination	NOUN
dpc-2912	23	24	.	.	PUNCT
dpc-2912	24	1	abstract	abstract	ADJ
dpc-2912	24	2	2	2	NUM
dpc-2912	24	3	original	original	ADJ
dpc-2912	24	4	article	article	NOUN
dpc-2912	24	5	|	|	ADV
dpc-2912	24	6	dermatol	dermatol	ADJ
dpc-2912	24	7	pract	pract	NOUN
dpc-2912	24	8	concept	concept	NOUN
dpc-2912	24	9	.	.	PUNCT
dpc-2912	25	1	2023;13(3):e2023145	2023;13(3):e2023145	NUM
dpc-2912	25	2	introduction	introduction	NOUN
dpc-2912	25	3	chronic	chronic	ADJ
dpc-2912	25	4	spontaneous	spontaneous	ADJ
dpc-2912	25	5	urticaria	urticaria	NOUN
dpc-2912	25	6	(	(	PUNCT
dpc-2912	25	7	csu	csu	PROPN
dpc-2912	25	8	)	)	PUNCT
dpc-2912	25	9	is	be	AUX
dpc-2912	25	10	a	a	DET
dpc-2912	25	11	disease	disease	NOUN
dpc-2912	25	12	lasting	last	VERB
dpc-2912	25	13	more	more	ADJ
dpc-2912	25	14	than	than	ADP
dpc-2912	25	15	six	six	NUM
dpc-2912	25	16	weeks	week	NOUN
dpc-2912	25	17	and	and	CCONJ
dpc-2912	25	18	characterized	characterize	VERB
dpc-2912	25	19	by	by	ADP
dpc-2912	25	20	recurrent	recurrent	ADJ
dpc-2912	25	21	erythematous	erythematous	ADJ
dpc-2912	25	22	,	,	PUNCT
dpc-2912	25	23	indurated	indurate	VERB
dpc-2912	25	24	lesions	lesion	NOUN
dpc-2912	25	25	.	.	PUNCT
dpc-2912	26	1	infections	infection	NOUN
dpc-2912	26	2	,	,	PUNCT
dpc-2912	26	3	drugs	drug	NOUN
dpc-2912	26	4	,	,	PUNCT
dpc-2912	26	5	and	and	CCONJ
dpc-2912	26	6	vaccines	vaccine	NOUN
dpc-2912	26	7	are	be	AUX
dpc-2912	26	8	possible	possible	ADJ
dpc-2912	26	9	triggers	trigger	NOUN
dpc-2912	26	10	that	that	PRON
dpc-2912	26	11	may	may	AUX
dpc-2912	26	12	cause	cause	VERB
dpc-2912	26	13	csu	csu	NOUN
dpc-2912	26	14	exacerbations	exacerbation	NOUN
dpc-2912	26	15	.	.	PUNCT
dpc-2912	27	1	the	the	DET
dpc-2912	27	2	current	current	ADJ
dpc-2912	27	3	csu	csu	PROPN
dpc-2912	27	4	management	management	NOUN
dpc-2912	27	5	guideline	guideline	NOUN
dpc-2912	27	6	recommends	recommend	VERB
dpc-2912	27	7	non	non	ADJ
dpc-2912	27	8	-	-	ADJ
dpc-2912	27	9	sedative	sedative	ADJ
dpc-2912	27	10	antihistamines	antihistamine	NOUN
dpc-2912	27	11	in	in	ADP
dpc-2912	27	12	standard	standard	NOUN
dpc-2912	27	13	or	or	CCONJ
dpc-2912	27	14	up	up	ADV
dpc-2912	27	15	to	to	PART
dpc-2912	27	16	4	4	NUM
dpc-2912	27	17	-	-	ADJ
dpc-2912	27	18	fold	fold	VERB
dpc-2912	27	19	higher	high	ADJ
dpc-2912	27	20	dosages	dosage	NOUN
dpc-2912	27	21	as	as	ADP
dpc-2912	27	22	the	the	DET
dpc-2912	27	23	first	first	ADJ
dpc-2912	27	24	-	-	PUNCT
dpc-2912	27	25	line	line	NOUN
dpc-2912	27	26	treatment	treatment	NOUN
dpc-2912	27	27	.	.	PUNCT
dpc-2912	28	1	in	in	ADP
dpc-2912	28	2	refractory	refractory	NOUN
dpc-2912	28	3	cases	case	NOUN
dpc-2912	28	4	,	,	PUNCT
dpc-2912	28	5	the	the	DET
dpc-2912	28	6	anti	anti	ADJ
dpc-2912	28	7	-	-	ADJ
dpc-2912	28	8	immunoglobulin	immunoglobulin	ADJ
dpc-2912	28	9	e	e	NOUN
dpc-2912	28	10	(	(	PUNCT
dpc-2912	28	11	anti	anti	ADJ
dpc-2912	28	12	-	-	ADJ
dpc-2912	28	13	ige	ige	ADJ
dpc-2912	28	14	)	)	PUNCT
dpc-2912	28	15	antibody	antibody	NOUN
dpc-2912	28	16	omalizumab	omalizumab	NOUN
dpc-2912	28	17	(	(	PUNCT
dpc-2912	28	18	omz	omz	PROPN
dpc-2912	28	19	)	)	PUNCT
dpc-2912	28	20	is	be	AUX
dpc-2912	28	21	the	the	DET
dpc-2912	28	22	therapy	therapy	NOUN
dpc-2912	28	23	of	of	ADP
dpc-2912	28	24	choice	choice	NOUN
dpc-2912	29	1	[	[	X
dpc-2912	29	2	1,2	1,2	NUM
dpc-2912	29	3	]	]	PUNCT
dpc-2912	29	4	.	.	PUNCT
dpc-2912	30	1	coronavirus	coronavirus	NOUN
dpc-2912	30	2	disease	disease	NOUN
dpc-2912	30	3	2019	2019	NUM
dpc-2912	30	4	(	(	PUNCT
dpc-2912	30	5	covid-19	covid-19	PROPN
dpc-2912	30	6	)	)	PUNCT
dpc-2912	30	7	had	have	VERB
dpc-2912	30	8	significant	significant	ADJ
dpc-2912	30	9	impacts	impact	NOUN
dpc-2912	30	10	on	on	ADP
dpc-2912	30	11	general	general	ADJ
dpc-2912	30	12	health	health	NOUN
dpc-2912	30	13	practices	practice	NOUN
dpc-2912	30	14	.	.	PUNCT
dpc-2912	31	1	several	several	ADJ
dpc-2912	31	2	cases	case	NOUN
dpc-2912	31	3	of	of	ADP
dpc-2912	31	4	urticaria	urticaria	NOUN
dpc-2912	31	5	triggered	trigger	VERB
dpc-2912	31	6	by	by	ADP
dpc-2912	31	7	covid-19	covid-19	PROPN
dpc-2912	31	8	or	or	CCONJ
dpc-2912	31	9	the	the	DET
dpc-2912	31	10	vaccines	vaccine	NOUN
dpc-2912	31	11	developed	develop	VERB
dpc-2912	31	12	against	against	ADP
dpc-2912	31	13	the	the	DET
dpc-2912	31	14	virus	virus	NOUN
dpc-2912	31	15	have	have	AUX
dpc-2912	31	16	recently	recently	ADV
dpc-2912	31	17	been	be	AUX
dpc-2912	31	18	reported	report	VERB
dpc-2912	31	19	[	[	PUNCT
dpc-2912	31	20	3	3	NUM
dpc-2912	31	21	-	-	SYM
dpc-2912	31	22	5	5	NUM
dpc-2912	31	23	]	]	PUNCT
dpc-2912	31	24	.	.	PUNCT
dpc-2912	32	1	csu	csu	VERB
dpc-2912	32	2	adversely	adversely	ADV
dpc-2912	32	3	affects	affect	VERB
dpc-2912	32	4	the	the	DET
dpc-2912	32	5	quality	quality	NOUN
dpc-2912	32	6	of	of	ADP
dpc-2912	32	7	life	life	NOUN
dpc-2912	32	8	of	of	ADP
dpc-2912	32	9	the	the	DET
dpc-2912	32	10	patients	patient	NOUN
dpc-2912	32	11	[	[	X
dpc-2912	32	12	1,2	1,2	NUM
dpc-2912	32	13	]	]	PUNCT
dpc-2912	32	14	.	.	PUNCT
dpc-2912	33	1	moreover	moreover	ADV
dpc-2912	33	2	,	,	PUNCT
dpc-2912	33	3	patients	patient	NOUN
dpc-2912	33	4	with	with	ADP
dpc-2912	33	5	treatment	treatment	NOUN
dpc-2912	33	6	-	-	PUNCT
dpc-2912	33	7	resistant	resistant	ADJ
dpc-2912	33	8	csu	csu	NOUN
dpc-2912	33	9	may	may	AUX
dpc-2912	33	10	be	be	AUX
dpc-2912	33	11	concerned	concern	VERB
dpc-2912	33	12	about	about	ADP
dpc-2912	33	13	the	the	DET
dpc-2912	33	14	reactivation	reactivation	NOUN
dpc-2912	33	15	of	of	ADP
dpc-2912	33	16	their	their	PRON
dpc-2912	33	17	disease	disease	NOUN
dpc-2912	33	18	.	.	PUNCT
dpc-2912	34	1	for	for	ADP
dpc-2912	34	2	this	this	DET
dpc-2912	34	3	reason	reason	NOUN
dpc-2912	34	4	,	,	PUNCT
dpc-2912	34	5	they	they	PRON
dpc-2912	34	6	may	may	AUX
dpc-2912	34	7	refrain	refrain	VERB
dpc-2912	34	8	from	from	ADP
dpc-2912	34	9	the	the	DET
dpc-2912	34	10	newly	newly	ADV
dpc-2912	34	11	developed	develop	VERB
dpc-2912	34	12	therapeutic	therapeutic	ADJ
dpc-2912	34	13	options	option	NOUN
dpc-2912	34	14	.	.	PUNCT
dpc-2912	35	1	at	at	ADP
dpc-2912	35	2	the	the	DET
dpc-2912	35	3	beginning	beginning	NOUN
dpc-2912	35	4	of	of	ADP
dpc-2912	35	5	the	the	DET
dpc-2912	35	6	covid-19	covid-19	PROPN
dpc-2912	35	7	pandemic	pandemic	NOUN
dpc-2912	35	8	,	,	PUNCT
dpc-2912	35	9	many	many	ADJ
dpc-2912	35	10	patients	patient	NOUN
dpc-2912	35	11	even	even	ADV
dpc-2912	35	12	considered	consider	VERB
dpc-2912	35	13	discontinuing	discontinue	VERB
dpc-2912	35	14	their	their	PRON
dpc-2912	35	15	regular	regular	ADJ
dpc-2912	35	16	medications	medication	NOUN
dpc-2912	35	17	due	due	ADP
dpc-2912	35	18	to	to	ADP
dpc-2912	35	19	possible	possible	ADJ
dpc-2912	35	20	immunosuppression	immunosuppression	NOUN
dpc-2912	35	21	.	.	PUNCT
dpc-2912	36	1	a	a	DET
dpc-2912	36	2	similar	similar	ADJ
dpc-2912	36	3	situation	situation	NOUN
dpc-2912	36	4	was	be	AUX
dpc-2912	36	5	observed	observe	VERB
dpc-2912	36	6	for	for	ADP
dpc-2912	36	7	omz	omz	ADJ
dpc-2912	36	8	treatment	treatment	NOUN
dpc-2912	36	9	,	,	PUNCT
dpc-2912	36	10	which	which	PRON
dpc-2912	36	11	has	have	VERB
dpc-2912	36	12	no	no	DET
dpc-2912	36	13	immunosuppressive	immunosuppressive	ADJ
dpc-2912	36	14	effect	effect	NOUN
dpc-2912	36	15	.	.	PUNCT
dpc-2912	37	1	objectives	objective	NOUN
dpc-2912	37	2	in	in	ADP
dpc-2912	37	3	this	this	DET
dpc-2912	37	4	study	study	NOUN
dpc-2912	37	5	,	,	PUNCT
dpc-2912	37	6	we	we	PRON
dpc-2912	37	7	aimed	aim	VERB
dpc-2912	37	8	to	to	PART
dpc-2912	37	9	investigate	investigate	VERB
dpc-2912	37	10	the	the	DET
dpc-2912	37	11	effect	effect	NOUN
dpc-2912	37	12	of	of	ADP
dpc-2912	37	13	omz	omz	ADJ
dpc-2912	37	14	treatment	treatment	NOUN
dpc-2912	37	15	on	on	ADP
dpc-2912	37	16	csu	csu	PROPN
dpc-2912	37	17	patients	patient	NOUN
dpc-2912	37	18	regarding	regard	VERB
dpc-2912	37	19	covid-19	covid-19	PROPN
dpc-2912	37	20	incidence	incidence	NOUN
dpc-2912	37	21	and	and	CCONJ
dpc-2912	37	22	prognosis	prognosis	NOUN
dpc-2912	37	23	.	.	PUNCT
dpc-2912	38	1	methods	method	NOUN
dpc-2912	38	2	in	in	ADP
dpc-2912	38	3	this	this	DET
dpc-2912	38	4	retrospective	retrospective	ADJ
dpc-2912	38	5	cohort	cohort	NOUN
dpc-2912	38	6	study	study	NOUN
dpc-2912	38	7	,	,	PUNCT
dpc-2912	38	8	csu	csu	VERB
dpc-2912	38	9	patients	patient	NOUN
dpc-2912	38	10	who	who	PRON
dpc-2912	38	11	were	be	AUX
dpc-2912	38	12	followed	follow	VERB
dpc-2912	38	13	up	up	ADP
dpc-2912	38	14	in	in	ADP
dpc-2912	38	15	a	a	DET
dpc-2912	38	16	tertiary	tertiary	ADJ
dpc-2912	38	17	referral	referral	NOUN
dpc-2912	38	18	center	center	NOUN
dpc-2912	38	19	and	and	CCONJ
dpc-2912	38	20	used	use	VERB
dpc-2912	38	21	at	at	ADP
dpc-2912	38	22	least	least	ADV
dpc-2912	38	23	six	six	NUM
dpc-2912	38	24	months	month	NOUN
dpc-2912	38	25	omz	omz	ADJ
dpc-2912	38	26	therapy	therapy	NOUN
dpc-2912	38	27	between	between	ADP
dpc-2912	38	28	april	april	PROPN
dpc-2912	38	29	2020	2020	NUM
dpc-2912	38	30	and	and	CCONJ
dpc-2912	38	31	april	april	PROPN
dpc-2912	38	32	2022	2022	NUM
dpc-2912	38	33	were	be	AUX
dpc-2912	38	34	assessed	assess	VERB
dpc-2912	38	35	.	.	PUNCT
dpc-2912	39	1	patients	patient	NOUN
dpc-2912	39	2	under	under	ADP
dpc-2912	39	3	the	the	DET
dpc-2912	39	4	age	age	NOUN
dpc-2912	39	5	of	of	ADP
dpc-2912	39	6	18	18	NUM
dpc-2912	39	7	and	and	CCONJ
dpc-2912	39	8	those	those	PRON
dpc-2912	39	9	receiving	receive	VERB
dpc-2912	39	10	omz	omz	ADJ
dpc-2912	39	11	treatment	treatment	NOUN
dpc-2912	39	12	for	for	ADP
dpc-2912	39	13	less	less	ADJ
dpc-2912	39	14	than	than	ADP
dpc-2912	39	15	six	six	NUM
dpc-2912	39	16	months	month	NOUN
dpc-2912	39	17	were	be	AUX
dpc-2912	39	18	excluded	exclude	VERB
dpc-2912	39	19	.	.	PUNCT
dpc-2912	40	1	the	the	DET
dpc-2912	40	2	medical	medical	ADJ
dpc-2912	40	3	files	file	NOUN
dpc-2912	40	4	of	of	ADP
dpc-2912	40	5	the	the	DET
dpc-2912	40	6	patients	patient	NOUN
dpc-2912	40	7	were	be	AUX
dpc-2912	40	8	evaluated	evaluate	VERB
dpc-2912	40	9	regarding	regard	VERB
dpc-2912	40	10	demographic	demographic	ADJ
dpc-2912	40	11	characteristics	characteristic	NOUN
dpc-2912	40	12	(	(	PUNCT
dpc-2912	40	13	gender	gender	NOUN
dpc-2912	40	14	,	,	PUNCT
dpc-2912	40	15	age	age	NOUN
dpc-2912	40	16	)	)	PUNCT
dpc-2912	40	17	,	,	PUNCT
dpc-2912	40	18	medical	medical	ADJ
dpc-2912	40	19	history	history	NOUN
dpc-2912	40	20	(	(	PUNCT
dpc-2912	40	21	comorbidities	comorbiditie	NOUN
dpc-2912	40	22	,	,	PUNCT
dpc-2912	40	23	concomitant	concomitant	ADJ
dpc-2912	40	24	treatments	treatment	NOUN
dpc-2912	40	25	including	include	VERB
dpc-2912	40	26	antihistamines	antihistamine	NOUN
dpc-2912	40	27	,	,	PUNCT
dpc-2912	40	28	covid-19	covid-19	PROPN
dpc-2912	40	29	vaccination	vaccination	NOUN
dpc-2912	40	30	status	status	NOUN
dpc-2912	40	31	)	)	PUNCT
dpc-2912	40	32	,	,	PUNCT
dpc-2912	40	33	clinical	clinical	ADJ
dpc-2912	40	34	features	feature	NOUN
dpc-2912	40	35	(	(	PUNCT
dpc-2912	40	36	presence	presence	NOUN
dpc-2912	40	37	of	of	ADP
dpc-2912	40	38	urticaria	urticaria	NOUN
dpc-2912	40	39	,	,	PUNCT
dpc-2912	40	40	angioedema	angioedema	VERB
dpc-2912	40	41	or	or	CCONJ
dpc-2912	40	42	both	both	PRON
dpc-2912	40	43	,	,	PUNCT
dpc-2912	40	44	disease	disease	NOUN
dpc-2912	40	45	activity	activity	NOUN
dpc-2912	40	46	)	)	PUNCT
dpc-2912	40	47	,	,	PUNCT
dpc-2912	40	48	laboratory	laboratory	NOUN
dpc-2912	40	49	findings	finding	NOUN
dpc-2912	40	50	(	(	PUNCT
dpc-2912	40	51	including	include	VERB
dpc-2912	40	52	pre	pre	ADJ
dpc-2912	40	53	-	-	NOUN
dpc-2912	40	54	treatment	treatment	ADJ
dpc-2912	40	55	ig	ig	PROPN
dpc-2912	40	56	-	-	ADJ
dpc-2912	40	57	e	e	NOUN
dpc-2912	40	58	levels	level	NOUN
dpc-2912	40	59	and	and	CCONJ
dpc-2912	40	60	blood	blood	NOUN
dpc-2912	40	61	eosinophil	eosinophil	ADJ
dpc-2912	40	62	counts	count	NOUN
dpc-2912	40	63	)	)	PUNCT
dpc-2912	40	64	,	,	PUNCT
dpc-2912	40	65	omz	omz	ADJ
dpc-2912	40	66	treatment	treatment	NOUN
dpc-2912	40	67	duration	duration	NOUN
dpc-2912	40	68	and	and	CCONJ
dpc-2912	40	69	dosing	dosing	NOUN
dpc-2912	40	70	frequency	frequency	NOUN
dpc-2912	40	71	.	.	PUNCT
dpc-2912	41	1	the	the	DET
dpc-2912	41	2	disease	disease	NOUN
dpc-2912	41	3	activity	activity	NOUN
dpc-2912	41	4	was	be	AUX
dpc-2912	41	5	evaluated	evaluate	VERB
dpc-2912	41	6	with	with	ADP
dpc-2912	41	7	urticaria	urticaria	NOUN
dpc-2912	41	8	activity	activity	NOUN
dpc-2912	41	9	score	score	NOUN
dpc-2912	41	10	7	7	NUM
dpc-2912	41	11	(	(	PUNCT
dpc-2912	41	12	uas7	uas7	ADV
dpc-2912	41	13	)	)	PUNCT
dpc-2912	42	1	[	[	X
dpc-2912	42	2	1,2	1,2	NUM
dpc-2912	42	3	]	]	PUNCT
dpc-2912	42	4	.	.	PUNCT
dpc-2912	43	1	the	the	DET
dpc-2912	43	2	rate	rate	NOUN
dpc-2912	43	3	of	of	ADP
dpc-2912	43	4	covid-19	covid-19	PROPN
dpc-2912	43	5	infection	infection	NOUN
dpc-2912	43	6	in	in	ADP
dpc-2912	43	7	patients	patient	NOUN
dpc-2912	43	8	during	during	ADP
dpc-2912	43	9	omz	omz	ADJ
dpc-2912	43	10	therapy	therapy	NOUN
dpc-2912	43	11	was	be	AUX
dpc-2912	43	12	recorded	record	VERB
dpc-2912	43	13	.	.	PUNCT
dpc-2912	44	1	patients	patient	NOUN
dpc-2912	44	2	with	with	ADP
dpc-2912	44	3	a	a	DET
dpc-2912	44	4	history	history	NOUN
dpc-2912	44	5	of	of	ADP
dpc-2912	44	6	covid-19	covid-19	PROPN
dpc-2912	44	7	infection	infection	NOUN
dpc-2912	44	8	while	while	SCONJ
dpc-2912	44	9	on	on	ADP
dpc-2912	44	10	omz	omz	ADJ
dpc-2912	44	11	therapy	therapy	NOUN
dpc-2912	44	12	and	and	CCONJ
dpc-2912	44	13	patients	patient	NOUN
dpc-2912	44	14	without	without	ADP
dpc-2912	44	15	covid-19	covid-19	PROPN
dpc-2912	44	16	history	history	NOUN
dpc-2912	44	17	were	be	AUX
dpc-2912	44	18	compared	compare	VERB
dpc-2912	44	19	with	with	ADP
dpc-2912	44	20	respect	respect	NOUN
dpc-2912	44	21	to	to	ADP
dpc-2912	44	22	the	the	DET
dpc-2912	44	23	parameters	parameter	NOUN
dpc-2912	44	24	mentioned	mention	VERB
dpc-2912	44	25	above	above	ADV
dpc-2912	44	26	.	.	PUNCT
dpc-2912	45	1	moreover	moreover	ADV
dpc-2912	45	2	,	,	PUNCT
dpc-2912	45	3	urticaria	urticaria	ADJ
dpc-2912	45	4	exacerbations	exacerbation	NOUN
dpc-2912	45	5	following	follow	VERB
dpc-2912	45	6	covid-19	covid-19	PROPN
dpc-2912	45	7	and	and	CCONJ
dpc-2912	45	8	covid-19	covid-19	PROPN
dpc-2912	45	9	vaccines	vaccine	NOUN
dpc-2912	45	10	were	be	AUX
dpc-2912	45	11	noted	note	VERB
dpc-2912	45	12	.	.	PUNCT
dpc-2912	46	1	the	the	DET
dpc-2912	46	2	kolmogorov	kolmogorov	ADJ
dpc-2912	46	3	-	-	PUNCT
dpc-2912	46	4	smirnov	smirnov	ADJ
dpc-2912	46	5	test	test	NOUN
dpc-2912	46	6	was	be	AUX
dpc-2912	46	7	used	use	VERB
dpc-2912	46	8	to	to	PART
dpc-2912	46	9	verify	verify	VERB
dpc-2912	46	10	the	the	DET
dpc-2912	46	11	normality	normality	NOUN
dpc-2912	46	12	of	of	ADP
dpc-2912	46	13	the	the	DET
dpc-2912	46	14	distribution	distribution	NOUN
dpc-2912	46	15	of	of	ADP
dpc-2912	46	16	continuous	continuous	ADJ
dpc-2912	46	17	variables	variable	NOUN
dpc-2912	46	18	which	which	PRON
dpc-2912	46	19	were	be	AUX
dpc-2912	46	20	expressed	express	VERB
dpc-2912	46	21	as	as	ADP
dpc-2912	46	22	mean	mean	NOUN
dpc-2912	46	23	±	±	NUM
dpc-2912	46	24	standard	standard	ADJ
dpc-2912	46	25	deviation	deviation	NOUN
dpc-2912	46	26	(	(	PUNCT
dpc-2912	46	27	sd	sd	NOUN
dpc-2912	46	28	)	)	PUNCT
dpc-2912	46	29	or	or	CCONJ
dpc-2912	46	30	median	median	ADJ
dpc-2912	46	31	(	(	PUNCT
dpc-2912	46	32	min	min	NOUN
dpc-2912	46	33	-	-	PUNCT
dpc-2912	46	34	max	max	NOUN
dpc-2912	46	35	)	)	PUNCT
dpc-2912	46	36	in	in	ADP
dpc-2912	46	37	the	the	DET
dpc-2912	46	38	presence	presence	NOUN
dpc-2912	46	39	of	of	ADP
dpc-2912	46	40	abnormal	abnormal	ADJ
dpc-2912	46	41	distribution	distribution	NOUN
dpc-2912	46	42	,	,	PUNCT
dpc-2912	46	43	and	and	CCONJ
dpc-2912	46	44	categorical	categorical	ADJ
dpc-2912	46	45	variables	variable	NOUN
dpc-2912	46	46	were	be	AUX
dpc-2912	46	47	expressed	express	VERB
dpc-2912	46	48	as	as	ADP
dpc-2912	46	49	percentages	percentage	NOUN
dpc-2912	46	50	.	.	PUNCT
dpc-2912	47	1	comparisons	comparison	NOUN
dpc-2912	47	2	between	between	ADP
dpc-2912	47	3	the	the	DET
dpc-2912	47	4	groups	group	NOUN
dpc-2912	47	5	were	be	AUX
dpc-2912	47	6	made	make	VERB
dpc-2912	47	7	by	by	ADP
dpc-2912	47	8	using	use	VERB
dpc-2912	47	9	chi	chi	ADJ
dpc-2912	47	10	-	-	PUNCT
dpc-2912	47	11	square	square	ADJ
dpc-2912	47	12	or	or	CCONJ
dpc-2912	47	13	fisher	fisher	PROPN
dpc-2912	47	14	exact	exact	ADJ
dpc-2912	47	15	test	test	NOUN
dpc-2912	47	16	for	for	ADP
dpc-2912	47	17	categorical	categorical	ADJ
dpc-2912	47	18	variables	variable	NOUN
dpc-2912	47	19	,	,	PUNCT
dpc-2912	47	20	independent	independent	ADJ
dpc-2912	47	21	samples	sample	NOUN
dpc-2912	47	22	t	t	NOUN
dpc-2912	47	23	-	-	PUNCT
dpc-2912	47	24	test	test	NOUN
dpc-2912	47	25	for	for	ADP
dpc-2912	47	26	normally	normally	ADV
dpc-2912	47	27	distributed	distribute	VERB
dpc-2912	47	28	continuous	continuous	ADJ
dpc-2912	47	29	variables	variable	NOUN
dpc-2912	47	30	,	,	PUNCT
dpc-2912	47	31	and	and	CCONJ
dpc-2912	47	32	mann	mann	PROPN
dpc-2912	47	33	-	-	PUNCT
dpc-2912	47	34	whitney	whitney	PROPN
dpc-2912	47	35	u	u	PROPN
dpc-2912	47	36	test	test	NOUN
dpc-2912	47	37	when	when	SCONJ
dpc-2912	47	38	the	the	DET
dpc-2912	47	39	distribution	distribution	NOUN
dpc-2912	47	40	was	be	AUX
dpc-2912	47	41	skewed	skewed	ADJ
dpc-2912	47	42	.	.	PUNCT
dpc-2912	48	1	a	a	DET
dpc-2912	48	2	 	 	SPACE
dpc-2912	48	3	p	p	NOUN
dpc-2912	48	4	 	 	SPACE
dpc-2912	48	5	-value	-value	ADJ
dpc-2912	48	6	less	less	ADJ
dpc-2912	48	7	than	than	ADP
dpc-2912	48	8	0.05	0.05	NUM
dpc-2912	48	9	was	be	AUX
dpc-2912	48	10	considered	consider	VERB
dpc-2912	48	11	statistically	statistically	ADV
dpc-2912	48	12	significant	significant	ADJ
dpc-2912	48	13	.	.	PUNCT
dpc-2912	49	1	all	all	DET
dpc-2912	49	2	statistical	statistical	ADJ
dpc-2912	49	3	procedures	procedure	NOUN
dpc-2912	49	4	were	be	AUX
dpc-2912	49	5	performed	perform	VERB
dpc-2912	49	6	using	use	VERB
dpc-2912	49	7	spss	spss	PROPN
dpc-2912	49	8	software	software	NOUN
dpc-2912	49	9	version	version	NOUN
dpc-2912	49	10	14.0	14.0	NUM
dpc-2912	49	11	(	(	PUNCT
dpc-2912	49	12	spss	spss	PROPN
dpc-2912	49	13	inc	inc	PROPN
dpc-2912	49	14	.	.	PROPN
dpc-2912	49	15	)	)	PUNCT
dpc-2912	49	16	.	.	PUNCT
dpc-2912	50	1	the	the	DET
dpc-2912	50	2	ethics	ethic	NOUN
dpc-2912	50	3	committes	committe	NOUN
dpc-2912	50	4	of	of	ADP
dpc-2912	50	5	18	18	NUM
dpc-2912	50	6	mart	mart	PROPN
dpc-2912	50	7	university	university	NOUN
dpc-2912	50	8	approved	approve	VERB
dpc-2912	50	9	the	the	DET
dpc-2912	50	10	study	study	NOUN
dpc-2912	50	11	with	with	ADP
dpc-2912	50	12	the	the	DET
dpc-2912	50	13	decision	decision	NOUN
dpc-2912	50	14	number	number	NOUN
dpc-2912	50	15	2022/14	2022/14	NUM
dpc-2912	50	16	-	-	SYM
dpc-2912	50	17	09	09	NUM
dpc-2912	50	18	.	.	PUNCT
dpc-2912	51	1	results	result	VERB
dpc-2912	51	2	a	a	DET
dpc-2912	51	3	total	total	NOUN
dpc-2912	51	4	of	of	ADP
dpc-2912	51	5	68	68	NUM
dpc-2912	51	6	patients	patient	NOUN
dpc-2912	51	7	with	with	ADP
dpc-2912	51	8	csu	csu	PROPN
dpc-2912	51	9	continued	continue	VERB
dpc-2912	51	10	to	to	PART
dpc-2912	51	11	receive	receive	VERB
dpc-2912	51	12	omz	omz	ADJ
dpc-2912	51	13	treatment	treatment	NOUN
dpc-2912	51	14	during	during	ADP
dpc-2912	51	15	the	the	DET
dpc-2912	51	16	study	study	NOUN
dpc-2912	51	17	period	period	NOUN
dpc-2912	51	18	.	.	PUNCT
dpc-2912	52	1	the	the	DET
dpc-2912	52	2	demographic	demographic	ADJ
dpc-2912	52	3	and	and	CCONJ
dpc-2912	52	4	clinical	clinical	ADJ
dpc-2912	52	5	characteristics	characteristic	NOUN
dpc-2912	52	6	of	of	ADP
dpc-2912	52	7	patients	patient	NOUN
dpc-2912	52	8	are	be	AUX
dpc-2912	52	9	summarized	summarize	VERB
dpc-2912	52	10	in	in	ADP
dpc-2912	52	11	table	table	NOUN
dpc-2912	52	12	1	1	NUM
dpc-2912	52	13	.	.	PUNCT
dpc-2912	53	1	the	the	DET
dpc-2912	53	2	female	female	NOUN
dpc-2912	53	3	:	:	PUNCT
dpc-2912	53	4	male	male	ADJ
dpc-2912	53	5	ratio	ratio	NOUN
dpc-2912	53	6	was	be	AUX
dpc-2912	53	7	1.8:1	1.8:1	NUM
dpc-2912	53	8	,	,	PUNCT
dpc-2912	53	9	while	while	SCONJ
dpc-2912	53	10	the	the	DET
dpc-2912	53	11	mean	mean	ADJ
dpc-2912	53	12	age	age	NOUN
dpc-2912	53	13	of	of	ADP
dpc-2912	53	14	the	the	DET
dpc-2912	53	15	patients	patient	NOUN
dpc-2912	53	16	was	be	AUX
dpc-2912	53	17	47.2	47.2	NUM
dpc-2912	53	18	±	±	NUM
dpc-2912	53	19	15.1	15.1	NUM
dpc-2912	53	20	years	year	NOUN
dpc-2912	53	21	.	.	PUNCT
dpc-2912	54	1	urticaria	urticaria	PROPN
dpc-2912	54	2	was	be	AUX
dpc-2912	54	3	accompanied	accompany	VERB
dpc-2912	54	4	by	by	ADP
dpc-2912	54	5	angioedema	angioedema	NOUN
dpc-2912	54	6	in	in	ADP
dpc-2912	54	7	25	25	NUM
dpc-2912	54	8	patients	patient	NOUN
dpc-2912	54	9	(	(	PUNCT
dpc-2912	54	10	36.8	36.8	NUM
dpc-2912	54	11	%	%	NOUN
dpc-2912	54	12	)	)	PUNCT
dpc-2912	54	13	.	.	PUNCT
dpc-2912	55	1	the	the	DET
dpc-2912	55	2	median	median	PROPN
dpc-2912	55	3	ige	ige	PROPN
dpc-2912	55	4	level	level	NOUN
dpc-2912	55	5	measured	measure	VERB
dpc-2912	55	6	prior	prior	ADV
dpc-2912	55	7	to	to	ADP
dpc-2912	55	8	omz	omz	ADJ
dpc-2912	55	9	treatment	treatment	NOUN
dpc-2912	55	10	was	be	AUX
dpc-2912	55	11	281	281	NUM
dpc-2912	55	12	ku	ku	NOUN
dpc-2912	55	13	/	/	SYM
dpc-2912	55	14	l	l	PROPN
dpc-2912	55	15	(	(	PUNCT
dpc-2912	55	16	range	range	NOUN
dpc-2912	55	17	:	:	PUNCT
dpc-2912	55	18	2	2	NUM
dpc-2912	55	19	-	-	SYM
dpc-2912	55	20	2730	2730	NUM
dpc-2912	55	21	)	)	PUNCT
dpc-2912	55	22	.	.	PUNCT
dpc-2912	56	1	pre	pre	ADJ
dpc-2912	56	2	-	-	ADJ
dpc-2912	56	3	treatment	treatment	ADJ
dpc-2912	56	4	eosinophilia	eosinophilia	PROPN
dpc-2912	56	5	was	be	AUX
dpc-2912	56	6	detected	detect	VERB
dpc-2912	56	7	in	in	ADP
dpc-2912	56	8	six	six	NUM
dpc-2912	56	9	patients	patient	NOUN
dpc-2912	56	10	(	(	PUNCT
dpc-2912	56	11	9	9	NUM
dpc-2912	56	12	%	%	NOUN
dpc-2912	56	13	)	)	PUNCT
dpc-2912	56	14	.	.	PUNCT
dpc-2912	57	1	the	the	DET
dpc-2912	57	2	median	median	ADJ
dpc-2912	57	3	duration	duration	NOUN
dpc-2912	57	4	of	of	ADP
dpc-2912	57	5	omz	omz	ADJ
dpc-2912	57	6	treatment	treatment	NOUN
dpc-2912	57	7	was	be	AUX
dpc-2912	57	8	12	12	NUM
dpc-2912	57	9	months	month	NOUN
dpc-2912	57	10	(	(	PUNCT
dpc-2912	57	11	range	range	NOUN
dpc-2912	57	12	:	:	PUNCT
dpc-2912	57	13	6	6	NUM
dpc-2912	57	14	-	-	SYM
dpc-2912	57	15	60	60	NUM
dpc-2912	57	16	)	)	PUNCT
dpc-2912	57	17	.	.	PUNCT
dpc-2912	58	1	a	a	DET
dpc-2912	58	2	standard	standard	ADJ
dpc-2912	58	3	dose	dose	NOUN
dpc-2912	58	4	regimen	regiman	NOUN
dpc-2912	58	5	(	(	PUNCT
dpc-2912	58	6	300	300	NUM
dpc-2912	58	7	mg	mg	NOUN
dpc-2912	58	8	every	every	DET
dpc-2912	58	9	four	four	NUM
dpc-2912	58	10	weeks	week	NOUN
dpc-2912	58	11	subcutaneously	subcutaneously	ADV
dpc-2912	58	12	)	)	PUNCT
dpc-2912	58	13	was	be	AUX
dpc-2912	58	14	initiated	initiate	VERB
dpc-2912	58	15	for	for	ADP
dpc-2912	58	16	all	all	DET
dpc-2912	58	17	patients	patient	NOUN
dpc-2912	58	18	,	,	PUNCT
dpc-2912	58	19	while	while	SCONJ
dpc-2912	58	20	two	two	NUM
dpc-2912	58	21	patients	patient	NOUN
dpc-2912	58	22	required	require	VERB
dpc-2912	58	23	a	a	DET
dpc-2912	58	24	reduction	reduction	NOUN
dpc-2912	58	25	in	in	ADP
dpc-2912	58	26	dosing	dosing	NOUN
dpc-2912	58	27	intervals	interval	NOUN
dpc-2912	58	28	(	(	PUNCT
dpc-2912	58	29	300	300	NUM
dpc-2912	58	30	mg	mg	NOUN
dpc-2912	58	31	every	every	DET
dpc-2912	58	32	two	two	NUM
dpc-2912	58	33	weeks	week	NOUN
dpc-2912	58	34	)	)	PUNCT
dpc-2912	58	35	.	.	PUNCT
dpc-2912	59	1	an	an	DET
dpc-2912	59	2	oral	oral	ADJ
dpc-2912	59	3	h1	h1	NOUN
dpc-2912	59	4	-	-	PUNCT
dpc-2912	59	5	antihistamine	antihistamine	PROPN
dpc-2912	59	6	was	be	AUX
dpc-2912	59	7	required	require	VERB
dpc-2912	59	8	in	in	ADP
dpc-2912	59	9	addition	addition	NOUN
dpc-2912	59	10	to	to	ADP
dpc-2912	59	11	omz	omz	NOUN
dpc-2912	59	12	in	in	ADP
dpc-2912	59	13	24	24	NUM
dpc-2912	59	14	patients	patient	NOUN
dpc-2912	59	15	(	(	PUNCT
dpc-2912	59	16	35.3	35.3	NUM
dpc-2912	59	17	%	%	NOUN
dpc-2912	59	18	)	)	PUNCT
dpc-2912	59	19	to	to	PART
dpc-2912	59	20	maintain	maintain	VERB
dpc-2912	59	21	the	the	DET
dpc-2912	59	22	disease	disease	NOUN
dpc-2912	59	23	control	control	NOUN
dpc-2912	59	24	.	.	PUNCT
dpc-2912	60	1	the	the	DET
dpc-2912	60	2	most	most	ADV
dpc-2912	60	3	commonly	commonly	ADV
dpc-2912	60	4	used	use	VERB
dpc-2912	60	5	h1	h1	PROPN
dpc-2912	60	6	-	-	PUNCT
dpc-2912	60	7	antihistamine	antihistamine	PROPN
dpc-2912	60	8	was	be	AUX
dpc-2912	60	9	levocetirizine	levocetirizine	ADJ
dpc-2912	60	10	(	(	PUNCT
dpc-2912	60	11	n	n	NOUN
dpc-2912	60	12	=	=	SYM
dpc-2912	60	13	17	17	NUM
dpc-2912	60	14	,	,	PUNCT
dpc-2912	60	15	70.8	70.8	NUM
dpc-2912	60	16	%	%	NOUN
dpc-2912	60	17	)	)	PUNCT
dpc-2912	60	18	.	.	PUNCT
dpc-2912	61	1	conclusions	conclusion	NOUN
dpc-2912	61	2	:	:	PUNCT
dpc-2912	61	3	considering	consider	VERB
dpc-2912	61	4	the	the	DET
dpc-2912	61	5	likelihood	likelihood	NOUN
dpc-2912	61	6	of	of	ADP
dpc-2912	61	7	increased	increase	VERB
dpc-2912	61	8	covid-19	covid-19	PROPN
dpc-2912	61	9	infection	infection	NOUN
dpc-2912	61	10	risk	risk	NOUN
dpc-2912	61	11	in	in	ADP
dpc-2912	61	12	the	the	DET
dpc-2912	61	13	setting	setting	NOUN
dpc-2912	61	14	of	of	ADP
dpc-2912	61	15	longterm	longterm	NOUN
dpc-2912	61	16	omz	omz	ADJ
dpc-2912	61	17	in	in	ADP
dpc-2912	61	18	csu	csu	PROPN
dpc-2912	61	19	patients	patient	NOUN
dpc-2912	61	20	,	,	PUNCT
dpc-2912	61	21	the	the	DET
dpc-2912	61	22	duration	duration	NOUN
dpc-2912	61	23	of	of	ADP
dpc-2912	61	24	omz	omz	ADJ
dpc-2912	61	25	therapy	therapy	NOUN
dpc-2912	61	26	might	might	AUX
dpc-2912	61	27	be	be	AUX
dpc-2912	61	28	kept	keep	VERB
dpc-2912	61	29	at	at	ADP
dpc-2912	61	30	a	a	DET
dpc-2912	61	31	minimum	minimum	NOUN
dpc-2912	61	32	,	,	PUNCT
dpc-2912	61	33	or	or	CCONJ
dpc-2912	61	34	a	a	DET
dpc-2912	61	35	temporary	temporary	ADJ
dpc-2912	61	36	interruption	interruption	NOUN
dpc-2912	61	37	of	of	ADP
dpc-2912	61	38	the	the	DET
dpc-2912	61	39	treatment	treatment	NOUN
dpc-2912	61	40	period	period	NOUN
dpc-2912	61	41	might	might	AUX
dpc-2912	61	42	be	be	AUX
dpc-2912	61	43	preferred	prefer	VERB
dpc-2912	61	44	,	,	PUNCT
dpc-2912	61	45	particularly	particularly	ADV
dpc-2912	61	46	in	in	ADP
dpc-2912	61	47	high	high	ADJ
dpc-2912	61	48	-	-	PUNCT
dpc-2912	61	49	risk	risk	NOUN
dpc-2912	61	50	patients	patient	NOUN
dpc-2912	61	51	regarding	regard	VERB
dpc-2912	61	52	covid-19	covid-19	PROPN
dpc-2912	61	53	.	.	PUNCT
dpc-2912	61	54	original	original	ADJ
dpc-2912	61	55	article	article	NOUN
dpc-2912	61	56	|	|	ADV
dpc-2912	61	57	dermatol	dermatol	ADJ
dpc-2912	61	58	pract	pract	NOUN
dpc-2912	61	59	concept	concept	NOUN
dpc-2912	61	60	.	.	PUNCT
dpc-2912	62	1	2023;13(3):e2023145	2023;13(3):e2023145	NUM
dpc-2912	62	2	3	3	NUM
dpc-2912	62	3	twelve	twelve	NUM
dpc-2912	62	4	of	of	ADP
dpc-2912	62	5	the	the	DET
dpc-2912	62	6	68	68	NUM
dpc-2912	62	7	csu	csu	NOUN
dpc-2912	62	8	patients	patient	NOUN
dpc-2912	62	9	(	(	PUNCT
dpc-2912	62	10	17.6	17.6	NUM
dpc-2912	62	11	%	%	NOUN
dpc-2912	62	12	)	)	PUNCT
dpc-2912	62	13	receiving	receive	VERB
dpc-2912	62	14	omz	omz	NOUN
dpc-2912	62	15	were	be	AUX
dpc-2912	62	16	diagnosed	diagnose	VERB
dpc-2912	62	17	with	with	ADP
dpc-2912	62	18	covid-19	covid-19	PROPN
dpc-2912	62	19	during	during	ADP
dpc-2912	62	20	omz	omz	ADJ
dpc-2912	62	21	treatment	treatment	NOUN
dpc-2912	62	22	.	.	PUNCT
dpc-2912	63	1	all	all	DET
dpc-2912	63	2	twelve	twelve	NUM
dpc-2912	63	3	patients	patient	NOUN
dpc-2912	63	4	(	(	PUNCT
dpc-2912	63	5	17.6	17.6	NUM
dpc-2912	63	6	%	%	NOUN
dpc-2912	63	7	)	)	PUNCT
dpc-2912	63	8	were	be	AUX
dpc-2912	63	9	diagnosed	diagnose	VERB
dpc-2912	63	10	with	with	ADP
dpc-2912	63	11	covid-19	covid-19	PROPN
dpc-2912	63	12	,	,	PUNCT
dpc-2912	63	13	confirmed	confirm	VERB
dpc-2912	63	14	by	by	ADP
dpc-2912	63	15	polymerase	polymerase	NOUN
dpc-2912	63	16	chain	chain	NOUN
dpc-2912	63	17	reaction	reaction	NOUN
dpc-2912	63	18	(	(	PUNCT
dpc-2912	63	19	pcr	pcr	NOUN
dpc-2912	63	20	)	)	PUNCT
dpc-2912	63	21	test	test	NOUN
dpc-2912	63	22	.	.	PUNCT
dpc-2912	64	1	none	none	NOUN
dpc-2912	64	2	of	of	ADP
dpc-2912	64	3	the	the	DET
dpc-2912	64	4	other	other	ADJ
dpc-2912	64	5	56	56	NUM
dpc-2912	64	6	patients	patient	NOUN
dpc-2912	64	7	had	have	VERB
dpc-2912	64	8	a	a	DET
dpc-2912	64	9	history	history	NOUN
dpc-2912	64	10	of	of	ADP
dpc-2912	64	11	covid-19	covid-19	PROPN
dpc-2912	64	12	before	before	ADP
dpc-2912	64	13	or	or	CCONJ
dpc-2912	64	14	during	during	ADP
dpc-2912	64	15	omz	omz	ADJ
dpc-2912	64	16	treatment	treatment	NOUN
dpc-2912	64	17	.	.	PUNCT
dpc-2912	65	1	all	all	DET
dpc-2912	65	2	patients	patient	NOUN
dpc-2912	65	3	had	have	VERB
dpc-2912	65	4	mild	mild	ADJ
dpc-2912	65	5	symptoms	symptom	NOUN
dpc-2912	65	6	during	during	ADP
dpc-2912	65	7	the	the	DET
dpc-2912	65	8	course	course	NOUN
dpc-2912	65	9	of	of	ADP
dpc-2912	65	10	the	the	DET
dpc-2912	65	11	disease	disease	NOUN
dpc-2912	65	12	and	and	CCONJ
dpc-2912	65	13	did	do	AUX
dpc-2912	65	14	not	not	PART
dpc-2912	65	15	require	require	VERB
dpc-2912	65	16	hospitalization	hospitalization	NOUN
dpc-2912	65	17	.	.	PUNCT
dpc-2912	66	1	furthermore	furthermore	ADV
dpc-2912	66	2	,	,	PUNCT
dpc-2912	66	3	no	no	DET
dpc-2912	66	4	urticaria	urticaria	NOUN
dpc-2912	66	5	activation	activation	NOUN
dpc-2912	66	6	was	be	AUX
dpc-2912	66	7	observed	observe	VERB
dpc-2912	66	8	in	in	ADP
dpc-2912	66	9	any	any	DET
dpc-2912	66	10	patients	patient	NOUN
dpc-2912	66	11	following	follow	VERB
dpc-2912	66	12	covid-19	covid-19	PROPN
dpc-2912	66	13	.	.	PUNCT
dpc-2912	67	1	the	the	DET
dpc-2912	67	2	uas7	uas7	PROPN
dpc-2912	67	3	score	score	NOUN
dpc-2912	67	4	was	be	AUX
dpc-2912	67	5	noted	note	VERB
dpc-2912	67	6	to	to	PART
dpc-2912	67	7	be	be	AUX
dpc-2912	67	8	zero	zero	NUM
dpc-2912	67	9	before	before	ADP
dpc-2912	67	10	and	and	CCONJ
dpc-2912	67	11	after	after	ADP
dpc-2912	67	12	covid-19	covid-19	PROPN
dpc-2912	67	13	.	.	PUNCT
dpc-2912	68	1	when	when	SCONJ
dpc-2912	68	2	the	the	DET
dpc-2912	68	3	patients	patient	NOUN
dpc-2912	68	4	with	with	ADP
dpc-2912	68	5	confirmed	confirm	VERB
dpc-2912	68	6	covid-19	covid-19	PROPN
dpc-2912	68	7	were	be	AUX
dpc-2912	68	8	compared	compare	VERB
dpc-2912	68	9	with	with	ADP
dpc-2912	68	10	those	those	PRON
dpc-2912	68	11	who	who	PRON
dpc-2912	68	12	did	do	AUX
dpc-2912	68	13	not	not	PART
dpc-2912	68	14	acquire	acquire	VERB
dpc-2912	68	15	the	the	DET
dpc-2912	68	16	infection	infection	NOUN
dpc-2912	68	17	,	,	PUNCT
dpc-2912	68	18	no	no	DET
dpc-2912	68	19	difference	difference	NOUN
dpc-2912	68	20	was	be	AUX
dpc-2912	68	21	detected	detect	VERB
dpc-2912	68	22	regarding	regard	VERB
dpc-2912	68	23	gender	gender	NOUN
dpc-2912	68	24	,	,	PUNCT
dpc-2912	68	25	age	age	NOUN
dpc-2912	68	26	,	,	PUNCT
dpc-2912	68	27	comorbidities	comorbiditie	NOUN
dpc-2912	68	28	,	,	PUNCT
dpc-2912	68	29	covid-19	covid-19	PROPN
dpc-2912	68	30	vaccination	vaccination	NOUN
dpc-2912	68	31	status	status	NOUN
dpc-2912	68	32	,	,	PUNCT
dpc-2912	68	33	pre	pre	ADJ
dpc-2912	68	34	-	-	NOUN
dpc-2912	68	35	treatment	treatment	ADJ
dpc-2912	68	36	ig	ig	PROPN
dpc-2912	68	37	e	e	PROPN
dpc-2912	68	38	levels	level	NOUN
dpc-2912	68	39	,	,	PUNCT
dpc-2912	68	40	pre	pre	ADJ
dpc-2912	68	41	-	-	ADJ
dpc-2912	68	42	treatment	treatment	ADJ
dpc-2912	68	43	eosinophilia	eosinophilia	NOUN
dpc-2912	68	44	,	,	PUNCT
dpc-2912	68	45	and	and	CCONJ
dpc-2912	68	46	treatment	treatment	NOUN
dpc-2912	68	47	regimens	regimen	NOUN
dpc-2912	68	48	utilized	utilize	VERB
dpc-2912	68	49	for	for	ADP
dpc-2912	68	50	csu	csu	PROPN
dpc-2912	68	51	.	.	PUNCT
dpc-2912	69	1	in	in	ADP
dpc-2912	69	2	four	four	NUM
dpc-2912	69	3	of	of	ADP
dpc-2912	69	4	12	12	NUM
dpc-2912	69	5	patients	patient	NOUN
dpc-2912	69	6	,	,	PUNCT
dpc-2912	69	7	the	the	DET
dpc-2912	69	8	total	total	ADJ
dpc-2912	69	9	ige	ige	PROPN
dpc-2912	69	10	level	level	NOUN
dpc-2912	69	11	prior	prior	ADV
dpc-2912	69	12	to	to	ADP
dpc-2912	69	13	omz	omz	ADJ
dpc-2912	69	14	treatment	treatment	NOUN
dpc-2912	69	15	was	be	AUX
dpc-2912	69	16	below	below	ADP
dpc-2912	69	17	110	110	NUM
dpc-2912	69	18	  	  	SPACE
dpc-2912	69	19	ku	ku	PROPN
dpc-2912	69	20	/	/	SYM
dpc-2912	69	21	l.	l.	PROPN
dpc-2912	69	22	on	on	ADP
dpc-2912	69	23	the	the	DET
dpc-2912	69	24	other	other	ADJ
dpc-2912	69	25	hand	hand	NOUN
dpc-2912	69	26	,	,	PUNCT
dpc-2912	69	27	the	the	DET
dpc-2912	69	28	duration	duration	NOUN
dpc-2912	69	29	of	of	ADP
dpc-2912	69	30	omz	omz	ADJ
dpc-2912	69	31	treatment	treatment	NOUN
dpc-2912	69	32	was	be	AUX
dpc-2912	69	33	significantly	significantly	ADV
dpc-2912	69	34	higher	high	ADJ
dpc-2912	69	35	in	in	ADP
dpc-2912	69	36	the	the	DET
dpc-2912	69	37	group	group	NOUN
dpc-2912	69	38	with	with	ADP
dpc-2912	69	39	covid-19	covid-19	PROPN
dpc-2912	69	40	infection	infection	NOUN
dpc-2912	69	41	history	history	NOUN
dpc-2912	69	42	(	(	PUNCT
dpc-2912	69	43	p	p	X
dpc-2912	69	44	=	=	NOUN
dpc-2912	69	45	0.01	0.01	NUM
dpc-2912	69	46	)	)	PUNCT
dpc-2912	69	47	(	(	PUNCT
dpc-2912	69	48	table	table	NOUN
dpc-2912	69	49	2	2	NUM
dpc-2912	69	50	)	)	PUNCT
dpc-2912	69	51	.	.	PUNCT
dpc-2912	70	1	fifty	fifty	NUM
dpc-2912	70	2	-	-	PUNCT
dpc-2912	70	3	one	one	NUM
dpc-2912	70	4	(	(	PUNCT
dpc-2912	70	5	75	75	NUM
dpc-2912	70	6	%	%	NOUN
dpc-2912	70	7	)	)	PUNCT
dpc-2912	70	8	patients	patient	NOUN
dpc-2912	70	9	had	have	AUX
dpc-2912	70	10	been	be	AUX
dpc-2912	70	11	vaccinated	vaccinate	VERB
dpc-2912	70	12	against	against	ADP
dpc-2912	70	13	covid-19	covid-19	PROPN
dpc-2912	70	14	while	while	SCONJ
dpc-2912	70	15	using	use	VERB
dpc-2912	70	16	omz	omz	PROPN
dpc-2912	70	17	.	.	PUNCT
dpc-2912	71	1	urticaria	urticaria	ADJ
dpc-2912	71	2	activation	activation	NOUN
dpc-2912	71	3	following	follow	VERB
dpc-2912	71	4	vaccination	vaccination	NOUN
dpc-2912	71	5	occurred	occur	VERB
dpc-2912	71	6	in	in	ADP
dpc-2912	71	7	four	four	NUM
dpc-2912	71	8	patients	patient	NOUN
dpc-2912	71	9	:	:	PUNCT
dpc-2912	71	10	one	one	NUM
dpc-2912	71	11	patient	patient	NOUN
dpc-2912	71	12	who	who	PRON
dpc-2912	71	13	had	have	AUX
dpc-2912	71	14	received	receive	VERB
dpc-2912	71	15	inactivated	inactivated	ADJ
dpc-2912	71	16	vaccine	vaccine	NOUN
dpc-2912	71	17	(	(	PUNCT
dpc-2912	71	18	sinovac	sinovac	PROPN
dpc-2912	71	19	®	®	PROPN
dpc-2912	71	20	)	)	PUNCT
dpc-2912	71	21	and	and	CCONJ
dpc-2912	71	22	three	three	NUM
dpc-2912	71	23	patients	patient	NOUN
dpc-2912	71	24	who	who	PRON
dpc-2912	71	25	had	have	AUX
dpc-2912	71	26	received	receive	VERB
dpc-2912	71	27	the	the	DET
dpc-2912	71	28	mrna	mrna	PROPN
dpc-2912	71	29	vaccine	vaccine	NOUN
dpc-2912	71	30	(	(	PUNCT
dpc-2912	71	31	biontech	biontech	PROPN
dpc-2912	71	32	®	®	PROPN
dpc-2912	71	33	)	)	PUNCT
dpc-2912	71	34	.	.	PUNCT
dpc-2912	72	1	activation	activation	NOUN
dpc-2912	72	2	developed	develop	VERB
dpc-2912	72	3	in	in	ADP
dpc-2912	72	4	all	all	DET
dpc-2912	72	5	patients	patient	NOUN
dpc-2912	72	6	after	after	ADP
dpc-2912	72	7	the	the	DET
dpc-2912	72	8	first	first	ADJ
dpc-2912	72	9	dose	dose	NOUN
dpc-2912	72	10	of	of	ADP
dpc-2912	72	11	vaccination	vaccination	NOUN
dpc-2912	72	12	and	and	CCONJ
dpc-2912	72	13	within	within	ADP
dpc-2912	72	14	an	an	DET
dpc-2912	72	15	average	average	NOUN
dpc-2912	72	16	of	of	ADP
dpc-2912	72	17	two	two	NUM
dpc-2912	72	18	days	day	NOUN
dpc-2912	72	19	.	.	PUNCT
dpc-2912	73	1	the	the	DET
dpc-2912	73	2	urticaria	urticaria	NOUN
dpc-2912	73	3	symptoms	symptom	NOUN
dpc-2912	73	4	subsided	subside	VERB
dpc-2912	73	5	rapidly	rapidly	ADV
dpc-2912	73	6	in	in	ADP
dpc-2912	73	7	all	all	DET
dpc-2912	73	8	patients	patient	NOUN
dpc-2912	73	9	with	with	ADP
dpc-2912	73	10	the	the	DET
dpc-2912	73	11	administration	administration	NOUN
dpc-2912	73	12	of	of	ADP
dpc-2912	73	13	oral	oral	ADJ
dpc-2912	73	14	antihistamine	antihistamine	PROPN
dpc-2912	73	15	treatment	treatment	NOUN
dpc-2912	73	16	(	(	PUNCT
dpc-2912	73	17	levocetirizine	levocetirizine	ADJ
dpc-2912	73	18	bid	bid	NOUN
dpc-2912	73	19	)	)	PUNCT
dpc-2912	73	20	.	.	PUNCT
dpc-2912	74	1	no	no	DET
dpc-2912	74	2	recurrence	recurrence	NOUN
dpc-2912	74	3	was	be	AUX
dpc-2912	74	4	observed	observe	VERB
dpc-2912	74	5	following	follow	VERB
dpc-2912	74	6	booster	booster	NOUN
dpc-2912	74	7	vaccinations	vaccination	NOUN
dpc-2912	74	8	in	in	ADP
dpc-2912	74	9	any	any	PRON
dpc-2912	74	10	of	of	ADP
dpc-2912	74	11	the	the	DET
dpc-2912	74	12	patients	patient	NOUN
dpc-2912	74	13	.	.	PUNCT
dpc-2912	75	1	conclusions	conclusion	NOUN
dpc-2912	75	2	severe	severe	ADJ
dpc-2912	75	3	acute	acute	NOUN
dpc-2912	75	4	 	 	SPACE
dpc-2912	75	5	respiratory	respiratory	ADJ
dpc-2912	75	6	syndrome	syndrome	NOUN
dpc-2912	75	7	coronavirus	coronavirus	NOUN
dpc-2912	75	8	2	2	NUM
dpc-2912	75	9	 	 	SPACE
dpc-2912	75	10	(	(	PUNCT
dpc-2912	75	11	sarscov-2	sarscov-2	NUM
dpc-2912	75	12	)	)	PUNCT
dpc-2912	75	13	has	have	VERB
dpc-2912	75	14	direct	direct	ADJ
dpc-2912	75	15	and	and	CCONJ
dpc-2912	75	16	indirect	indirect	ADJ
dpc-2912	75	17	impacts	impact	NOUN
dpc-2912	75	18	on	on	ADP
dpc-2912	75	19	the	the	DET
dpc-2912	75	20	immune	immune	ADJ
dpc-2912	75	21	system	system	NOUN
dpc-2912	75	22	.	.	PUNCT
dpc-2912	76	1	table	table	NOUN
dpc-2912	76	2	1	1	NUM
dpc-2912	76	3	.	.	PUNCT
dpc-2912	76	4	demographic	demographic	ADJ
dpc-2912	76	5	and	and	CCONJ
dpc-2912	76	6	clinical	clinical	ADJ
dpc-2912	76	7	characteristics	characteristic	NOUN
dpc-2912	76	8	of	of	ADP
dpc-2912	76	9	the	the	DET
dpc-2912	76	10	chronic	chronic	ADJ
dpc-2912	76	11	spontaneous	spontaneous	ADJ
dpc-2912	76	12	urticaria	urticaria	NOUN
dpc-2912	76	13	patients	patient	NOUN
dpc-2912	76	14	using	use	VERB
dpc-2912	76	15	omalizumab	omalizumab	NOUN
dpc-2912	76	16	treatment	treatment	NOUN
dpc-2912	76	17	.	.	PUNCT
dpc-2912	77	1	characteristics	characteristic	NOUN
dpc-2912	77	2	number	number	NOUN
dpc-2912	77	3	of	of	ADP
dpc-2912	77	4	patients	patient	NOUN
dpc-2912	77	5	,	,	PUNCT
dpc-2912	77	6	n	n	CCONJ
dpc-2912	77	7	(	(	PUNCT
dpc-2912	77	8	%	%	INTJ
dpc-2912	77	9	)	)	PUNCT
dpc-2912	77	10	68	68	NUM
dpc-2912	77	11	(	(	PUNCT
dpc-2912	77	12	100	100	NUM
dpc-2912	77	13	%	%	NOUN
dpc-2912	77	14	)	)	PUNCT
dpc-2912	77	15	gender	gender	NOUN
dpc-2912	77	16	,	,	PUNCT
dpc-2912	77	17	n	n	CCONJ
dpc-2912	77	18	(	(	PUNCT
dpc-2912	77	19	%	%	INTJ
dpc-2912	77	20	)	)	PUNCT
dpc-2912	77	21	female	female	NOUN
dpc-2912	77	22	44	44	NUM
dpc-2912	77	23	(	(	PUNCT
dpc-2912	77	24	64.7	64.7	NUM
dpc-2912	77	25	)	)	PUNCT
dpc-2912	77	26	age	age	NOUN
dpc-2912	77	27	(	(	PUNCT
dpc-2912	77	28	years	year	NOUN
dpc-2912	77	29	)	)	PUNCT
dpc-2912	77	30	,	,	PUNCT
dpc-2912	77	31	mean	mean	VERB
dpc-2912	77	32	±sd	±sd	NOUN
dpc-2912	77	33	47.2±15.1	47.2±15.1	NUM
dpc-2912	77	34	comorbidities	comorbiditie	VERB
dpc-2912	77	35	hypothyroidism	hypothyroidism	NOUN
dpc-2912	77	36	hypertension	hypertension	NOUN
dpc-2912	77	37	depression	depression	NOUN
dpc-2912	77	38	4	4	NUM
dpc-2912	77	39	(	(	PUNCT
dpc-2912	77	40	5.8	5.8	NUM
dpc-2912	77	41	)	)	PUNCT
dpc-2912	77	42	2	2	NUM
dpc-2912	77	43	(	(	PUNCT
dpc-2912	77	44	2.9	2.9	NUM
dpc-2912	77	45	)	)	SYM
dpc-2912	77	46	1	1	NUM
dpc-2912	77	47	(	(	PUNCT
dpc-2912	77	48	1.5	1.5	NUM
dpc-2912	77	49	)	)	SYM
dpc-2912	77	50	1	1	NUM
dpc-2912	77	51	(	(	PUNCT
dpc-2912	77	52	1.5	1.5	NUM
dpc-2912	77	53	)	)	PUNCT
dpc-2912	77	54	oral	oral	ADJ
dpc-2912	77	55	h1	h1	PROPN
dpc-2912	77	56	antihistamine	antihistamine	NOUN
dpc-2912	77	57	therapy	therapy	NOUN
dpc-2912	77	58	,	,	PUNCT
dpc-2912	77	59	n	n	PROPN
dpc-2912	77	60	(	(	PUNCT
dpc-2912	77	61	%	%	INTJ
dpc-2912	77	62	)	)	PUNCT
dpc-2912	77	63	levocetirizine	levocetirizine	ADJ
dpc-2912	77	64	ebastine	ebastine	PROPN
dpc-2912	77	65	hydroxyzine	hydroxyzine	PROPN
dpc-2912	77	66	bilastine	bilastine	PROPN
dpc-2912	77	67	rupatadine	rupatadine	PROPN
dpc-2912	77	68	fexofenadine	fexofenadine	PROPN
dpc-2912	77	69	24	24	NUM
dpc-2912	77	70	(	(	PUNCT
dpc-2912	77	71	35.3	35.3	NUM
dpc-2912	77	72	)	)	PUNCT
dpc-2912	77	73	17	17	NUM
dpc-2912	77	74	(	(	PUNCT
dpc-2912	77	75	25	25	NUM
dpc-2912	77	76	)	)	SYM
dpc-2912	77	77	2	2	NUM
dpc-2912	77	78	(	(	PUNCT
dpc-2912	77	79	2.9	2.9	NUM
dpc-2912	77	80	)	)	SYM
dpc-2912	77	81	2	2	NUM
dpc-2912	77	82	(	(	PUNCT
dpc-2912	77	83	2.9	2.9	NUM
dpc-2912	77	84	)	)	SYM
dpc-2912	77	85	1	1	NUM
dpc-2912	77	86	(	(	PUNCT
dpc-2912	77	87	1.59	1.59	NUM
dpc-2912	77	88	1	1	NUM
dpc-2912	77	89	(	(	PUNCT
dpc-2912	77	90	1.5	1.5	NUM
dpc-2912	77	91	)	)	SYM
dpc-2912	77	92	1	1	NUM
dpc-2912	77	93	(	(	PUNCT
dpc-2912	77	94	1.5	1.5	NUM
dpc-2912	77	95	)	)	PUNCT
dpc-2912	77	96	vaccination	vaccination	NOUN
dpc-2912	77	97	status	status	NOUN
dpc-2912	77	98	,	,	PUNCT
dpc-2912	77	99	n	n	PROPN
dpc-2912	77	100	(	(	PUNCT
dpc-2912	77	101	%	%	INTJ
dpc-2912	77	102	)	)	PUNCT
dpc-2912	78	1	no	no	DET
dpc-2912	78	2	vaccination	vaccination	NOUN
dpc-2912	78	3	inactivated	inactivate	VERB
dpc-2912	78	4	vaccinea	vaccinea	NOUN
dpc-2912	78	5	mrna	mrna	PROPN
dpc-2912	78	6	vaccineb	vaccineb	PROPN
dpc-2912	78	7	inactivated	inactivate	VERB
dpc-2912	78	8	vaccinea+mrnavaccineb	vaccinea+mrnavaccineb	PROPN
dpc-2912	78	9	10	10	NUM
dpc-2912	78	10	(	(	PUNCT
dpc-2912	78	11	14.7	14.7	NUM
dpc-2912	78	12	)	)	PUNCT
dpc-2912	78	13	27	27	NUM
dpc-2912	78	14	(	(	PUNCT
dpc-2912	78	15	39.7	39.7	NUM
dpc-2912	78	16	)	)	SYM
dpc-2912	78	17	19	19	NUM
dpc-2912	78	18	(	(	PUNCT
dpc-2912	78	19	27.9	27.9	NUM
dpc-2912	78	20	)	)	PUNCT
dpc-2912	78	21	12	12	NUM
dpc-2912	78	22	(	(	PUNCT
dpc-2912	78	23	17.6	17.6	NUM
dpc-2912	78	24	)	)	PUNCT
dpc-2912	78	25	presence	presence	NOUN
dpc-2912	78	26	of	of	ADP
dpc-2912	78	27	angioedema	angioedema	NOUN
dpc-2912	78	28	,	,	PUNCT
dpc-2912	78	29	n	n	PROPN
dpc-2912	78	30	(	(	PUNCT
dpc-2912	78	31	%	%	INTJ
dpc-2912	78	32	)	)	PUNCT
dpc-2912	78	33	25	25	NUM
dpc-2912	78	34	(	(	PUNCT
dpc-2912	78	35	36.8	36.8	NUM
dpc-2912	78	36	)	)	PUNCT
dpc-2912	78	37	total	total	NOUN
dpc-2912	78	38	ige	ige	PROPN
dpc-2912	78	39	prior	prior	ADV
dpc-2912	78	40	to	to	ADP
dpc-2912	78	41	omz	omz	NOUN
dpc-2912	78	42	treatment(ku	treatment(ku	PROPN
dpc-2912	78	43	/	/	SYM
dpc-2912	78	44	l	l	NOUN
dpc-2912	78	45	)	)	PUNCT
dpc-2912	78	46	,	,	PUNCT
dpc-2912	78	47	median	median	NOUN
dpc-2912	78	48	(	(	PUNCT
dpc-2912	78	49	range	range	NOUN
dpc-2912	78	50	)	)	PUNCT
dpc-2912	78	51	281	281	NUM
dpc-2912	78	52	(	(	PUNCT
dpc-2912	78	53	2	2	NUM
dpc-2912	78	54	-	-	SYM
dpc-2912	78	55	2730	2730	NUM
dpc-2912	78	56	)	)	PUNCT
dpc-2912	78	57	presence	presence	NOUN
dpc-2912	78	58	of	of	ADP
dpc-2912	78	59	eosinophilia	eosinophilia	PROPN
dpc-2912	78	60	prior	prior	ADV
dpc-2912	78	61	to	to	ADP
dpc-2912	78	62	omz	omz	ADJ
dpc-2912	78	63	treatment	treatment	NOUN
dpc-2912	78	64	,	,	PUNCT
dpc-2912	78	65	n	n	CCONJ
dpc-2912	78	66	(	(	PUNCT
dpc-2912	78	67	%	%	INTJ
dpc-2912	78	68	)	)	PUNCT
dpc-2912	78	69	6	6	NUM
dpc-2912	78	70	(	(	PUNCT
dpc-2912	78	71	9	9	NUM
dpc-2912	78	72	)	)	PUNCT
dpc-2912	78	73	omz	omz	ADJ
dpc-2912	78	74	treatment	treatment	NOUN
dpc-2912	78	75	duration	duration	NOUN
dpc-2912	78	76	(	(	PUNCT
dpc-2912	78	77	month	month	NOUN
dpc-2912	78	78	)	)	PUNCT
dpc-2912	78	79	,	,	PUNCT
dpc-2912	78	80	median	median	NOUN
dpc-2912	78	81	(	(	PUNCT
dpc-2912	78	82	range	range	NOUN
dpc-2912	78	83	)	)	PUNCT
dpc-2912	78	84	12	12	NUM
dpc-2912	78	85	(	(	PUNCT
dpc-2912	78	86	6	6	NUM
dpc-2912	78	87	-	-	SYM
dpc-2912	78	88	60	60	NUM
dpc-2912	78	89	)	)	PUNCT
dpc-2912	78	90	dosing	dose	VERB
dpc-2912	78	91	regimen	regiman	NOUN
dpc-2912	78	92	of	of	ADP
dpc-2912	78	93	omz	omz	PROPN
dpc-2912	78	94	,	,	PUNCT
dpc-2912	78	95	n	n	CCONJ
dpc-2912	78	96	(	(	PUNCT
dpc-2912	78	97	%	%	INTJ
dpc-2912	78	98	)	)	PUNCT
dpc-2912	78	99	300	300	NUM
dpc-2912	78	100	mg	mg	NOUN
dpc-2912	78	101	every	every	DET
dpc-2912	78	102	4	4	NUM
dpc-2912	78	103	weeks	week	NOUN
dpc-2912	78	104	300	300	NUM
dpc-2912	78	105	mg	mg	NOUN
dpc-2912	78	106	every	every	DET
dpc-2912	78	107	2	2	NUM
dpc-2912	78	108	weeks	week	NOUN
dpc-2912	78	109	66	66	NUM
dpc-2912	78	110	(	(	PUNCT
dpc-2912	78	111	97.1	97.1	NUM
dpc-2912	78	112	)	)	SYM
dpc-2912	78	113	2	2	NUM
dpc-2912	78	114	(	(	PUNCT
dpc-2912	78	115	2.9	2.9	NUM
dpc-2912	78	116	)	)	PUNCT
dpc-2912	78	117	omz	omz	ADJ
dpc-2912	78	118	=	=	PUNCT
dpc-2912	78	119	omalizumab	omalizumab	NOUN
dpc-2912	78	120	;	;	PUNCT
dpc-2912	78	121	sd	sd	NOUN
dpc-2912	78	122	=	=	SYM
dpc-2912	78	123	standard	standard	ADJ
dpc-2912	78	124	deviation	deviation	NOUN
dpc-2912	78	125	.	.	PUNCT
dpc-2912	79	1	ainactivated	ainactivate	VERB
dpc-2912	79	2	vaccine	vaccine	NOUN
dpc-2912	79	3	produced	produce	VERB
dpc-2912	79	4	by	by	ADP
dpc-2912	79	5	sinovacbiotech	sinovacbiotech	PROPN
dpc-2912	79	6	®	®	PROPN
dpc-2912	79	7	.	.	PUNCT
dpc-2912	80	1	bmrna	bmrna	NOUN
dpc-2912	80	2	vaccine	vaccine	NOUN
dpc-2912	80	3	produced	produce	VERB
dpc-2912	80	4	by	by	ADP
dpc-2912	80	5	pfizer	pfizer	NOUN
dpc-2912	80	6	/	/	SYM
dpc-2912	80	7	biontech	biontech	PROPN
dpc-2912	80	8	®	®	NOUN
dpc-2912	80	9	.	.	PUNCT
dpc-2912	81	1	4	4	NUM
dpc-2912	81	2	original	original	ADJ
dpc-2912	81	3	article	article	NOUN
dpc-2912	81	4	|	|	ADV
dpc-2912	81	5	dermatol	dermatol	ADJ
dpc-2912	81	6	pract	pract	NOUN
dpc-2912	81	7	concept	concept	NOUN
dpc-2912	81	8	.	.	PUNCT
dpc-2912	82	1	2023;13(3):e2023145	2023;13(3):e2023145	NUM
dpc-2912	83	1	the	the	DET
dpc-2912	83	2	level	level	NOUN
dpc-2912	83	3	of	of	ADP
dpc-2912	83	4	ige	ige	PROPN
dpc-2912	83	5	and	and	CCONJ
dpc-2912	83	6	fcεris	fcεris	PROPN
dpc-2912	84	1	[	[	X
dpc-2912	84	2	8	8	NUM
dpc-2912	84	3	-	-	SYM
dpc-2912	84	4	10	10	NUM
dpc-2912	84	5	]	]	PUNCT
dpc-2912	84	6	.	.	PUNCT
dpc-2912	85	1	moreover	moreover	ADV
dpc-2912	85	2	,	,	PUNCT
dpc-2912	85	3	omz	omz	NOUN
dpc-2912	85	4	has	have	AUX
dpc-2912	85	5	been	be	AUX
dpc-2912	85	6	demonstrated	demonstrate	VERB
dpc-2912	85	7	to	to	PART
dpc-2912	85	8	improve	improve	VERB
dpc-2912	85	9	nasal	nasal	ADJ
dpc-2912	85	10	sinus	sinus	NOUN
dpc-2912	85	11	function	function	NOUN
dpc-2912	85	12	,	,	PUNCT
dpc-2912	85	13	which	which	PRON
dpc-2912	85	14	has	have	VERB
dpc-2912	85	15	a	a	DET
dpc-2912	85	16	significant	significant	ADJ
dpc-2912	85	17	role	role	NOUN
dpc-2912	85	18	in	in	ADP
dpc-2912	85	19	the	the	DET
dpc-2912	85	20	first	first	ADJ
dpc-2912	85	21	line	line	NOUN
dpc-2912	85	22	of	of	ADP
dpc-2912	85	23	defense	defense	NOUN
dpc-2912	85	24	against	against	ADP
dpc-2912	85	25	sarscov-2	sarscov-2	PROPN
dpc-2912	86	1	[	[	X
dpc-2912	86	2	11,12	11,12	NOUN
dpc-2912	86	3	]	]	PUNCT
dpc-2912	86	4	.	.	PUNCT
dpc-2912	87	1	hence	hence	ADV
dpc-2912	87	2	,	,	PUNCT
dpc-2912	87	3	patients	patient	NOUN
dpc-2912	87	4	using	use	VERB
dpc-2912	87	5	omz	omz	NOUN
dpc-2912	87	6	might	might	AUX
dpc-2912	87	7	benefit	benefit	VERB
dpc-2912	87	8	from	from	ADP
dpc-2912	87	9	the	the	DET
dpc-2912	87	10	treatment	treatment	NOUN
dpc-2912	87	11	during	during	ADP
dpc-2912	87	12	the	the	DET
dpc-2912	87	13	initial	initial	ADJ
dpc-2912	87	14	phase	phase	NOUN
dpc-2912	87	15	of	of	ADP
dpc-2912	87	16	covid-19	covid-19	PROPN
dpc-2912	87	17	,	,	PUNCT
dpc-2912	87	18	and	and	CCONJ
dpc-2912	87	19	some	some	DET
dpc-2912	87	20	studies	study	NOUN
dpc-2912	87	21	highlighted	highlight	VERB
dpc-2912	87	22	that	that	SCONJ
dpc-2912	87	23	omz	omz	NOUN
dpc-2912	87	24	might	might	AUX
dpc-2912	87	25	be	be	AUX
dpc-2912	87	26	a	a	DET
dpc-2912	87	27	preferable	preferable	ADJ
dpc-2912	87	28	treatment	treatment	NOUN
dpc-2912	87	29	option	option	NOUN
dpc-2912	87	30	for	for	ADP
dpc-2912	87	31	covid-19	covid-19	PROPN
dpc-2912	88	1	[	[	X
dpc-2912	88	2	12,13	12,13	NUM
dpc-2912	88	3	]	]	PUNCT
dpc-2912	88	4	.	.	PUNCT
dpc-2912	89	1	omz	omz	PROPN
dpc-2912	89	2	also	also	ADV
dpc-2912	89	3	lessens	lessen	VERB
dpc-2912	89	4	the	the	DET
dpc-2912	89	5	disease	disease	NOUN
dpc-2912	89	6	severity	severity	NOUN
dpc-2912	89	7	by	by	ADP
dpc-2912	89	8	reducing	reduce	VERB
dpc-2912	89	9	fcεris	fcεris	PROPN
dpc-2912	89	10	on	on	ADP
dpc-2912	89	11	the	the	DET
dpc-2912	89	12	surface	surface	NOUN
dpc-2912	89	13	of	of	ADP
dpc-2912	89	14	mast	mast	NOUN
dpc-2912	89	15	cells	cell	NOUN
dpc-2912	89	16	,	,	PUNCT
dpc-2912	89	17	which	which	PRON
dpc-2912	89	18	play	play	VERB
dpc-2912	89	19	a	a	DET
dpc-2912	89	20	key	key	ADJ
dpc-2912	89	21	role	role	NOUN
dpc-2912	89	22	in	in	ADP
dpc-2912	89	23	the	the	DET
dpc-2912	89	24	inflammatory	inflammatory	ADJ
dpc-2912	89	25	response	response	NOUN
dpc-2912	89	26	during	during	ADP
dpc-2912	89	27	the	the	DET
dpc-2912	89	28	second	second	ADJ
dpc-2912	89	29	and	and	CCONJ
dpc-2912	89	30	third	third	ADJ
dpc-2912	89	31	phases	phase	NOUN
dpc-2912	89	32	of	of	ADP
dpc-2912	89	33	covid-19	covid-19	PROPN
dpc-2912	89	34	and	and	CCONJ
dpc-2912	89	35	the	the	DET
dpc-2912	89	36	prolonged	prolonged	ADJ
dpc-2912	89	37	covid-19	covid-19	PROPN
dpc-2912	89	38	symptoms	symptom	NOUN
dpc-2912	89	39	referred	refer	VERB
dpc-2912	89	40	to	to	ADP
dpc-2912	89	41	as	as	ADP
dpc-2912	89	42	“	"	PUNCT
dpc-2912	89	43	long	long	ADJ
dpc-2912	89	44	-	-	PUNCT
dpc-2912	89	45	covid	covid	NOUN
dpc-2912	89	46	”	"	PUNCT
dpc-2912	90	1	[	[	X
dpc-2912	90	2	12	12	NUM
dpc-2912	90	3	-	-	SYM
dpc-2912	90	4	14	14	NUM
dpc-2912	90	5	]	]	PUNCT
dpc-2912	90	6	.	.	PUNCT
dpc-2912	91	1	in	in	ADP
dpc-2912	91	2	our	our	PRON
dpc-2912	91	3	study	study	NOUN
dpc-2912	91	4	,	,	PUNCT
dpc-2912	91	5	among	among	ADP
dpc-2912	91	6	68	68	NUM
dpc-2912	91	7	patients	patient	NOUN
dpc-2912	91	8	using	use	VERB
dpc-2912	91	9	omz	omz	NOUN
dpc-2912	91	10	during	during	ADP
dpc-2912	91	11	the	the	DET
dpc-2912	91	12	covid-19	covid-19	PROPN
dpc-2912	91	13	pandemic	pandemic	NOUN
dpc-2912	91	14	,	,	PUNCT
dpc-2912	91	15	twelve	twelve	NUM
dpc-2912	91	16	contracted	contract	VERB
dpc-2912	91	17	the	the	DET
dpc-2912	91	18	sars	sar	NOUN
dpc-2912	91	19	-	-	PUNCT
dpc-2912	91	20	cov-2	cov-2	NOUN
dpc-2912	91	21	infection	infection	NOUN
dpc-2912	91	22	.	.	PUNCT
dpc-2912	92	1	all	all	DET
dpc-2912	92	2	patients	patient	NOUN
dpc-2912	92	3	recovered	recover	VERB
dpc-2912	92	4	without	without	ADP
dpc-2912	92	5	progressing	progress	VERB
dpc-2912	92	6	to	to	ADP
dpc-2912	92	7	the	the	DET
dpc-2912	92	8	second	second	ADJ
dpc-2912	92	9	pulmonary	pulmonary	ADJ
dpc-2912	92	10	phase	phase	NOUN
dpc-2912	92	11	.	.	PUNCT
dpc-2912	93	1	apart	apart	ADV
dpc-2912	93	2	from	from	ADP
dpc-2912	93	3	these	these	DET
dpc-2912	93	4	twelve	twelve	NUM
dpc-2912	93	5	patients	patient	NOUN
dpc-2912	93	6	whose	whose	DET
dpc-2912	93	7	diagnoses	diagnosis	NOUN
dpc-2912	93	8	were	be	AUX
dpc-2912	93	9	established	establish	VERB
dpc-2912	93	10	with	with	ADP
dpc-2912	93	11	a	a	DET
dpc-2912	93	12	positive	positive	ADJ
dpc-2912	93	13	pcr	pcr	ADJ
dpc-2912	93	14	test	test	NOUN
dpc-2912	93	15	,	,	PUNCT
dpc-2912	93	16	there	there	PRON
dpc-2912	93	17	might	might	AUX
dpc-2912	93	18	be	be	AUX
dpc-2912	93	19	asymptomatic	asymptomatic	ADJ
dpc-2912	93	20	and	and	CCONJ
dpc-2912	93	21	underdiagnosed	underdiagnosed	ADJ
dpc-2912	93	22	patients	patient	NOUN
dpc-2912	93	23	.	.	PUNCT
dpc-2912	94	1	the	the	DET
dpc-2912	94	2	duration	duration	NOUN
dpc-2912	94	3	of	of	ADP
dpc-2912	94	4	omz	omz	ADJ
dpc-2912	94	5	treatment	treatment	NOUN
dpc-2912	94	6	was	be	AUX
dpc-2912	94	7	significantly	significantly	ADV
dpc-2912	94	8	longer	long	ADJ
dpc-2912	94	9	in	in	ADP
dpc-2912	94	10	the	the	DET
dpc-2912	94	11	patient	patient	ADJ
dpc-2912	94	12	group	group	NOUN
dpc-2912	94	13	with	with	ADP
dpc-2912	94	14	a	a	DET
dpc-2912	94	15	history	history	NOUN
dpc-2912	94	16	of	of	ADP
dpc-2912	94	17	covid-19	covid-19	PROPN
dpc-2912	94	18	compared	compare	VERB
dpc-2912	94	19	to	to	ADP
dpc-2912	94	20	patients	patient	NOUN
dpc-2912	94	21	who	who	PRON
dpc-2912	94	22	did	do	AUX
dpc-2912	94	23	not	not	PART
dpc-2912	94	24	acquire	acquire	VERB
dpc-2912	94	25	the	the	DET
dpc-2912	94	26	infection	infection	NOUN
dpc-2912	94	27	in	in	ADP
dpc-2912	94	28	our	our	PRON
dpc-2912	94	29	series	series	NOUN
dpc-2912	94	30	,	,	PUNCT
dpc-2912	94	31	although	although	SCONJ
dpc-2912	94	32	there	there	PRON
dpc-2912	94	33	was	be	VERB
dpc-2912	94	34	no	no	DET
dpc-2912	94	35	difference	difference	NOUN
dpc-2912	94	36	between	between	ADP
dpc-2912	94	37	the	the	DET
dpc-2912	94	38	two	two	NUM
dpc-2912	94	39	groups	group	NOUN
dpc-2912	94	40	in	in	ADP
dpc-2912	94	41	terms	term	NOUN
dpc-2912	94	42	of	of	ADP
dpc-2912	94	43	covid-19	covid-19	PROPN
dpc-2912	94	44	vaccination	vaccination	NOUN
dpc-2912	94	45	status	status	NOUN
dpc-2912	94	46	.	.	PUNCT
dpc-2912	95	1	this	this	PRON
dpc-2912	95	2	might	might	AUX
dpc-2912	95	3	the	the	DET
dpc-2912	95	4	virus	virus	NOUN
dpc-2912	95	5	is	be	AUX
dpc-2912	95	6	considered	consider	VERB
dpc-2912	95	7	to	to	PART
dpc-2912	95	8	cause	cause	VERB
dpc-2912	95	9	a	a	DET
dpc-2912	95	10	three	three	NUM
dpc-2912	95	11	-	-	PUNCT
dpc-2912	95	12	phase	phase	NOUN
dpc-2912	95	13	disease	disease	NOUN
dpc-2912	95	14	.	.	PUNCT
dpc-2912	96	1	the	the	DET
dpc-2912	96	2	initial	initial	ADJ
dpc-2912	96	3	phase	phase	NOUN
dpc-2912	96	4	begins	begin	VERB
dpc-2912	96	5	with	with	ADP
dpc-2912	96	6	the	the	DET
dpc-2912	96	7	entry	entry	NOUN
dpc-2912	96	8	of	of	ADP
dpc-2912	96	9	the	the	DET
dpc-2912	96	10	virus	virus	NOUN
dpc-2912	96	11	into	into	ADP
dpc-2912	96	12	the	the	DET
dpc-2912	96	13	host	host	NOUN
dpc-2912	96	14	and	and	CCONJ
dpc-2912	96	15	lasts	last	VERB
dpc-2912	96	16	about	about	ADV
dpc-2912	96	17	5	5	NUM
dpc-2912	96	18	-	-	SYM
dpc-2912	96	19	7	7	NUM
dpc-2912	96	20	days	day	NOUN
dpc-2912	96	21	.	.	PUNCT
dpc-2912	97	1	the	the	DET
dpc-2912	97	2	second	second	ADJ
dpc-2912	97	3	phase	phase	NOUN
dpc-2912	97	4	,	,	PUNCT
dpc-2912	97	5	namely	namely	ADV
dpc-2912	97	6	the	the	DET
dpc-2912	97	7	pulmonary	pulmonary	ADJ
dpc-2912	97	8	phase	phase	NOUN
dpc-2912	97	9	,	,	PUNCT
dpc-2912	97	10	is	be	AUX
dpc-2912	97	11	characterized	characterize	VERB
dpc-2912	97	12	by	by	ADP
dpc-2912	97	13	pulmonary	pulmonary	ADJ
dpc-2912	97	14	involvement	involvement	NOUN
dpc-2912	97	15	and	and	CCONJ
dpc-2912	97	16	occurs	occur	VERB
dpc-2912	97	17	within	within	ADP
dpc-2912	97	18	7	7	NUM
dpc-2912	97	19	-	-	SYM
dpc-2912	97	20	15	15	NUM
dpc-2912	97	21	days	day	NOUN
dpc-2912	97	22	following	follow	VERB
dpc-2912	97	23	the	the	DET
dpc-2912	97	24	disease	disease	NOUN
dpc-2912	97	25	onset	onset	VERB
dpc-2912	97	26	.	.	PUNCT
dpc-2912	98	1	in	in	ADP
dpc-2912	98	2	the	the	DET
dpc-2912	98	3	third	third	ADJ
dpc-2912	98	4	phase	phase	NOUN
dpc-2912	98	5	,	,	PUNCT
dpc-2912	98	6	the	the	DET
dpc-2912	98	7	inflammatory	inflammatory	ADJ
dpc-2912	98	8	phase	phase	NOUN
dpc-2912	98	9	,	,	PUNCT
dpc-2912	98	10	overactivation	overactivation	NOUN
dpc-2912	98	11	of	of	ADP
dpc-2912	98	12	the	the	DET
dpc-2912	98	13	immune	immune	ADJ
dpc-2912	98	14	system	system	NOUN
dpc-2912	98	15	leads	lead	VERB
dpc-2912	98	16	to	to	PART
dpc-2912	98	17	cytokine	cytokine	VERB
dpc-2912	98	18	storm	storm	NOUN
dpc-2912	98	19	and	and	CCONJ
dpc-2912	98	20	consequent	consequent	ADJ
dpc-2912	98	21	development	development	NOUN
dpc-2912	98	22	of	of	ADP
dpc-2912	98	23	acute	acute	ADJ
dpc-2912	98	24	respiratory	respiratory	ADJ
dpc-2912	98	25	distress	distress	NOUN
dpc-2912	98	26	syndrome	syndrome	NOUN
dpc-2912	98	27	(	(	PUNCT
dpc-2912	98	28	ards	ard	NOUN
dpc-2912	98	29	)	)	PUNCT
dpc-2912	98	30	 	 	SPACE
dpc-2912	99	1	[	[	X
dpc-2912	99	2	6	6	NUM
dpc-2912	99	3	]	]	PUNCT
dpc-2912	99	4	.	.	PUNCT
dpc-2912	100	1	an	an	DET
dpc-2912	100	2	adequate	adequate	ADJ
dpc-2912	100	3	immune	immune	ADJ
dpc-2912	100	4	response	response	NOUN
dpc-2912	100	5	during	during	ADP
dpc-2912	100	6	the	the	DET
dpc-2912	100	7	initial	initial	ADJ
dpc-2912	100	8	phase	phase	NOUN
dpc-2912	100	9	is	be	AUX
dpc-2912	100	10	desirable	desirable	ADJ
dpc-2912	100	11	,	,	PUNCT
dpc-2912	100	12	while	while	SCONJ
dpc-2912	100	13	the	the	DET
dpc-2912	100	14	primary	primary	ADJ
dpc-2912	100	15	goal	goal	NOUN
dpc-2912	100	16	of	of	ADP
dpc-2912	100	17	the	the	DET
dpc-2912	100	18	treatment	treatment	NOUN
dpc-2912	100	19	is	be	AUX
dpc-2912	100	20	the	the	DET
dpc-2912	100	21	prevention	prevention	NOUN
dpc-2912	100	22	of	of	ADP
dpc-2912	100	23	the	the	DET
dpc-2912	100	24	over	over	NOUN
dpc-2912	100	25	-	-	PUNCT
dpc-2912	100	26	activation	activation	NOUN
dpc-2912	100	27	encountered	encounter	VERB
dpc-2912	100	28	during	during	ADP
dpc-2912	100	29	the	the	DET
dpc-2912	100	30	following	follow	VERB
dpc-2912	100	31	two	two	NUM
dpc-2912	100	32	phases	phase	NOUN
dpc-2912	100	33	resulting	result	VERB
dpc-2912	100	34	in	in	ADP
dpc-2912	100	35	cytokine	cytokine	ADJ
dpc-2912	100	36	storm	storm	NOUN
dpc-2912	101	1	[	[	X
dpc-2912	101	2	7	7	NUM
dpc-2912	101	3	]	]	PUNCT
dpc-2912	101	4	.	.	PUNCT
dpc-2912	102	1	omz	omz	NOUN
dpc-2912	102	2	is	be	AUX
dpc-2912	102	3	a	a	DET
dpc-2912	102	4	recombinant	recombinant	ADJ
dpc-2912	102	5	human	human	ADJ
dpc-2912	102	6	ige	ige	PROPN
dpc-2912	102	7	antibody	antibody	NOUN
dpc-2912	102	8	that	that	PRON
dpc-2912	102	9	exerts	exert	VERB
dpc-2912	102	10	its	its	PRON
dpc-2912	102	11	effect	effect	NOUN
dpc-2912	102	12	by	by	ADP
dpc-2912	102	13	preventing	prevent	VERB
dpc-2912	102	14	the	the	DET
dpc-2912	102	15	binding	binding	NOUN
dpc-2912	102	16	of	of	ADP
dpc-2912	102	17	ige	ige	PROPN
dpc-2912	102	18	with	with	ADP
dpc-2912	102	19	high	high	ADJ
dpc-2912	102	20	-	-	PUNCT
dpc-2912	102	21	affinity	affinity	NOUN
dpc-2912	102	22	ige	ige	NOUN
dpc-2912	102	23	receptors	receptor	NOUN
dpc-2912	102	24	(	(	PUNCT
dpc-2912	102	25	fcεri	fcεri	ADJ
dpc-2912	102	26	)	)	PUNCT
dpc-2912	102	27	.	.	PUNCT
dpc-2912	103	1	it	it	PRON
dpc-2912	103	2	is	be	AUX
dpc-2912	103	3	utilized	utilize	VERB
dpc-2912	103	4	in	in	ADP
dpc-2912	103	5	disorders	disorder	NOUN
dpc-2912	103	6	in	in	ADP
dpc-2912	103	7	which	which	PRON
dpc-2912	103	8	ige	ige	PROPN
dpc-2912	103	9	plays	play	VERB
dpc-2912	103	10	a	a	DET
dpc-2912	103	11	major	major	ADJ
dpc-2912	103	12	role	role	NOUN
dpc-2912	103	13	in	in	ADP
dpc-2912	103	14	pathogenesis	pathogenesis	NOUN
dpc-2912	103	15	,	,	PUNCT
dpc-2912	103	16	such	such	ADJ
dpc-2912	103	17	as	as	ADP
dpc-2912	103	18	csu	csu	PROPN
dpc-2912	103	19	and	and	CCONJ
dpc-2912	103	20	asthma	asthma	NOUN
dpc-2912	103	21	.	.	PUNCT
dpc-2912	104	1	furthermore	furthermore	ADV
dpc-2912	104	2	,	,	PUNCT
dpc-2912	104	3	the	the	DET
dpc-2912	104	4	antiviral	antiviral	ADJ
dpc-2912	104	5	effect	effect	NOUN
dpc-2912	104	6	of	of	ADP
dpc-2912	104	7	omz	omz	NOUN
dpc-2912	104	8	has	have	AUX
dpc-2912	104	9	been	be	AUX
dpc-2912	104	10	reported	report	VERB
dpc-2912	104	11	in	in	ADP
dpc-2912	104	12	various	various	ADJ
dpc-2912	104	13	studies	study	NOUN
dpc-2912	104	14	.	.	PUNCT
dpc-2912	105	1	this	this	DET
dpc-2912	105	2	antiviral	antiviral	ADJ
dpc-2912	105	3	effect	effect	NOUN
dpc-2912	105	4	occurs	occur	VERB
dpc-2912	105	5	in	in	ADP
dpc-2912	105	6	several	several	ADJ
dpc-2912	105	7	different	different	ADJ
dpc-2912	105	8	ways	way	NOUN
dpc-2912	105	9	.	.	PUNCT
dpc-2912	106	1	there	there	PRON
dpc-2912	106	2	is	be	VERB
dpc-2912	106	3	a	a	DET
dpc-2912	106	4	considerable	considerable	ADJ
dpc-2912	106	5	number	number	NOUN
dpc-2912	106	6	of	of	ADP
dpc-2912	106	7	fcεris	fcεris	PROPN
dpc-2912	106	8	on	on	ADP
dpc-2912	106	9	the	the	DET
dpc-2912	106	10	surface	surface	NOUN
dpc-2912	106	11	of	of	ADP
dpc-2912	106	12	plasmacytoid	plasmacytoid	NOUN
dpc-2912	106	13	dendritic	dendritic	ADJ
dpc-2912	106	14	cells	cell	NOUN
dpc-2912	106	15	(	(	PUNCT
dpc-2912	106	16	pdcs	pdcs	PROPN
dpc-2912	106	17	)	)	PUNCT
dpc-2912	106	18	responsible	responsible	ADJ
dpc-2912	106	19	for	for	ADP
dpc-2912	106	20	ifnα	ifnα	ADJ
dpc-2912	106	21	production	production	NOUN
dpc-2912	106	22	.	.	PUNCT
dpc-2912	107	1	in	in	ADP
dpc-2912	107	2	several	several	ADJ
dpc-2912	107	3	studies	study	NOUN
dpc-2912	107	4	,	,	PUNCT
dpc-2912	107	5	it	it	PRON
dpc-2912	107	6	has	have	AUX
dpc-2912	107	7	been	be	AUX
dpc-2912	107	8	suggested	suggest	VERB
dpc-2912	107	9	that	that	SCONJ
dpc-2912	107	10	elevated	elevated	ADJ
dpc-2912	107	11	serum	serum	NOUN
dpc-2912	107	12	ige	ige	PROPN
dpc-2912	107	13	levels	level	NOUN
dpc-2912	107	14	and	and	CCONJ
dpc-2912	107	15	increased	increase	VERB
dpc-2912	107	16	pdc	pdc	PROPN
dpc-2912	107	17	fcεri	fcεri	ADJ
dpc-2912	107	18	expression	expression	NOUN
dpc-2912	107	19	might	might	AUX
dpc-2912	107	20	reduce	reduce	VERB
dpc-2912	107	21	ifnα	ifnα	ADJ
dpc-2912	107	22	secretion	secretion	NOUN
dpc-2912	107	23	from	from	ADP
dpc-2912	107	24	pdcs	pdcs	PROPN
dpc-2912	107	25	.	.	PUNCT
dpc-2912	108	1	thus	thus	ADV
dpc-2912	108	2	,	,	PUNCT
dpc-2912	108	3	omz	omz	PROPN
dpc-2912	108	4	contributes	contribute	VERB
dpc-2912	108	5	to	to	ADP
dpc-2912	108	6	the	the	DET
dpc-2912	108	7	release	release	NOUN
dpc-2912	108	8	of	of	ADP
dpc-2912	108	9	ifn	ifn	PROPN
dpc-2912	108	10	-	-	PUNCT
dpc-2912	108	11	α	α	NOUN
dpc-2912	108	12	by	by	ADP
dpc-2912	108	13	reducing	reduce	VERB
dpc-2912	108	14	table	table	NOUN
dpc-2912	108	15	2	2	NUM
dpc-2912	108	16	.	.	PUNCT
dpc-2912	108	17	comparison	comparison	NOUN
dpc-2912	108	18	of	of	ADP
dpc-2912	108	19	demographic	demographic	ADJ
dpc-2912	108	20	and	and	CCONJ
dpc-2912	108	21	clinical	clinical	ADJ
dpc-2912	108	22	characteristics	characteristic	NOUN
dpc-2912	108	23	of	of	ADP
dpc-2912	108	24	patients	patient	NOUN
dpc-2912	108	25	according	accord	VERB
dpc-2912	108	26	to	to	ADP
dpc-2912	108	27	covid-19	covid-19	PROPN
dpc-2912	108	28	infection	infection	NOUN
dpc-2912	108	29	history	history	NOUN
dpc-2912	108	30	.	.	PUNCT
dpc-2912	109	1	covid-19	covid-19	PROPN
dpc-2912	109	2	(	(	PUNCT
dpc-2912	109	3	+	+	NOUN
dpc-2912	109	4	)	)	PUNCT
dpc-2912	109	5	n=12	n=12	NOUN
dpc-2912	109	6	(	(	PUNCT
dpc-2912	109	7	17.6	17.6	NUM
dpc-2912	109	8	%	%	NOUN
dpc-2912	109	9	)	)	PUNCT
dpc-2912	109	10	covid-19	covid-19	PROPN
dpc-2912	109	11	(	(	PUNCT
dpc-2912	109	12	-	-	PUNCT
dpc-2912	109	13	)	)	PUNCT
dpc-2912	109	14	n=56	n=56	NOUN
dpc-2912	109	15	(	(	PUNCT
dpc-2912	109	16	82.4	82.4	NUM
dpc-2912	109	17	%	%	NOUN
dpc-2912	109	18	)	)	PUNCT
dpc-2912	109	19	p	p	PRON
dpc-2912	109	20	gender	gender	NOUN
dpc-2912	109	21	,	,	PUNCT
dpc-2912	109	22	n	n	CCONJ
dpc-2912	109	23	(	(	PUNCT
dpc-2912	109	24	%	%	INTJ
dpc-2912	109	25	)	)	PUNCT
dpc-2912	109	26	female	female	NOUN
dpc-2912	109	27	10	10	NUM
dpc-2912	109	28	(	(	PUNCT
dpc-2912	109	29	83.3	83.3	NUM
dpc-2912	109	30	)	)	PUNCT
dpc-2912	109	31	34	34	NUM
dpc-2912	109	32	(	(	PUNCT
dpc-2912	109	33	60.7	60.7	NUM
dpc-2912	109	34	)	)	PUNCT
dpc-2912	109	35	0.190	0.190	NUM
dpc-2912	109	36	age	age	NOUN
dpc-2912	109	37	(	(	PUNCT
dpc-2912	109	38	years	year	NOUN
dpc-2912	109	39	)	)	PUNCT
dpc-2912	109	40	,	,	PUNCT
dpc-2912	109	41	mean	mean	VERB
dpc-2912	109	42	±sd	±sd	NOUN
dpc-2912	109	43	39.6±12.8	39.6±12.8	NUM
dpc-2912	109	44	48.8±15.1	48.8±15.1	NUM
dpc-2912	109	45	0.056	0.056	NUM
dpc-2912	109	46	ccomorbidity	ccomorbidity	NOUN
dpc-2912	109	47	,	,	PUNCT
dpc-2912	109	48	n	n	PROPN
dpc-2912	109	49	(	(	PUNCT
dpc-2912	109	50	%	%	INTJ
dpc-2912	109	51	)	)	PUNCT
dpc-2912	109	52	1	1	NUM
dpc-2912	109	53	(	(	PUNCT
dpc-2912	109	54	8.3	8.3	NUM
dpc-2912	109	55	)	)	PUNCT
dpc-2912	109	56	3(5.4	3(5.4	NUM
dpc-2912	109	57	)	)	PUNCT
dpc-2912	109	58	0.549	0.549	NUM
dpc-2912	109	59	oral	oral	ADJ
dpc-2912	109	60	h1	h1	PROPN
dpc-2912	109	61	-	-	PUNCT
dpc-2912	109	62	antihistamine	antihistamine	PROPN
dpc-2912	109	63	therapy	therapy	NOUN
dpc-2912	109	64	,	,	PUNCT
dpc-2912	109	65	n	n	PROPN
dpc-2912	109	66	(	(	PUNCT
dpc-2912	109	67	%	%	INTJ
dpc-2912	109	68	)	)	PUNCT
dpc-2912	109	69	4	4	NUM
dpc-2912	109	70	(	(	PUNCT
dpc-2912	109	71	33.3	33.3	NUM
dpc-2912	109	72	)	)	PUNCT
dpc-2912	109	73	20	20	NUM
dpc-2912	109	74	(	(	PUNCT
dpc-2912	109	75	35.7	35.7	NUM
dpc-2912	109	76	)	)	SYM
dpc-2912	109	77	1	1	NUM
dpc-2912	109	78	vaccination	vaccination	NOUN
dpc-2912	109	79	status	status	NOUN
dpc-2912	109	80	,	,	PUNCT
dpc-2912	109	81	n	n	PROPN
dpc-2912	109	82	(	(	PUNCT
dpc-2912	109	83	%	%	INTJ
dpc-2912	109	84	)	)	PUNCT
dpc-2912	110	1	no	no	DET
dpc-2912	110	2	vaccination	vaccination	NOUN
dpc-2912	110	3	inactivated	inactivate	VERB
dpc-2912	110	4	vaccinea	vaccinea	NOUN
dpc-2912	110	5	mrna	mrna	PROPN
dpc-2912	110	6	vaccineb	vaccineb	PROPN
dpc-2912	110	7	inactivated	inactivate	VERB
dpc-2912	110	8	vaccinea+mrna	vaccinea+mrna	PROPN
dpc-2912	110	9	vaccineb	vaccineb	NOUN
dpc-2912	110	10	2	2	NUM
dpc-2912	110	11	(	(	PUNCT
dpc-2912	110	12	16.7	16.7	NUM
dpc-2912	110	13	)	)	PUNCT
dpc-2912	110	14	3	3	NUM
dpc-2912	110	15	(	(	PUNCT
dpc-2912	110	16	25	25	NUM
dpc-2912	110	17	)	)	PUNCT
dpc-2912	110	18	4	4	NUM
dpc-2912	110	19	(	(	PUNCT
dpc-2912	110	20	33.3	33.3	NUM
dpc-2912	110	21	)	)	PUNCT
dpc-2912	110	22	3	3	NUM
dpc-2912	110	23	(	(	PUNCT
dpc-2912	110	24	25	25	NUM
dpc-2912	110	25	)	)	PUNCT
dpc-2912	110	26	8	8	NUM
dpc-2912	110	27	(	(	PUNCT
dpc-2912	110	28	14.3	14.3	NUM
dpc-2912	110	29	)	)	PUNCT
dpc-2912	110	30	24	24	NUM
dpc-2912	110	31	(	(	PUNCT
dpc-2912	110	32	42.9	42.9	NUM
dpc-2912	110	33	)	)	PUNCT
dpc-2912	110	34	15	15	NUM
dpc-2912	110	35	(	(	PUNCT
dpc-2912	110	36	26.8	26.8	NUM
dpc-2912	110	37	)	)	PUNCT
dpc-2912	110	38	9	9	NUM
dpc-2912	110	39	(	(	PUNCT
dpc-2912	110	40	16.1	16.1	NUM
dpc-2912	110	41	)	)	PUNCT
dpc-2912	110	42	0.699	0.699	NUM
dpc-2912	110	43	presence	presence	NOUN
dpc-2912	110	44	of	of	ADP
dpc-2912	110	45	angioedema	angioedema	NOUN
dpc-2912	110	46	,	,	PUNCT
dpc-2912	110	47	n	n	PROPN
dpc-2912	110	48	(	(	PUNCT
dpc-2912	110	49	%	%	INTJ
dpc-2912	110	50	)	)	PUNCT
dpc-2912	110	51	6	6	NUM
dpc-2912	110	52	(	(	PUNCT
dpc-2912	110	53	50	50	NUM
dpc-2912	110	54	)	)	PUNCT
dpc-2912	110	55	19	19	NUM
dpc-2912	110	56	(	(	PUNCT
dpc-2912	110	57	33.9	33.9	NUM
dpc-2912	110	58	)	)	PUNCT
dpc-2912	110	59	0.335	0.335	NUM
dpc-2912	110	60	total	total	NOUN
dpc-2912	110	61	ige	ige	PROPN
dpc-2912	110	62	prior	prior	ADV
dpc-2912	110	63	to	to	ADP
dpc-2912	110	64	omz	omz	ADJ
dpc-2912	110	65	treatment	treatment	NOUN
dpc-2912	110	66	(	(	PUNCT
dpc-2912	110	67	ku	ku	PROPN
dpc-2912	110	68	/	/	SYM
dpc-2912	110	69	l	l	NOUN
dpc-2912	110	70	)	)	PUNCT
dpc-2912	110	71	,	,	PUNCT
dpc-2912	110	72	median	median	NOUN
dpc-2912	110	73	(	(	PUNCT
dpc-2912	110	74	range	range	NOUN
dpc-2912	110	75	)	)	PUNCT
dpc-2912	110	76	312.5	312.5	NUM
dpc-2912	110	77	(	(	PUNCT
dpc-2912	110	78	31	31	NUM
dpc-2912	110	79	-	-	SYM
dpc-2912	110	80	740	740	NUM
dpc-2912	110	81	)	)	PUNCT
dpc-2912	110	82	280	280	NUM
dpc-2912	110	83	(	(	PUNCT
dpc-2912	110	84	2	2	NUM
dpc-2912	110	85	-	-	SYM
dpc-2912	110	86	2730	2730	NUM
dpc-2912	110	87	)	)	PUNCT
dpc-2912	110	88	0.876	0.876	NUM
dpc-2912	110	89	presence	presence	NOUN
dpc-2912	110	90	of	of	ADP
dpc-2912	110	91	eosinophilia	eosinophilia	PROPN
dpc-2912	110	92	prior	prior	ADV
dpc-2912	110	93	to	to	ADP
dpc-2912	110	94	omz	omz	ADJ
dpc-2912	110	95	treatment	treatment	NOUN
dpc-2912	110	96	,	,	PUNCT
dpc-2912	110	97	n	n	CCONJ
dpc-2912	110	98	(	(	PUNCT
dpc-2912	110	99	%	%	INTJ
dpc-2912	110	100	)	)	PUNCT
dpc-2912	110	101	2	2	NUM
dpc-2912	110	102	(	(	PUNCT
dpc-2912	110	103	16.7	16.7	NUM
dpc-2912	110	104	)	)	PUNCT
dpc-2912	110	105	4	4	NUM
dpc-2912	110	106	(	(	PUNCT
dpc-2912	110	107	7.7	7.7	NUM
dpc-2912	110	108	)	)	PUNCT
dpc-2912	110	109	0.291	0.291	NUM
dpc-2912	110	110	omz	omz	ADJ
dpc-2912	110	111	treatment	treatment	NOUN
dpc-2912	110	112	duration	duration	NOUN
dpc-2912	110	113	(	(	PUNCT
dpc-2912	110	114	months	month	NOUN
dpc-2912	110	115	)	)	PUNCT
dpc-2912	110	116	,	,	PUNCT
dpc-2912	110	117	median	median	NOUN
dpc-2912	110	118	(	(	PUNCT
dpc-2912	110	119	range	range	NOUN
dpc-2912	110	120	)	)	PUNCT
dpc-2912	110	121	22.5	22.5	NUM
dpc-2912	110	122	(	(	PUNCT
dpc-2912	110	123	10	10	NUM
dpc-2912	110	124	-	-	SYM
dpc-2912	110	125	60	60	NUM
dpc-2912	110	126	)	)	PUNCT
dpc-2912	110	127	12	12	NUM
dpc-2912	110	128	(	(	PUNCT
dpc-2912	110	129	6	6	NUM
dpc-2912	110	130	-	-	SYM
dpc-2912	110	131	60	60	NUM
dpc-2912	110	132	)	)	PUNCT
dpc-2912	110	133	0.01	0.01	NUM
dpc-2912	110	134	dosing	dose	VERB
dpc-2912	110	135	regimen	regiman	NOUN
dpc-2912	110	136	of	of	ADP
dpc-2912	110	137	omz	omz	PROPN
dpc-2912	110	138	,	,	PUNCT
dpc-2912	110	139	n	n	CCONJ
dpc-2912	110	140	(	(	PUNCT
dpc-2912	110	141	%	%	INTJ
dpc-2912	110	142	)	)	PUNCT
dpc-2912	110	143	300	300	NUM
dpc-2912	110	144	mg	mg	NOUN
dpc-2912	110	145	every	every	DET
dpc-2912	110	146	4	4	NUM
dpc-2912	110	147	weeks	week	NOUN
dpc-2912	110	148	300	300	NUM
dpc-2912	110	149	mg	mg	NOUN
dpc-2912	110	150	every	every	DET
dpc-2912	110	151	2	2	NUM
dpc-2912	110	152	weeks	week	NOUN
dpc-2912	110	153	12	12	NUM
dpc-2912	110	154	(	(	PUNCT
dpc-2912	110	155	100	100	NUM
dpc-2912	110	156	)	)	PUNCT
dpc-2912	110	157	0	0	NUM
dpc-2912	111	1	(	(	PUNCT
dpc-2912	111	2	0	0	NUM
dpc-2912	111	3	)	)	PUNCT
dpc-2912	111	4	54	54	NUM
dpc-2912	111	5	(	(	PUNCT
dpc-2912	111	6	96.4	96.4	NUM
dpc-2912	111	7	)	)	SYM
dpc-2912	111	8	2	2	NUM
dpc-2912	111	9	(	(	PUNCT
dpc-2912	111	10	3.6	3.6	NUM
dpc-2912	111	11	)	)	PUNCT
dpc-2912	111	12	1	1	NUM
dpc-2912	111	13	omz	omz	NOUN
dpc-2912	111	14	=	=	PUNCT
dpc-2912	111	15	omalizumab	omalizumab	NOUN
dpc-2912	111	16	;	;	PUNCT
dpc-2912	112	1	sd	sd	NOUN
dpc-2912	112	2	=	=	SYM
dpc-2912	112	3	standard	standard	ADJ
dpc-2912	112	4	deviation	deviation	NOUN
dpc-2912	112	5	.	.	PUNCT
dpc-2912	113	1	ainactivated	ainactivate	VERB
dpc-2912	113	2	vaccine	vaccine	NOUN
dpc-2912	113	3	produced	produce	VERB
dpc-2912	113	4	by	by	ADP
dpc-2912	113	5	sinovacbiotech	sinovacbiotech	PROPN
dpc-2912	113	6	®	®	PROPN
dpc-2912	113	7	.	.	PUNCT
dpc-2912	114	1	bmrna	bmrna	NOUN
dpc-2912	114	2	vaccine	vaccine	NOUN
dpc-2912	114	3	produced	produce	VERB
dpc-2912	114	4	by	by	ADP
dpc-2912	114	5	pfizer	pfizer	NOUN
dpc-2912	114	6	/	/	SYM
dpc-2912	114	7	biontech	biontech	PROPN
dpc-2912	114	8	®	®	NOUN
dpc-2912	114	9	.	.	PUNCT
dpc-2912	115	1	cin	cin	PROPN
dpc-2912	115	2	the	the	DET
dpc-2912	115	3	covid-19	covid-19	PROPN
dpc-2912	115	4	+	+	PROPN
dpc-2912	115	5	group	group	NOUN
dpc-2912	115	6	,	,	PUNCT
dpc-2912	115	7	one	one	NUM
dpc-2912	115	8	patient	patient	NOUN
dpc-2912	115	9	had	have	VERB
dpc-2912	115	10	hypertension	hypertension	NOUN
dpc-2912	115	11	,	,	PUNCT
dpc-2912	115	12	while	while	SCONJ
dpc-2912	115	13	in	in	ADP
dpc-2912	115	14	the	the	DET
dpc-2912	115	15	covid-19	covid-19	PROPN
dpc-2912	115	16	-group	-group	NOUN
dpc-2912	115	17	,	,	PUNCT
dpc-2912	115	18	two	two	NUM
dpc-2912	115	19	patients	patient	NOUN
dpc-2912	115	20	had	have	VERB
dpc-2912	115	21	hypothyroidism	hypothyroidism	NOUN
dpc-2912	115	22	and	and	CCONJ
dpc-2912	115	23	one	one	NUM
dpc-2912	115	24	patient	patient	NOUN
dpc-2912	115	25	had	have	VERB
dpc-2912	115	26	depression	depression	NOUN
dpc-2912	115	27	.	.	PUNCT
dpc-2912	116	1	original	original	ADJ
dpc-2912	116	2	article	article	NOUN
dpc-2912	116	3	|	|	ADV
dpc-2912	116	4	dermatol	dermatol	ADJ
dpc-2912	116	5	pract	pract	NOUN
dpc-2912	116	6	concept	concept	NOUN
dpc-2912	116	7	.	.	PUNCT
dpc-2912	117	1	2023;13(3):e2023145	2023;13(3):e2023145	NUM
dpc-2912	117	2	5	5	NUM
dpc-2912	117	3	of	of	ADP
dpc-2912	117	4	omz	omz	ADJ
dpc-2912	117	5	therapy	therapy	NOUN
dpc-2912	117	6	following	follow	VERB
dpc-2912	117	7	control	control	NOUN
dpc-2912	117	8	of	of	ADP
dpc-2912	117	9	csu	csu	PROPN
dpc-2912	117	10	symptoms	symptom	NOUN
dpc-2912	117	11	to	to	PART
dpc-2912	117	12	allow	allow	VERB
dpc-2912	117	13	et-1	et-1	PUNCT
dpc-2912	117	14	and	and	CCONJ
dpc-2912	117	15	eosinophil	eosinophil	ADJ
dpc-2912	117	16	levels	level	NOUN
dpc-2912	117	17	to	to	PART
dpc-2912	117	18	return	return	VERB
dpc-2912	117	19	to	to	ADP
dpc-2912	117	20	levels	level	NOUN
dpc-2912	117	21	before	before	ADP
dpc-2912	117	22	omz	omz	PROPN
dpc-2912	117	23	administration	administration	NOUN
dpc-2912	117	24	.	.	PUNCT
dpc-2912	118	1	references	reference	NOUN
dpc-2912	118	2	1	1	NUM
dpc-2912	118	3	.	.	PUNCT
dpc-2912	118	4	zuberbier	zuberbier	PROPN
dpc-2912	118	5	t	t	PROPN
dpc-2912	118	6	,	,	PUNCT
dpc-2912	118	7	aberer	aberer	PROPN
dpc-2912	118	8	w	w	PROPN
dpc-2912	118	9	,	,	PUNCT
dpc-2912	118	10	asero	asero	NOUN
dpc-2912	118	11	r	r	NOUN
dpc-2912	118	12	,	,	PUNCT
dpc-2912	118	13	et	et	PROPN
dpc-2912	118	14	al	al	PROPN
dpc-2912	118	15	.	.	PUNCT
dpc-2912	119	1	the	the	DET
dpc-2912	119	2	eaaci	eaaci	NOUN
dpc-2912	119	3	/	/	SYM
dpc-2912	119	4	ga²len	ga²len	PROPN
dpc-2912	119	5	/edf	/edf	PROPN
dpc-2912	119	6	/	/	SYM
dpc-2912	119	7	wao	wao	PROPN
dpc-2912	119	8	guideline	guideline	NOUN
dpc-2912	119	9	for	for	ADP
dpc-2912	119	10	the	the	DET
dpc-2912	119	11	definition	definition	NOUN
dpc-2912	119	12	,	,	PUNCT
dpc-2912	119	13	classification	classification	NOUN
dpc-2912	119	14	,	,	PUNCT
dpc-2912	119	15	diagnosis	diagnosis	NOUN
dpc-2912	119	16	and	and	CCONJ
dpc-2912	119	17	management	management	NOUN
dpc-2912	119	18	of	of	ADP
dpc-2912	119	19	urticaria	urticaria	NOUN
dpc-2912	119	20	.	.	PUNCT
dpc-2912	120	1	allergy	allergy	NOUN
dpc-2912	120	2	.	.	PUNCT
dpc-2912	121	1	2018;73(7):1393	2018;73(7):1393	PROPN
dpc-2912	121	2	-	-	SYM
dpc-2912	121	3	1414	1414	NUM
dpc-2912	121	4	.	.	PUNCT
dpc-2912	122	1	doi:10.1111	doi:10.1111	ADJ
dpc-2912	122	2	/	/	SYM
dpc-2912	122	3	all.13397	all.13397	PROPN
dpc-2912	122	4	.	.	PUNCT
dpc-2912	123	1	pmid	pmid	NOUN
dpc-2912	123	2	:	:	PUNCT
dpc-2912	123	3	29336054	29336054	NUM
dpc-2912	123	4	.	.	PUNCT
dpc-2912	124	1	2	2	NUM
dpc-2912	124	2	.	.	NUM
dpc-2912	124	3	zuberbier	zuberbier	PROPN
dpc-2912	124	4	t	t	PROPN
dpc-2912	124	5	,	,	PUNCT
dpc-2912	124	6	abdul	abdul	PROPN
dpc-2912	124	7	latiff	latiff	PROPN
dpc-2912	124	8	ah	ah	INTJ
dpc-2912	124	9	,	,	PUNCT
dpc-2912	124	10	abuzakouk	abuzakouk	PROPN
dpc-2912	124	11	m	m	PROPN
dpc-2912	124	12	,	,	PUNCT
dpc-2912	124	13	et	et	PROPN
dpc-2912	124	14	al	al	PROPN
dpc-2912	124	15	.	.	PUNCT
dpc-2912	125	1	the	the	DET
dpc-2912	125	2	international	international	PROPN
dpc-2912	125	3	eaaci	eaaci	PROPN
dpc-2912	125	4	/	/	SYM
dpc-2912	125	5	ga²len	ga²len	PROPN
dpc-2912	125	6	/	/	SYM
dpc-2912	125	7	euroguiderm	euroguiderm	NOUN
dpc-2912	125	8	/	/	SYM
dpc-2912	125	9	apaaaci	apaaaci	NOUN
dpc-2912	125	10	guideline	guideline	NOUN
dpc-2912	125	11	for	for	ADP
dpc-2912	125	12	the	the	DET
dpc-2912	125	13	definition	definition	NOUN
dpc-2912	125	14	,	,	PUNCT
dpc-2912	125	15	classification	classification	NOUN
dpc-2912	125	16	,	,	PUNCT
dpc-2912	125	17	diagnosis	diagnosis	NOUN
dpc-2912	125	18	,	,	PUNCT
dpc-2912	125	19	and	and	CCONJ
dpc-2912	125	20	management	management	NOUN
dpc-2912	125	21	of	of	ADP
dpc-2912	125	22	urticaria	urticaria	NOUN
dpc-2912	125	23	.	.	PUNCT
dpc-2912	125	24	 	 	SPACE
dpc-2912	125	25	allergy	allergy	NOUN
dpc-2912	125	26	.	.	PUNCT
dpc-2912	126	1	2022;77(3):734	2022;77(3):734	NUM
dpc-2912	126	2	-	-	PUNCT
dpc-2912	126	3	766	766	NUM
dpc-2912	126	4	.	.	PUNCT
dpc-2912	127	1	doi	doi	NOUN
dpc-2912	127	2	:	:	PUNCT
dpc-2912	127	3	10.1111	10.1111	NUM
dpc-2912	127	4	/	/	SYM
dpc-2912	127	5	all.15090	all.15090	NOUN
dpc-2912	127	6	.	.	PUNCT
dpc-2912	128	1	pmid	pmid	NOUN
dpc-2912	128	2	:	:	PUNCT
dpc-2912	128	3	34536239	34536239	NUM
dpc-2912	128	4	.	.	PUNCT
dpc-2912	129	1	3	3	X
dpc-2912	129	2	.	.	X
dpc-2912	129	3	muntean	muntean	PROPN
dpc-2912	129	4	ia	ia	PROPN
dpc-2912	129	5	,	,	PUNCT
dpc-2912	129	6	pintea	pintea	PROPN
dpc-2912	129	7	i	i	PROPN
dpc-2912	129	8	,	,	PUNCT
dpc-2912	129	9	bocsan	bocsan	PROPN
dpc-2912	129	10	ic	ic	PROPN
dpc-2912	129	11	,	,	PUNCT
dpc-2912	129	12	dobrican	dobrican	PROPN
dpc-2912	129	13	ct	ct	PROPN
dpc-2912	129	14	,	,	PUNCT
dpc-2912	129	15	deleanu	deleanu	VERB
dpc-2912	129	16	d.	d.	PROPN
dpc-2912	129	17	covid-19	covid-19	PROPN
dpc-2912	129	18	disease	disease	NOUN
dpc-2912	129	19	leading	lead	VERB
dpc-2912	129	20	to	to	ADP
dpc-2912	129	21	chronic	chronic	ADJ
dpc-2912	129	22	spontaneous	spontaneous	ADJ
dpc-2912	129	23	urticaria	urticaria	NOUN
dpc-2912	129	24	exacerbation	exacerbation	NOUN
dpc-2912	129	25	:	:	PUNCT
dpc-2912	129	26	a	a	DET
dpc-2912	129	27	romanian	romanian	ADJ
dpc-2912	129	28	retrospective	retrospective	ADJ
dpc-2912	129	29	study	study	NOUN
dpc-2912	129	30	.	.	PUNCT
dpc-2912	129	31	  	  	SPACE
dpc-2912	130	1	healthcare	healthcare	PROPN
dpc-2912	130	2	(	(	PUNCT
dpc-2912	130	3	basel	basel	PROPN
dpc-2912	130	4	)	)	PUNCT
dpc-2912	130	5	.	.	PUNCT
dpc-2912	131	1	2021;9(9):1144	2021;9(9):1144	NUM
dpc-2912	131	2	.	.	PUNCT
dpc-2912	132	1	doi	doi	NOUN
dpc-2912	132	2	:	:	PUNCT
dpc-2912	132	3	10.3390	10.3390	NUM
dpc-2912	132	4	/	/	SYM
dpc-2912	132	5	healthcare9091144	healthcare9091144	PROPN
dpc-2912	132	6	.	.	PUNCT
dpc-2912	133	1	pmid	pmid	NOUN
dpc-2912	133	2	:	:	PUNCT
dpc-2912	133	3	34574918	34574918	NUM
dpc-2912	133	4	.	.	PUNCT
dpc-2912	134	1	pmcid	pmcid	NOUN
dpc-2912	134	2	:	:	PUNCT
dpc-2912	134	3	pmc8470475	pmc8470475	NOUN
dpc-2912	134	4	.	.	PUNCT
dpc-2912	135	1	4	4	X
dpc-2912	135	2	.	.	X
dpc-2912	135	3	allegra	allegra	PROPN
dpc-2912	135	4	a	a	PRON
dpc-2912	135	5	,	,	PUNCT
dpc-2912	135	6	asero	asero	NOUN
dpc-2912	135	7	r	r	NOUN
dpc-2912	135	8	,	,	PUNCT
dpc-2912	135	9	giovannetti	giovannetti	NOUN
dpc-2912	135	10	a	a	X
dpc-2912	135	11	,	,	PUNCT
dpc-2912	135	12	isola	isola	PROPN
dpc-2912	135	13	s	s	PART
dpc-2912	135	14	,	,	PUNCT
dpc-2912	135	15	gangemi	gangemi	NOUN
dpc-2912	135	16	s.	s.	PROPN
dpc-2912	135	17	urticaria	urticaria	PROPN
dpc-2912	135	18	and	and	CCONJ
dpc-2912	135	19	coronavirus	coronavirus	NOUN
dpc-2912	135	20	infection	infection	NOUN
dpc-2912	135	21	:	:	PUNCT
dpc-2912	135	22	a	a	DET
dpc-2912	135	23	lesson	lesson	NOUN
dpc-2912	135	24	from	from	ADP
dpc-2912	135	25	sars	sar	NOUN
dpc-2912	135	26	-	-	PUNCT
dpc-2912	135	27	cov-2	cov-2	NOUN
dpc-2912	135	28	pandemic	pandemic	NOUN
dpc-2912	135	29	.	.	PUNCT
dpc-2912	135	30	 	 	SPACE
dpc-2912	136	1	eur	eur	PROPN
dpc-2912	136	2	ann	ann	PROPN
dpc-2912	136	3	allergy	allergy	PROPN
dpc-2912	136	4	clin	clin	PROPN
dpc-2912	136	5	immunol	immunol	NOUN
dpc-2912	136	6	.	.	PUNCT
dpc-2912	137	1	2021;53(2):51	2021;53(2):51	NUM
dpc-2912	137	2	-	-	SYM
dpc-2912	137	3	54	54	NUM
dpc-2912	137	4	.	.	PUNCT
dpc-2912	138	1	doi	doi	NOUN
dpc-2912	138	2	:	:	PUNCT
dpc-2912	138	3	10.23822	10.23822	NUM
dpc-2912	138	4	/	/	SYM
dpc-2912	138	5	eurannaci.1764	eurannaci.1764	PROPN
dpc-2912	138	6	-	-	PUNCT
dpc-2912	138	7	1489.173	1489.173	PROPN
dpc-2912	138	8	.	.	PUNCT
dpc-2912	139	1	pmid	pmid	NOUN
dpc-2912	139	2	:	:	PUNCT
dpc-2912	139	3	33034169	33034169	NUM
dpc-2912	139	4	.	.	PUNCT
dpc-2912	140	1	5	5	X
dpc-2912	140	2	.	.	X
dpc-2912	140	3	algaadi	algaadi	PROPN
dpc-2912	140	4	sa	sa	PROPN
dpc-2912	140	5	.	.	PUNCT
dpc-2912	140	6	urticaria	urticaria	PROPN
dpc-2912	140	7	and	and	CCONJ
dpc-2912	140	8	covid-19	covid-19	PROPN
dpc-2912	140	9	:	:	PUNCT
dpc-2912	140	10	a	a	DET
dpc-2912	140	11	review	review	NOUN
dpc-2912	140	12	.	.	PUNCT
dpc-2912	140	13	  	  	SPACE
dpc-2912	141	1	dermatol	dermatol	NOUN
dpc-2912	141	2	ther	ther	ADV
dpc-2912	141	3	.	.	PUNCT
dpc-2912	142	1	2020;33(6):e14290	2020;33(6):e14290	X
dpc-2912	142	2	.	.	PUNCT
dpc-2912	142	3	doi	doi	NOUN
dpc-2912	142	4	:	:	PUNCT
dpc-2912	142	5	10.1111	10.1111	NUM
dpc-2912	142	6	/	/	SYM
dpc-2912	142	7	dth.14290	dth.14290	PROPN
dpc-2912	142	8	.	.	PUNCT
dpc-2912	143	1	pmid	pmid	NOUN
dpc-2912	143	2	:	:	PUNCT
dpc-2912	143	3	32902087	32902087	NUM
dpc-2912	143	4	.	.	PUNCT
dpc-2912	144	1	6	6	NUM
dpc-2912	144	2	.	.	X
dpc-2912	144	3	siddiqi	siddiqi	PROPN
dpc-2912	144	4	hk	hk	PROPN
dpc-2912	144	5	,	,	PUNCT
dpc-2912	144	6	mehra	mehra	PROPN
dpc-2912	144	7	mr	mr	PROPN
dpc-2912	144	8	.	.	PROPN
dpc-2912	144	9	covid-19	covid-19	PROPN
dpc-2912	144	10	illness	illness	NOUN
dpc-2912	144	11	in	in	ADP
dpc-2912	144	12	native	native	ADJ
dpc-2912	144	13	and	and	CCONJ
dpc-2912	144	14	immunosuppressed	immunosuppressed	ADJ
dpc-2912	144	15	states	state	NOUN
dpc-2912	144	16	:	:	PUNCT
dpc-2912	144	17	a	a	DET
dpc-2912	144	18	clinical	clinical	ADJ
dpc-2912	144	19	-	-	PUNCT
dpc-2912	144	20	therapeutic	therapeutic	ADJ
dpc-2912	144	21	staging	staging	NOUN
dpc-2912	144	22	proposal	proposal	NOUN
dpc-2912	144	23	.	.	PUNCT
dpc-2912	145	1	j	j	PROPN
dpc-2912	145	2	heart	heart	NOUN
dpc-2912	145	3	lung	lung	NOUN
dpc-2912	145	4	transplant	transplant	NOUN
dpc-2912	145	5	.	.	PUNCT
dpc-2912	146	1	2020;39(5):405	2020;39(5):405	NUM
dpc-2912	146	2	-	-	SYM
dpc-2912	146	3	407	407	NUM
dpc-2912	146	4	.	.	PUNCT
dpc-2912	147	1	doi	doi	NOUN
dpc-2912	147	2	:	:	PUNCT
dpc-2912	147	3	10.1016	10.1016	NUM
dpc-2912	147	4	/	/	SYM
dpc-2912	147	5	j.healun.2020.03.012	j.healun.2020.03.012	PROPN
dpc-2912	147	6	.	.	PUNCT
dpc-2912	148	1	pmid	pmid	NOUN
dpc-2912	148	2	:	:	PUNCT
dpc-2912	148	3	32362390	32362390	NUM
dpc-2912	148	4	.	.	PUNCT
dpc-2912	149	1	pmcid	pmcid	NOUN
dpc-2912	149	2	:	:	PUNCT
dpc-2912	149	3	pmc7118652	pmc7118652	NOUN
dpc-2912	149	4	.	.	PUNCT
dpc-2912	150	1	7	7	X
dpc-2912	150	2	.	.	X
dpc-2912	150	3	nicastri	nicastri	PROPN
dpc-2912	150	4	e	e	PROPN
dpc-2912	150	5	,	,	PUNCT
dpc-2912	150	6	petrosillo	petrosillo	NOUN
dpc-2912	150	7	n	n	CCONJ
dpc-2912	150	8	,	,	PUNCT
dpc-2912	150	9	ascoli	ascoli	PROPN
dpc-2912	150	10	bartoli	bartoli	PROPN
dpc-2912	150	11	t	t	PROPN
dpc-2912	150	12	,	,	PUNCT
dpc-2912	150	13	et	et	PROPN
dpc-2912	150	14	al	al	PROPN
dpc-2912	150	15	.	.	PROPN
dpc-2912	150	16	national	national	PROPN
dpc-2912	150	17	institute	institute	PROPN
dpc-2912	150	18	for	for	ADP
dpc-2912	150	19	the	the	DET
dpc-2912	150	20	infectious	infectious	ADJ
dpc-2912	150	21	diseases	disease	NOUN
dpc-2912	150	22	“	"	PUNCT
dpc-2912	150	23	l.	l.	PROPN
dpc-2912	150	24	spallanzani	spallanzani	PROPN
dpc-2912	150	25	”	"	PUNCT
dpc-2912	150	26	,	,	PUNCT
dpc-2912	150	27	irccs	irccs	NOUN
dpc-2912	150	28	.	.	PUNCT
dpc-2912	151	1	recommendations	recommendation	NOUN
dpc-2912	151	2	for	for	ADP
dpc-2912	151	3	covid-19	covid-19	PROPN
dpc-2912	151	4	clinical	clinical	ADJ
dpc-2912	151	5	management	management	NOUN
dpc-2912	151	6	.	.	PUNCT
dpc-2912	152	1	infect	infect	VERB
dpc-2912	152	2	dis	dis	PROPN
dpc-2912	152	3	rep	rep	PROPN
dpc-2912	152	4	.	.	PROPN
dpc-2912	152	5	2020	2020	NUM
dpc-2912	152	6	mar	mar	PROPN
dpc-2912	152	7	16;12(1):8543	16;12(1):8543	NUM
dpc-2912	152	8	.	.	PUNCT
dpc-2912	153	1	doi	doi	NOUN
dpc-2912	153	2	:	:	PUNCT
dpc-2912	153	3	10.4081	10.4081	NUM
dpc-2912	153	4	/	/	SYM
dpc-2912	153	5	idr.2020.8543	idr.2020.8543	ADJ
dpc-2912	153	6	.	.	PUNCT
dpc-2912	154	1	pmid	pmid	NOUN
dpc-2912	154	2	:	:	PUNCT
dpc-2912	154	3	32218915	32218915	NUM
dpc-2912	154	4	.	.	PUNCT
dpc-2912	155	1	pmcid	pmcid	NOUN
dpc-2912	155	2	:	:	PUNCT
dpc-2912	155	3	pmc7097833	pmc7097833	ADJ
dpc-2912	155	4	.	.	PUNCT
dpc-2912	156	1	8	8	NUM
dpc-2912	156	2	.	.	X
dpc-2912	156	3	esquivel	esquivel	PROPN
dpc-2912	156	4	a	a	PROPN
dpc-2912	156	5	,	,	PUNCT
dpc-2912	156	6	busse	busse	PROPN
dpc-2912	156	7	ww	ww	PROPN
dpc-2912	156	8	,	,	PUNCT
dpc-2912	156	9	calatroni	calatroni	NOUN
dpc-2912	156	10	a	a	X
dpc-2912	156	11	,	,	PUNCT
dpc-2912	156	12	et	et	PROPN
dpc-2912	156	13	al	al	PROPN
dpc-2912	156	14	.	.	PUNCT
dpc-2912	157	1	effects	effect	NOUN
dpc-2912	157	2	of	of	ADP
dpc-2912	157	3	omalizumab	omalizumab	NOUN
dpc-2912	157	4	on	on	ADP
dpc-2912	157	5	rhinovirus	rhinovirus	NOUN
dpc-2912	157	6	infections	infection	NOUN
dpc-2912	157	7	,	,	PUNCT
dpc-2912	157	8	illnesses	illness	NOUN
dpc-2912	157	9	,	,	PUNCT
dpc-2912	157	10	and	and	CCONJ
dpc-2912	157	11	exacerbations	exacerbation	NOUN
dpc-2912	157	12	of	of	ADP
dpc-2912	157	13	asthma	asthma	NOUN
dpc-2912	157	14	.	.	PUNCT
dpc-2912	158	1	am	be	AUX
dpc-2912	158	2	j	j	PROPN
dpc-2912	158	3	respir	respir	NOUN
dpc-2912	158	4	crit	crit	PROPN
dpc-2912	158	5	care	care	NOUN
dpc-2912	158	6	med	me	VERB
dpc-2912	158	7	.	.	PUNCT
dpc-2912	159	1	2017;196(8):985	2017;196(8):985	NUM
dpc-2912	159	2	-	-	SYM
dpc-2912	159	3	992	992	NUM
dpc-2912	159	4	.	.	PUNCT
dpc-2912	159	5	doi	doi	NOUN
dpc-2912	159	6	:	:	PUNCT
dpc-2912	159	7	10.1164	10.1164	NUM
dpc-2912	159	8	/	/	SYM
dpc-2912	159	9	rccm.201701	rccm.201701	NOUN
dpc-2912	159	10	-	-	PUNCT
dpc-2912	159	11	0120oc	0120oc	PROPN
dpc-2912	159	12	.	.	PUNCT
dpc-2912	160	1	pmid	pmid	NOUN
dpc-2912	160	2	:	:	PUNCT
dpc-2912	160	3	28608756	28608756	NUM
dpc-2912	160	4	.	.	PUNCT
dpc-2912	161	1	pmcid	pmcid	NOUN
dpc-2912	161	2	:	:	PUNCT
dpc-2912	161	3	pmc5649984	pmc5649984	ADJ
dpc-2912	161	4	.	.	PUNCT
dpc-2912	162	1	9	9	X
dpc-2912	162	2	.	.	X
dpc-2912	162	3	gill	gill	PROPN
dpc-2912	162	4	ma	ma	PROPN
dpc-2912	162	5	,	,	PUNCT
dpc-2912	162	6	bajwa	bajwa	PROPN
dpc-2912	162	7	g	g	PROPN
dpc-2912	162	8	,	,	PUNCT
dpc-2912	162	9	george	george	PROPN
dpc-2912	162	10	ta	ta	PROPN
dpc-2912	162	11	,	,	PUNCT
dpc-2912	162	12	et	et	PROPN
dpc-2912	162	13	al	al	PROPN
dpc-2912	162	14	.	.	PROPN
dpc-2912	162	15	counterregulation	counterregulation	NOUN
dpc-2912	162	16	between	between	ADP
dpc-2912	162	17	the	the	DET
dpc-2912	162	18	fcepsilonri	fcepsilonri	ADJ
dpc-2912	162	19	pathway	pathway	NOUN
dpc-2912	162	20	and	and	CCONJ
dpc-2912	162	21	antiviral	antiviral	ADJ
dpc-2912	162	22	responses	response	NOUN
dpc-2912	162	23	in	in	ADP
dpc-2912	162	24	human	human	ADJ
dpc-2912	162	25	plasmacytoid	plasmacytoid	NOUN
dpc-2912	162	26	dendritic	dendritic	ADJ
dpc-2912	162	27	cells	cell	NOUN
dpc-2912	162	28	.	.	PUNCT
dpc-2912	163	1	j	j	PROPN
dpc-2912	163	2	immunol	immunol	NOUN
dpc-2912	163	3	.	.	PUNCT
dpc-2912	164	1	2010;184(11):5999	2010;184(11):5999	X
dpc-2912	164	2	-	-	SYM
dpc-2912	164	3	6006	6006	NUM
dpc-2912	164	4	.	.	PUNCT
dpc-2912	165	1	doi:10.4049	doi:10.4049	PROPN
dpc-2912	165	2	/	/	SYM
dpc-2912	165	3	jimmunol.0901194	jimmunol.0901194	PROPN
dpc-2912	165	4	.	.	PUNCT
dpc-2912	166	1	pmid	pmid	NOUN
dpc-2912	166	2	:	:	PUNCT
dpc-2912	166	3	20410486	20410486	NUM
dpc-2912	166	4	.	.	PUNCT
dpc-2912	167	1	pmcid	pmcid	NOUN
dpc-2912	167	2	:	:	PUNCT
dpc-2912	167	3	pmc4820019	pmc4820019	ADJ
dpc-2912	167	4	.	.	PUNCT
dpc-2912	168	1	10	10	NUM
dpc-2912	168	2	.	.	X
dpc-2912	168	3	durrani	durrani	PROPN
dpc-2912	168	4	sr	sr	PROPN
dpc-2912	168	5	,	,	PUNCT
dpc-2912	168	6	montville	montville	PROPN
dpc-2912	168	7	dj	dj	PROPN
dpc-2912	168	8	,	,	PUNCT
dpc-2912	168	9	pratt	pratt	PROPN
dpc-2912	168	10	as	as	ADP
dpc-2912	168	11	,	,	PUNCT
dpc-2912	168	12	et	et	PROPN
dpc-2912	168	13	al	al	PROPN
dpc-2912	168	14	.	.	PROPN
dpc-2912	168	15	innate	innate	ADJ
dpc-2912	168	16	immune	immune	ADJ
dpc-2912	168	17	responses	response	NOUN
dpc-2912	168	18	to	to	ADP
dpc-2912	168	19	rhinovirus	rhinovirus	NOUN
dpc-2912	168	20	are	be	AUX
dpc-2912	168	21	reduced	reduce	VERB
dpc-2912	168	22	by	by	ADP
dpc-2912	168	23	the	the	DET
dpc-2912	168	24	high	high	ADJ
dpc-2912	168	25	-	-	PUNCT
dpc-2912	168	26	affinity	affinity	NOUN
dpc-2912	168	27	ige	ige	NOUN
dpc-2912	168	28	receptor	receptor	NOUN
dpc-2912	168	29	in	in	ADP
dpc-2912	168	30	allergic	allergic	ADJ
dpc-2912	168	31	asthmatic	asthmatic	ADJ
dpc-2912	168	32	children	child	NOUN
dpc-2912	168	33	.	.	PUNCT
dpc-2912	169	1	j	j	PROPN
dpc-2912	169	2	allergy	allergy	PROPN
dpc-2912	169	3	clin	clin	PROPN
dpc-2912	169	4	immunol	immunol	PROPN
dpc-2912	169	5	.	.	PUNCT
dpc-2912	170	1	2012;130(2):489	2012;130(2):489	NOUN
dpc-2912	170	2	-	-	SYM
dpc-2912	170	3	495	495	NUM
dpc-2912	170	4	.	.	PUNCT
dpc-2912	171	1	doi:10.1016	doi:10.1016	PROPN
dpc-2912	171	2	/	/	SYM
dpc-2912	171	3	j.jaci.2012.05.023	j.jaci.2012.05.023	PROPN
dpc-2912	171	4	.	.	PUNCT
dpc-2912	172	1	pmid	pmid	NOUN
dpc-2912	172	2	:	:	PUNCT
dpc-2912	172	3	22766097	22766097	NUM
dpc-2912	172	4	.	.	PUNCT
dpc-2912	173	1	pmcid	pmcid	ADJ
dpc-2912	173	2	:	:	PUNCT
dpc-2912	173	3	pmc3437329	pmc3437329	ADJ
dpc-2912	173	4	.	.	PUNCT
dpc-2912	174	1	11	11	NUM
dpc-2912	174	2	.	.	X
dpc-2912	175	1	gevaert	gevaert	PROPN
dpc-2912	175	2	p	p	NOUN
dpc-2912	175	3	,	,	PUNCT
dpc-2912	175	4	calus	calus	PROPN
dpc-2912	175	5	l	l	PROPN
dpc-2912	175	6	,	,	PUNCT
dpc-2912	175	7	van	van	PROPN
dpc-2912	175	8	zele	zele	PROPN
dpc-2912	175	9	t	t	PROPN
dpc-2912	175	10	,	,	PUNCT
dpc-2912	175	11	et	et	PROPN
dpc-2912	175	12	al	al	PROPN
dpc-2912	175	13	.	.	PROPN
dpc-2912	175	14	omalizumab	omalizumab	NOUN
dpc-2912	175	15	is	be	AUX
dpc-2912	175	16	effective	effective	ADJ
dpc-2912	175	17	in	in	ADP
dpc-2912	175	18	allergic	allergic	ADJ
dpc-2912	175	19	and	and	CCONJ
dpc-2912	175	20	nonallergic	nonallergic	ADJ
dpc-2912	175	21	patients	patient	NOUN
dpc-2912	175	22	with	with	ADP
dpc-2912	175	23	nasal	nasal	ADJ
dpc-2912	175	24	polyps	polyp	NOUN
dpc-2912	175	25	and	and	CCONJ
dpc-2912	175	26	asthma	asthma	NOUN
dpc-2912	175	27	.	.	PUNCT
dpc-2912	176	1	j	j	PROPN
dpc-2912	176	2	allergy	allergy	PROPN
dpc-2912	176	3	clin	clin	PROPN
dpc-2912	176	4	immunol	immunol	NOUN
dpc-2912	176	5	.	.	PUNCT
dpc-2912	177	1	2013;131(1):110	2013;131(1):110	NUM
dpc-2912	177	2	-	-	SYM
dpc-2912	177	3	6.e1	6.e1	PROPN
dpc-2912	177	4	.	.	PUNCT
dpc-2912	178	1	doi	doi	NOUN
dpc-2912	178	2	:	:	PUNCT
dpc-2912	178	3	10.1016	10.1016	NUM
dpc-2912	178	4	/	/	SYM
dpc-2912	178	5	j.	j.	PROPN
dpc-2912	178	6	jaci.2012.07.047	jaci.2012.07.047	PROPN
dpc-2912	178	7	.	.	PUNCT
dpc-2912	179	1	pmid	pmid	NOUN
dpc-2912	179	2	:	:	PUNCT
dpc-2912	179	3	23021878	23021878	NUM
dpc-2912	179	4	.	.	PUNCT
dpc-2912	180	1	12	12	NUM
dpc-2912	180	2	.	.	PUNCT
dpc-2912	180	3	farmani	farmani	PROPN
dpc-2912	180	4	ar	ar	PROPN
dpc-2912	180	5	,	,	PUNCT
dpc-2912	180	6	mahdavinezhad	mahdavinezhad	VERB
dpc-2912	180	7	f	f	PROPN
dpc-2912	180	8	,	,	PUNCT
dpc-2912	180	9	moslemi	moslemi	ADV
dpc-2912	180	10	r	r	X
dpc-2912	180	11	,	,	PUNCT
dpc-2912	180	12	et	et	PROPN
dpc-2912	180	13	al	al	PROPN
dpc-2912	180	14	.	.	PUNCT
dpc-2912	181	1	anti	anti	ADJ
dpc-2912	181	2	-	-	ADJ
dpc-2912	181	3	ige	ige	ADJ
dpc-2912	181	4	monoclonal	monoclonal	NOUN
dpc-2912	181	5	antibodies	antibody	NOUN
dpc-2912	181	6	as	as	ADP
dpc-2912	181	7	potential	potential	ADJ
dpc-2912	181	8	treatment	treatment	NOUN
dpc-2912	181	9	in	in	ADP
dpc-2912	181	10	covid-19	covid-19	PROPN
dpc-2912	181	11	.	.	PUNCT
dpc-2912	182	1	immunopharmacol	immunopharmacol	PROPN
dpc-2912	182	2	immunotoxicol	immunotoxicol	PROPN
dpc-2912	182	3	.	.	PUNCT
dpc-2912	183	1	2021;43(3):259	2021;43(3):259	NOUN
dpc-2912	183	2	-	-	SYM
dpc-2912	183	3	264	264	NUM
dpc-2912	183	4	.	.	PUNCT
dpc-2912	184	1	doi	doi	NOUN
dpc-2912	184	2	:	:	PUNCT
dpc-2912	184	3	10	10	NUM
dpc-2912	184	4	be	be	AUX
dpc-2912	184	5	attributed	attribute	VERB
dpc-2912	184	6	to	to	ADP
dpc-2912	184	7	a	a	DET
dpc-2912	184	8	paucity	paucity	NOUN
dpc-2912	184	9	in	in	ADP
dpc-2912	184	10	immune	immune	ADJ
dpc-2912	184	11	response	response	NOUN
dpc-2912	184	12	in	in	ADP
dpc-2912	184	13	the	the	DET
dpc-2912	184	14	initial	initial	ADJ
dpc-2912	184	15	covid-19	covid-19	PROPN
dpc-2912	184	16	phase	phase	NOUN
dpc-2912	184	17	in	in	ADP
dpc-2912	184	18	patients	patient	NOUN
dpc-2912	184	19	on	on	ADP
dpc-2912	184	20	long	long	ADJ
dpc-2912	184	21	-	-	PUNCT
dpc-2912	184	22	term	term	NOUN
dpc-2912	184	23	omz	omz	ADJ
dpc-2912	184	24	therapy	therapy	NOUN
dpc-2912	184	25	.	.	PUNCT
dpc-2912	185	1	sars	sar	NOUN
dpc-2912	185	2	-	-	PUNCT
dpc-2912	185	3	cov-2	cov-2	PART
dpc-2912	185	4	enters	enter	VERB
dpc-2912	185	5	the	the	DET
dpc-2912	185	6	host	host	NOUN
dpc-2912	185	7	cells	cell	NOUN
dpc-2912	185	8	through	through	ADP
dpc-2912	185	9	binding	bind	VERB
dpc-2912	185	10	the	the	DET
dpc-2912	185	11	angiotensin	angiotensin	NOUN
dpc-2912	185	12	-	-	PUNCT
dpc-2912	185	13	converting	convert	VERB
dpc-2912	185	14	enzyme	enzyme	NOUN
dpc-2912	185	15	2	2	NUM
dpc-2912	185	16	(	(	PUNCT
dpc-2912	185	17	ace2	ace2	PROPN
dpc-2912	185	18	)	)	PUNCT
dpc-2912	185	19	via	via	ADP
dpc-2912	185	20	s	s	NOUN
dpc-2912	185	21	-	-	NOUN
dpc-2912	185	22	protein	protein	NOUN
dpc-2912	185	23	[	[	X
dpc-2912	185	24	15	15	NUM
dpc-2912	185	25	]	]	PUNCT
dpc-2912	185	26	.	.	PUNCT
dpc-2912	186	1	ace2	ace2	PROPN
dpc-2912	186	2	receptor	receptor	NOUN
dpc-2912	186	3	possesses	possess	VERB
dpc-2912	186	4	a	a	DET
dpc-2912	186	5	significant	significant	ADJ
dpc-2912	186	6	role	role	NOUN
dpc-2912	186	7	in	in	ADP
dpc-2912	186	8	the	the	DET
dpc-2912	186	9	initiation	initiation	NOUN
dpc-2912	186	10	of	of	ADP
dpc-2912	186	11	covid-19	covid-19	PROPN
dpc-2912	186	12	since	since	SCONJ
dpc-2912	186	13	sars	sar	NOUN
dpc-2912	186	14	-	-	PUNCT
dpc-2912	186	15	cov-2	cov-2	NUM
dpc-2912	186	16	can	can	AUX
dpc-2912	186	17	only	only	ADV
dpc-2912	186	18	enter	enter	VERB
dpc-2912	186	19	cells	cell	NOUN
dpc-2912	186	20	with	with	ADP
dpc-2912	186	21	ace2	ace2	NOUN
dpc-2912	186	22	receptors	receptor	NOUN
dpc-2912	186	23	.	.	PUNCT
dpc-2912	187	1	zietkowski	zietkowski	NOUN
dpc-2912	187	2	et	et	PROPN
dpc-2912	187	3	al	al	PROPN
dpc-2912	187	4	demonstrated	demonstrate	VERB
dpc-2912	187	5	lowered	lower	VERB
dpc-2912	187	6	endothelin-1	endothelin-1	PRON
dpc-2912	187	7	(	(	PUNCT
dpc-2912	187	8	et-1	et-1	NUM
dpc-2912	187	9	)	)	PUNCT
dpc-2912	187	10	levels	level	NOUN
dpc-2912	187	11	in	in	ADP
dpc-2912	187	12	patients	patient	NOUN
dpc-2912	187	13	receiving	receive	VERB
dpc-2912	187	14	omz	omz	NOUN
dpc-2912	187	15	.	.	PUNCT
dpc-2912	188	1	the	the	DET
dpc-2912	188	2	authors	author	NOUN
dpc-2912	188	3	reported	report	VERB
dpc-2912	188	4	that	that	SCONJ
dpc-2912	188	5	the	the	DET
dpc-2912	188	6	reduction	reduction	NOUN
dpc-2912	188	7	was	be	AUX
dpc-2912	188	8	more	more	ADV
dpc-2912	188	9	pronounced	pronounced	ADJ
dpc-2912	188	10	in	in	ADP
dpc-2912	188	11	patients	patient	NOUN
dpc-2912	188	12	with	with	ADP
dpc-2912	188	13	more	more	ADV
dpc-2912	188	14	extended	extended	ADJ
dpc-2912	188	15	treatment	treatment	NOUN
dpc-2912	188	16	duration	duration	NOUN
dpc-2912	188	17	[	[	X
dpc-2912	188	18	16	16	NUM
dpc-2912	188	19	]	]	PUNCT
dpc-2912	188	20	.	.	PUNCT
dpc-2912	189	1	in	in	ADP
dpc-2912	189	2	another	another	DET
dpc-2912	189	3	study	study	NOUN
dpc-2912	189	4	,	,	PUNCT
dpc-2912	189	5	a	a	DET
dpc-2912	189	6	negative	negative	ADJ
dpc-2912	189	7	correlation	correlation	NOUN
dpc-2912	189	8	was	be	AUX
dpc-2912	189	9	revealed	reveal	VERB
dpc-2912	189	10	between	between	ADP
dpc-2912	189	11	et-1	et-1	PUNCT
dpc-2912	189	12	and	and	CCONJ
dpc-2912	189	13	ace2	ace2	NOUN
dpc-2912	189	14	receptor	receptor	NOUN
dpc-2912	189	15	,	,	PUNCT
dpc-2912	189	16	ie	ie	X
dpc-2912	189	17	,	,	PUNCT
dpc-2912	189	18	the	the	DET
dpc-2912	189	19	number	number	NOUN
dpc-2912	189	20	of	of	ADP
dpc-2912	189	21	ace2	ace2	NOUN
dpc-2912	189	22	receptors	receptor	NOUN
dpc-2912	189	23	was	be	AUX
dpc-2912	189	24	elevated	elevate	VERB
dpc-2912	189	25	as	as	SCONJ
dpc-2912	189	26	the	the	DET
dpc-2912	189	27	et-1	et-1	NUM
dpc-2912	189	28	level	level	NOUN
dpc-2912	189	29	declined	decline	VERB
dpc-2912	189	30	[	[	X
dpc-2912	189	31	17	17	NUM
dpc-2912	189	32	]	]	PUNCT
dpc-2912	189	33	.	.	PUNCT
dpc-2912	190	1	in	in	ADP
dpc-2912	190	2	addition	addition	NOUN
dpc-2912	190	3	,	,	PUNCT
dpc-2912	190	4	patients	patient	NOUN
dpc-2912	190	5	with	with	ADP
dpc-2912	190	6	higher	high	ADJ
dpc-2912	190	7	ace2	ace2	NOUN
dpc-2912	190	8	receptor	receptor	NOUN
dpc-2912	190	9	levels	level	NOUN
dpc-2912	190	10	were	be	AUX
dpc-2912	190	11	shown	show	VERB
dpc-2912	190	12	to	to	PART
dpc-2912	190	13	have	have	VERB
dpc-2912	190	14	a	a	DET
dpc-2912	190	15	better	well	ADJ
dpc-2912	190	16	covid-19	covid-19	PROPN
dpc-2912	190	17	prognosis	prognosis	NOUN
dpc-2912	190	18	[	[	X
dpc-2912	190	19	18	18	NUM
dpc-2912	190	20	]	]	PUNCT
dpc-2912	190	21	.	.	PUNCT
dpc-2912	191	1	it	it	PRON
dpc-2912	191	2	might	might	AUX
dpc-2912	191	3	be	be	AUX
dpc-2912	191	4	a	a	DET
dpc-2912	191	5	possible	possible	ADJ
dpc-2912	191	6	explanation	explanation	NOUN
dpc-2912	191	7	for	for	ADP
dpc-2912	191	8	the	the	DET
dpc-2912	191	9	higher	high	ADJ
dpc-2912	191	10	incidence	incidence	NOUN
dpc-2912	191	11	of	of	ADP
dpc-2912	191	12	covid-19	covid-19	PROPN
dpc-2912	191	13	in	in	ADP
dpc-2912	191	14	our	our	PRON
dpc-2912	191	15	patients	patient	NOUN
dpc-2912	191	16	with	with	ADP
dpc-2912	191	17	a	a	DET
dpc-2912	191	18	longer	long	ADJ
dpc-2912	191	19	duration	duration	NOUN
dpc-2912	191	20	of	of	ADP
dpc-2912	191	21	omz	omz	NOUN
dpc-2912	191	22	therapy	therapy	NOUN
dpc-2912	191	23	and	and	CCONJ
dpc-2912	191	24	the	the	DET
dpc-2912	191	25	low	low	ADJ
dpc-2912	191	26	disease	disease	NOUN
dpc-2912	191	27	activity	activity	NOUN
dpc-2912	191	28	that	that	PRON
dpc-2912	191	29	did	do	AUX
dpc-2912	191	30	not	not	PART
dpc-2912	191	31	necessitate	necessitate	VERB
dpc-2912	191	32	hospitalization	hospitalization	NOUN
dpc-2912	191	33	in	in	ADP
dpc-2912	191	34	any	any	PRON
dpc-2912	191	35	of	of	ADP
dpc-2912	191	36	these	these	DET
dpc-2912	191	37	patients	patient	NOUN
dpc-2912	191	38	.	.	PUNCT
dpc-2912	192	1	in	in	ADP
dpc-2912	192	2	the	the	DET
dpc-2912	192	3	aforementioned	aforementioned	ADJ
dpc-2912	192	4	study	study	NOUN
dpc-2912	192	5	,	,	PUNCT
dpc-2912	192	6	zietkowski	zietkowski	VERB
dpc-2912	192	7	et	et	NOUN
dpc-2912	192	8	al	al	PROPN
dpc-2912	192	9	observed	observe	VERB
dpc-2912	192	10	a	a	DET
dpc-2912	192	11	reduction	reduction	NOUN
dpc-2912	192	12	in	in	ADP
dpc-2912	192	13	the	the	DET
dpc-2912	192	14	eosinophilic	eosinophilic	ADJ
dpc-2912	192	15	cationic	cationic	ADJ
dpc-2912	192	16	protein	protein	NOUN
dpc-2912	192	17	(	(	PUNCT
dpc-2912	192	18	ecp	ecp	NOUN
dpc-2912	192	19	)	)	PUNCT
dpc-2912	192	20	levels	level	NOUN
dpc-2912	192	21	and	and	CCONJ
dpc-2912	192	22	the	the	DET
dpc-2912	192	23	blood	blood	NOUN
dpc-2912	192	24	eosinophil	eosinophil	ADJ
dpc-2912	192	25	counts	count	NOUN
dpc-2912	192	26	in	in	ADP
dpc-2912	192	27	subjects	subject	NOUN
dpc-2912	192	28	on	on	ADP
dpc-2912	192	29	omz	omz	ADJ
dpc-2912	192	30	therapy	therapy	NOUN
dpc-2912	192	31	in	in	ADP
dpc-2912	192	32	proportion	proportion	NOUN
dpc-2912	192	33	to	to	ADP
dpc-2912	192	34	the	the	DET
dpc-2912	192	35	treatment	treatment	NOUN
dpc-2912	192	36	duration	duration	NOUN
dpc-2912	192	37	[	[	X
dpc-2912	192	38	16	16	NUM
dpc-2912	192	39	]	]	PUNCT
dpc-2912	192	40	.	.	PUNCT
dpc-2912	193	1	studies	study	NOUN
dpc-2912	193	2	investigating	investigate	VERB
dpc-2912	193	3	the	the	DET
dpc-2912	193	4	relation	relation	NOUN
dpc-2912	193	5	between	between	ADP
dpc-2912	193	6	covid-19	covid-19	PROPN
dpc-2912	193	7	and	and	CCONJ
dpc-2912	193	8	eosinophil	eosinophil	ADJ
dpc-2912	193	9	levels	level	NOUN
dpc-2912	193	10	indicated	indicate	VERB
dpc-2912	193	11	eosinopenia	eosinopenia	NOUN
dpc-2912	193	12	,	,	PUNCT
dpc-2912	193	13	particularly	particularly	ADV
dpc-2912	193	14	in	in	ADP
dpc-2912	193	15	the	the	DET
dpc-2912	193	16	initial	initial	ADJ
dpc-2912	193	17	disease	disease	NOUN
dpc-2912	193	18	phase	phase	NOUN
dpc-2912	193	19	[	[	X
dpc-2912	193	20	19,20	19,20	NOUN
dpc-2912	193	21	]	]	PUNCT
dpc-2912	193	22	.	.	PUNCT
dpc-2912	194	1	on	on	ADP
dpc-2912	194	2	the	the	DET
dpc-2912	194	3	other	other	ADJ
dpc-2912	194	4	hand	hand	NOUN
dpc-2912	194	5	,	,	PUNCT
dpc-2912	194	6	covid-19	covid-19	PROPN
dpc-2912	194	7	incidence	incidence	NOUN
dpc-2912	194	8	was	be	AUX
dpc-2912	194	9	relatively	relatively	ADV
dpc-2912	194	10	low	low	ADJ
dpc-2912	194	11	in	in	ADP
dpc-2912	194	12	patients	patient	NOUN
dpc-2912	194	13	with	with	ADP
dpc-2912	194	14	asthma	asthma	NOUN
dpc-2912	194	15	,	,	PUNCT
dpc-2912	194	16	a	a	DET
dpc-2912	194	17	disease	disease	NOUN
dpc-2912	194	18	associated	associate	VERB
dpc-2912	194	19	with	with	ADP
dpc-2912	194	20	elevated	elevated	ADJ
dpc-2912	194	21	eosinophil	eosinophil	ADJ
dpc-2912	194	22	count	count	NOUN
dpc-2912	194	23	,	,	PUNCT
dpc-2912	194	24	suggesting	suggest	VERB
dpc-2912	194	25	eosinophilia	eosinophilia	PROPN
dpc-2912	194	26	might	might	AUX
dpc-2912	194	27	be	be	AUX
dpc-2912	194	28	a	a	DET
dpc-2912	194	29	protective	protective	ADJ
dpc-2912	194	30	factor	factor	NOUN
dpc-2912	194	31	against	against	ADP
dpc-2912	194	32	covid-19	covid-19	PROPN
dpc-2912	195	1	[	[	X
dpc-2912	195	2	21	21	NUM
dpc-2912	195	3	-	-	SYM
dpc-2912	195	4	22	22	NUM
dpc-2912	195	5	]	]	PUNCT
dpc-2912	195	6	.	.	PUNCT
dpc-2912	196	1	in	in	ADP
dpc-2912	196	2	the	the	DET
dpc-2912	196	3	light	light	NOUN
dpc-2912	196	4	of	of	ADP
dpc-2912	196	5	these	these	DET
dpc-2912	196	6	findings	finding	NOUN
dpc-2912	196	7	,	,	PUNCT
dpc-2912	196	8	it	it	PRON
dpc-2912	196	9	might	might	AUX
dpc-2912	196	10	be	be	AUX
dpc-2912	196	11	speculated	speculate	VERB
dpc-2912	196	12	that	that	SCONJ
dpc-2912	196	13	the	the	DET
dpc-2912	196	14	extended	extended	ADJ
dpc-2912	196	15	use	use	NOUN
dpc-2912	196	16	of	of	ADP
dpc-2912	196	17	omz	omz	NOUN
dpc-2912	196	18	facilitated	facilitate	VERB
dpc-2912	196	19	the	the	DET
dpc-2912	196	20	entry	entry	NOUN
dpc-2912	196	21	of	of	ADP
dpc-2912	196	22	sars	sar	NOUN
dpc-2912	196	23	-	-	PUNCT
dpc-2912	196	24	cov-2	cov-2	NOUN
dpc-2912	196	25	in	in	ADP
dpc-2912	196	26	the	the	DET
dpc-2912	196	27	host	host	NOUN
dpc-2912	196	28	cell	cell	NOUN
dpc-2912	196	29	by	by	ADP
dpc-2912	196	30	increasing	increase	VERB
dpc-2912	196	31	the	the	DET
dpc-2912	196	32	ace2	ace2	NOUN
dpc-2912	196	33	receptors	receptor	NOUN
dpc-2912	196	34	and	and	CCONJ
dpc-2912	196	35	reducing	reduce	VERB
dpc-2912	196	36	eosinophil	eosinophil	ADJ
dpc-2912	196	37	counts	count	NOUN
dpc-2912	196	38	,	,	PUNCT
dpc-2912	196	39	while	while	SCONJ
dpc-2912	196	40	hindering	hinder	VERB
dpc-2912	196	41	the	the	DET
dpc-2912	196	42	progression	progression	NOUN
dpc-2912	196	43	of	of	ADP
dpc-2912	196	44	the	the	DET
dpc-2912	196	45	disease	disease	NOUN
dpc-2912	196	46	into	into	ADP
dpc-2912	196	47	more	more	ADV
dpc-2912	196	48	severe	severe	ADJ
dpc-2912	196	49	forms	form	NOUN
dpc-2912	196	50	with	with	ADP
dpc-2912	196	51	its	its	PRON
dpc-2912	196	52	antiviral	antiviral	NOUN
dpc-2912	196	53	and	and	CCONJ
dpc-2912	196	54	anti	anti	ADJ
dpc-2912	196	55	-	-	ADJ
dpc-2912	196	56	inflammatory	inflammatory	ADJ
dpc-2912	196	57	effects	effect	NOUN
dpc-2912	196	58	.	.	PUNCT
dpc-2912	197	1	various	various	ADJ
dpc-2912	197	2	case	case	NOUN
dpc-2912	197	3	reports	report	NOUN
dpc-2912	197	4	and	and	CCONJ
dpc-2912	197	5	studies	study	NOUN
dpc-2912	197	6	confirmed	confirm	VERB
dpc-2912	197	7	urticaria	urticaria	NOUN
dpc-2912	197	8	activation	activation	NOUN
dpc-2912	197	9	triggered	trigger	VERB
dpc-2912	197	10	either	either	CCONJ
dpc-2912	197	11	with	with	ADP
dpc-2912	197	12	covid-19	covid-19	PROPN
dpc-2912	197	13	or	or	CCONJ
dpc-2912	197	14	covid-19	covid-19	PROPN
dpc-2912	197	15	vaccines	vaccine	NOUN
dpc-2912	197	16	[	[	X
dpc-2912	197	17	23	23	NUM
dpc-2912	197	18	-	-	SYM
dpc-2912	197	19	25	25	NUM
dpc-2912	197	20	]	]	PUNCT
dpc-2912	197	21	.	.	PUNCT
dpc-2912	198	1	in	in	ADP
dpc-2912	198	2	contrast	contrast	NOUN
dpc-2912	198	3	,	,	PUNCT
dpc-2912	198	4	none	none	NOUN
dpc-2912	198	5	of	of	ADP
dpc-2912	198	6	the	the	DET
dpc-2912	198	7	patients	patient	NOUN
dpc-2912	198	8	in	in	ADP
dpc-2912	198	9	our	our	PRON
dpc-2912	198	10	series	series	NOUN
dpc-2912	198	11	who	who	PRON
dpc-2912	198	12	had	have	VERB
dpc-2912	198	13	covid-19	covid-19	PROPN
dpc-2912	198	14	showed	show	VERB
dpc-2912	198	15	activation	activation	NOUN
dpc-2912	198	16	of	of	ADP
dpc-2912	198	17	urticaria	urticaria	NOUN
dpc-2912	198	18	.	.	PUNCT
dpc-2912	199	1	similarly	similarly	ADV
dpc-2912	199	2	,	,	PUNCT
dpc-2912	199	3	some	some	DET
dpc-2912	199	4	studies	study	NOUN
dpc-2912	199	5	observed	observe	VERB
dpc-2912	199	6	no	no	DET
dpc-2912	199	7	urticaria	urticaria	NOUN
dpc-2912	199	8	activation	activation	NOUN
dpc-2912	199	9	in	in	ADP
dpc-2912	199	10	patients	patient	NOUN
dpc-2912	199	11	on	on	ADP
dpc-2912	199	12	omz	omz	NOUN
dpc-2912	199	13	in	in	ADP
dpc-2912	199	14	the	the	DET
dpc-2912	199	15	setting	setting	NOUN
dpc-2912	199	16	of	of	ADP
dpc-2912	199	17	covid-19	covid-19	PROPN
dpc-2912	199	18	[	[	X
dpc-2912	199	19	13,25	13,25	NUM
dpc-2912	199	20	]	]	X
dpc-2912	199	21	.	.	PUNCT
dpc-2912	200	1	on	on	ADP
dpc-2912	200	2	the	the	DET
dpc-2912	200	3	other	other	ADJ
dpc-2912	200	4	hand	hand	NOUN
dpc-2912	200	5	,	,	PUNCT
dpc-2912	200	6	the	the	DET
dpc-2912	200	7	urticaria	urticaria	NOUN
dpc-2912	200	8	flares	flare	VERB
dpc-2912	200	9	following	follow	VERB
dpc-2912	200	10	vaccination	vaccination	NOUN
dpc-2912	200	11	were	be	AUX
dpc-2912	200	12	not	not	PART
dpc-2912	200	13	uncommon	uncommon	ADJ
dpc-2912	200	14	and	and	CCONJ
dpc-2912	200	15	were	be	AUX
dpc-2912	200	16	mainly	mainly	ADV
dpc-2912	200	17	detected	detect	VERB
dpc-2912	200	18	following	follow	VERB
dpc-2912	200	19	mrna	mrna	PROPN
dpc-2912	200	20	vaccines	vaccine	NOUN
dpc-2912	200	21	as	as	ADP
dpc-2912	200	22	in	in	ADP
dpc-2912	200	23	our	our	PRON
dpc-2912	200	24	patients	patient	NOUN
dpc-2912	200	25	[	[	X
dpc-2912	200	26	24	24	NUM
dpc-2912	200	27	]	]	PUNCT
dpc-2912	200	28	.	.	PUNCT
dpc-2912	201	1	in	in	ADP
dpc-2912	201	2	conclusion	conclusion	NOUN
dpc-2912	201	3	,	,	PUNCT
dpc-2912	201	4	our	our	PRON
dpc-2912	201	5	study	study	NOUN
dpc-2912	201	6	highlights	highlight	VERB
dpc-2912	201	7	the	the	DET
dpc-2912	201	8	positive	positive	ADJ
dpc-2912	201	9	relationship	relationship	NOUN
dpc-2912	201	10	between	between	ADP
dpc-2912	201	11	the	the	DET
dpc-2912	201	12	duration	duration	NOUN
dpc-2912	201	13	of	of	ADP
dpc-2912	201	14	omz	omz	ADJ
dpc-2912	201	15	treatment	treatment	NOUN
dpc-2912	201	16	and	and	CCONJ
dpc-2912	201	17	the	the	DET
dpc-2912	201	18	risk	risk	NOUN
dpc-2912	201	19	of	of	ADP
dpc-2912	201	20	acquiring	acquire	VERB
dpc-2912	201	21	sars	sar	NOUN
dpc-2912	201	22	-	-	PUNCT
dpc-2912	201	23	cov-2	cov-2	NOUN
dpc-2912	201	24	.	.	PUNCT
dpc-2912	202	1	older	old	ADJ
dpc-2912	202	2	age	age	NOUN
dpc-2912	202	3	(	(	PUNCT
dpc-2912	202	4	≥65	≥65	NUM
dpc-2912	202	5	years	year	NOUN
dpc-2912	202	6	old	old	ADJ
dpc-2912	202	7	)	)	PUNCT
dpc-2912	202	8	,	,	PUNCT
dpc-2912	202	9	male	male	ADJ
dpc-2912	202	10	gender	gender	NOUN
dpc-2912	202	11	,	,	PUNCT
dpc-2912	202	12	hypertension	hypertension	NOUN
dpc-2912	202	13	,	,	PUNCT
dpc-2912	202	14	cardiovascular	cardiovascular	ADJ
dpc-2912	202	15	diseases	disease	NOUN
dpc-2912	202	16	,	,	PUNCT
dpc-2912	202	17	diabetes	diabetes	NOUN
dpc-2912	202	18	,	,	PUNCT
dpc-2912	202	19	chronic	chronic	ADJ
dpc-2912	202	20	obstructive	obstructive	ADJ
dpc-2912	202	21	pulmonary	pulmonary	ADJ
dpc-2912	202	22	disease	disease	NOUN
dpc-2912	202	23	,	,	PUNCT
dpc-2912	202	24	and	and	CCONJ
dpc-2912	202	25	malignancies	malignancy	NOUN
dpc-2912	202	26	were	be	AUX
dpc-2912	202	27	associated	associate	VERB
dpc-2912	202	28	with	with	ADP
dpc-2912	202	29	a	a	DET
dpc-2912	202	30	higher	high	ADJ
dpc-2912	202	31	risk	risk	NOUN
dpc-2912	202	32	of	of	ADP
dpc-2912	202	33	death	death	NOUN
dpc-2912	202	34	from	from	ADP
dpc-2912	202	35	covid-19	covid-19	PROPN
dpc-2912	202	36	infection	infection	NOUN
dpc-2912	202	37	[	[	X
dpc-2912	202	38	26	26	NUM
dpc-2912	202	39	]	]	PUNCT
dpc-2912	202	40	.	.	PUNCT
dpc-2912	203	1	in	in	ADP
dpc-2912	203	2	this	this	DET
dpc-2912	203	3	regard	regard	NOUN
dpc-2912	203	4	,	,	PUNCT
dpc-2912	203	5	in	in	ADP
dpc-2912	203	6	patients	patient	NOUN
dpc-2912	203	7	with	with	ADP
dpc-2912	203	8	aforementioned	aforementioned	ADJ
dpc-2912	203	9	risk	risk	NOUN
dpc-2912	203	10	factors	factor	NOUN
dpc-2912	203	11	,	,	PUNCT
dpc-2912	203	12	the	the	DET
dpc-2912	203	13	physicians	physician	NOUN
dpc-2912	203	14	might	might	AUX
dpc-2912	203	15	consider	consider	VERB
dpc-2912	203	16	a	a	DET
dpc-2912	203	17	temporary	temporary	ADJ
dpc-2912	203	18	interruption	interruption	NOUN
dpc-2912	203	19	6	6	NUM
dpc-2912	203	20	original	original	ADJ
dpc-2912	203	21	article	article	NOUN
dpc-2912	203	22	|	|	ADV
dpc-2912	203	23	dermatol	dermatol	ADJ
dpc-2912	203	24	pract	pract	NOUN
dpc-2912	203	25	concept	concept	NOUN
dpc-2912	203	26	.	.	PUNCT
dpc-2912	204	1	2023;13(3):e2023145	2023;13(3):e2023145	NUM
dpc-2912	205	1	j	j	PROPN
dpc-2912	205	2	allergy	allergy	NOUN
dpc-2912	205	3	clin	clin	PROPN
dpc-2912	205	4	immunol	immunol	NOUN
dpc-2912	205	5	.	.	PUNCT
dpc-2912	206	1	2020;146(1):1	2020;146(1):1	NUM
dpc-2912	206	2	-	-	SYM
dpc-2912	206	3	7	7	NUM
dpc-2912	206	4	.	.	PUNCT
dpc-2912	206	5	doi	doi	NOUN
dpc-2912	206	6	:	:	PUNCT
dpc-2912	206	7	10.1016	10.1016	NUM
dpc-2912	206	8	/	/	SYM
dpc-2912	206	9	j.	j.	PROPN
dpc-2912	206	10	jaci.2020.04.021	jaci.2020.04.021	PROPN
dpc-2912	206	11	.	.	PUNCT
dpc-2912	207	1	pmid	pmid	NOUN
dpc-2912	207	2	:	:	PUNCT
dpc-2912	207	3	32344056	32344056	NUM
dpc-2912	207	4	.	.	PUNCT
dpc-2912	208	1	pmcid	pmcid	NOUN
dpc-2912	208	2	:	:	PUNCT
dpc-2912	208	3	pmc7194727	pmc7194727	NOUN
dpc-2912	208	4	.	.	PUNCT
dpc-2912	209	1	20	20	NUM
dpc-2912	209	2	.	.	PUNCT
dpc-2912	210	1	tanni	tanni	PROPN
dpc-2912	210	2	f	f	PROPN
dpc-2912	210	3	,	,	PUNCT
dpc-2912	210	4	akker	akker	NOUN
dpc-2912	210	5	e	e	PROPN
dpc-2912	210	6	,	,	PUNCT
dpc-2912	210	7	zaman	zaman	PROPN
dpc-2912	210	8	mm	mm	PROPN
dpc-2912	210	9	,	,	PUNCT
dpc-2912	210	10	figueroa	figueroa	PROPN
dpc-2912	210	11	n	n	CCONJ
dpc-2912	210	12	,	,	PUNCT
dpc-2912	210	13	tharian	tharian	PROPN
dpc-2912	210	14	b	b	PROPN
dpc-2912	210	15	,	,	PUNCT
dpc-2912	210	16	hupart	hupart	PROPN
dpc-2912	210	17	kh	kh	PROPN
dpc-2912	210	18	.	.	PROPN
dpc-2912	210	19	eosinopenia	eosinopenia	PROPN
dpc-2912	210	20	and	and	CCONJ
dpc-2912	210	21	covid-19	covid-19	PROPN
dpc-2912	210	22	.	.	PUNCT
dpc-2912	211	1	j	j	PROPN
dpc-2912	211	2	am	be	AUX
dpc-2912	211	3	osteopath	osteopath	NOUN
dpc-2912	211	4	assoc	assoc	NOUN
dpc-2912	211	5	.	.	PUNCT
dpc-2912	212	1	2020	2020	NUM
dpc-2912	212	2	jul	jul	PROPN
dpc-2912	212	3	16	16	NUM
dpc-2912	212	4	.	.	PUNCT
dpc-2912	213	1	doi	doi	NOUN
dpc-2912	213	2	:	:	PUNCT
dpc-2912	213	3	10.7556	10.7556	NUM
dpc-2912	213	4	/	/	SYM
dpc-2912	213	5	jaoa.2020.091	jaoa.2020.091	PROPN
dpc-2912	213	6	.	.	PUNCT
dpc-2912	214	1	epub	epub	NOUN
dpc-2912	214	2	ahead	ahead	ADV
dpc-2912	214	3	of	of	ADP
dpc-2912	214	4	print	print	NOUN
dpc-2912	214	5	.	.	PUNCT
dpc-2912	215	1	pmid	pmid	NOUN
dpc-2912	215	2	:	:	PUNCT
dpc-2912	215	3	32672799	32672799	NUM
dpc-2912	215	4	.	.	PUNCT
dpc-2912	216	1	21	21	NUM
dpc-2912	216	2	.	.	PUNCT
dpc-2912	217	1	zhang	zhang	PROPN
dpc-2912	217	2	jj	jj	PROPN
dpc-2912	217	3	,	,	PUNCT
dpc-2912	217	4	dong	dong	PROPN
dpc-2912	217	5	x	x	PROPN
dpc-2912	217	6	,	,	PUNCT
dpc-2912	217	7	cao	cao	PROPN
dpc-2912	217	8	yy	yy	PROPN
dpc-2912	217	9	,	,	PUNCT
dpc-2912	217	10	et	et	PROPN
dpc-2912	217	11	al	al	PROPN
dpc-2912	217	12	.	.	PROPN
dpc-2912	218	1	clinical	clinical	ADJ
dpc-2912	218	2	characteristics	characteristic	NOUN
dpc-2912	218	3	of	of	ADP
dpc-2912	218	4	140	140	NUM
dpc-2912	218	5	patients	patient	NOUN
dpc-2912	218	6	infected	infect	VERB
dpc-2912	218	7	with	with	ADP
dpc-2912	218	8	sars	sar	NOUN
dpc-2912	218	9	-	-	PUNCT
dpc-2912	218	10	cov-2	cov-2	NOUN
dpc-2912	218	11	in	in	ADP
dpc-2912	218	12	wuhan	wuhan	PROPN
dpc-2912	218	13	,	,	PUNCT
dpc-2912	218	14	china	china	PROPN
dpc-2912	218	15	.	.	PUNCT
dpc-2912	219	1	allergy	allergy	PROPN
dpc-2912	219	2	.	.	PUNCT
dpc-2912	220	1	2020;75(7):1730	2020;75(7):1730	NUM
dpc-2912	220	2	-	-	SYM
dpc-2912	220	3	1741	1741	NUM
dpc-2912	220	4	.	.	PUNCT
dpc-2912	221	1	doi:10.1111	doi:10.1111	NOUN
dpc-2912	221	2	/	/	SYM
dpc-2912	221	3	all.14238	all.14238	PROPN
dpc-2912	221	4	.	.	PUNCT
dpc-2912	222	1	pmid	pmid	NOUN
dpc-2912	222	2	:	:	PUNCT
dpc-2912	222	3	32077115	32077115	NUM
dpc-2912	222	4	.	.	PUNCT
dpc-2912	223	1	22	22	NUM
dpc-2912	223	2	.	.	PUNCT
dpc-2912	224	1	li	li	PROPN
dpc-2912	224	2	x	x	PROPN
dpc-2912	224	3	,	,	PUNCT
dpc-2912	224	4	xu	xu	PROPN
dpc-2912	224	5	s	s	PROPN
dpc-2912	224	6	,	,	PUNCT
dpc-2912	224	7	yu	yu	PROPN
dpc-2912	224	8	m	m	PROPN
dpc-2912	224	9	,	,	PUNCT
dpc-2912	224	10	et	et	PROPN
dpc-2912	224	11	al	al	PROPN
dpc-2912	224	12	.	.	PUNCT
dpc-2912	225	1	risk	risk	NOUN
dpc-2912	225	2	factors	factor	NOUN
dpc-2912	225	3	for	for	ADP
dpc-2912	225	4	severity	severity	NOUN
dpc-2912	225	5	and	and	CCONJ
dpc-2912	225	6	mortality	mortality	NOUN
dpc-2912	225	7	in	in	ADP
dpc-2912	225	8	adult	adult	NOUN
dpc-2912	225	9	covid-19	covid-19	PROPN
dpc-2912	225	10	inpatients	inpatient	NOUN
dpc-2912	225	11	in	in	ADP
dpc-2912	225	12	wuhan	wuhan	PROPN
dpc-2912	225	13	.	.	PUNCT
dpc-2912	226	1	j	j	PROPN
dpc-2912	226	2	allergy	allergy	PROPN
dpc-2912	226	3	clin	clin	PROPN
dpc-2912	226	4	immunol	immunol	PROPN
dpc-2912	226	5	.	.	PUNCT
dpc-2912	227	1	2020;146(1):110	2020;146(1):110	PROPN
dpc-2912	227	2	-	-	SYM
dpc-2912	227	3	118	118	NUM
dpc-2912	227	4	.	.	PUNCT
dpc-2912	228	1	doi:10.1016	doi:10.1016	PROPN
dpc-2912	228	2	/	/	SYM
dpc-2912	228	3	j.jaci.2020.04.006	j.jaci.2020.04.006	PROPN
dpc-2912	228	4	.	.	PUNCT
dpc-2912	229	1	pmcid	pmcid	NOUN
dpc-2912	229	2	:	:	PUNCT
dpc-2912	229	3	pmc7152876	pmc7152876	NOUN
dpc-2912	229	4	.	.	PUNCT
dpc-2912	230	1	23	23	NUM
dpc-2912	230	2	.	.	X
dpc-2912	231	1	polly	polly	PROPN
dpc-2912	231	2	s	s	PROPN
dpc-2912	231	3	,	,	PUNCT
dpc-2912	231	4	fernandez	fernandez	PROPN
dpc-2912	231	5	ap	ap	PROPN
dpc-2912	231	6	.	.	PUNCT
dpc-2912	232	1	common	common	ADJ
dpc-2912	232	2	skin	skin	NOUN
dpc-2912	232	3	signs	sign	NOUN
dpc-2912	232	4	of	of	ADP
dpc-2912	232	5	covid-19	covid-19	PROPN
dpc-2912	232	6	in	in	ADP
dpc-2912	232	7	adults	adult	NOUN
dpc-2912	232	8	:	:	PUNCT
dpc-2912	232	9	an	an	DET
dpc-2912	232	10	update	update	NOUN
dpc-2912	232	11	.	.	PUNCT
dpc-2912	233	1	cleve	cleve	PROPN
dpc-2912	233	2	clin	clin	PROPN
dpc-2912	233	3	j	j	PROPN
dpc-2912	233	4	med	med	PROPN
dpc-2912	233	5	.	.	PUNCT
dpc-2912	234	1	2022;89(3):161	2022;89(3):161	NUM
dpc-2912	234	2	-	-	PUNCT
dpc-2912	234	3	167	167	NUM
dpc-2912	234	4	.	.	PUNCT
dpc-2912	235	1	doi	doi	NOUN
dpc-2912	235	2	:	:	PUNCT
dpc-2912	235	3	10.3949	10.3949	NUM
dpc-2912	235	4	/	/	SYM
dpc-2912	235	5	ccjm.89a.21126	ccjm.89a.21126	NOUN
dpc-2912	235	6	.	.	PUNCT
dpc-2912	236	1	pmid	pmid	NOUN
dpc-2912	236	2	:	:	PUNCT
dpc-2912	236	3	35232829	35232829	NUM
dpc-2912	236	4	.	.	PUNCT
dpc-2912	237	1	24	24	NUM
dpc-2912	237	2	.	.	X
dpc-2912	238	1	sun	sun	PROPN
dpc-2912	238	2	q	q	PROPN
dpc-2912	238	3	,	,	PUNCT
dpc-2912	238	4	fathy	fathy	PROPN
dpc-2912	238	5	r	r	PROPN
dpc-2912	238	6	,	,	PUNCT
dpc-2912	238	7	mcmahon	mcmahon	PROPN
dpc-2912	238	8	de	de	PROPN
dpc-2912	238	9	,	,	PUNCT
dpc-2912	238	10	freeman	freeman	PROPN
dpc-2912	238	11	ee	ee	PROPN
dpc-2912	238	12	.	.	PUNCT
dpc-2912	239	1	covid-19	covid-19	PROPN
dpc-2912	239	2	vaccines	vaccine	NOUN
dpc-2912	239	3	and	and	CCONJ
dpc-2912	239	4	the	the	DET
dpc-2912	239	5	skin	skin	NOUN
dpc-2912	239	6	:	:	PUNCT
dpc-2912	239	7	the	the	DET
dpc-2912	239	8	landscape	landscape	NOUN
dpc-2912	239	9	of	of	ADP
dpc-2912	239	10	cutaneous	cutaneous	ADJ
dpc-2912	239	11	vaccine	vaccine	NOUN
dpc-2912	239	12	reactions	reaction	NOUN
dpc-2912	239	13	worldwide	worldwide	ADV
dpc-2912	239	14	.	.	PUNCT
dpc-2912	240	1	dermatol	dermatol	NOUN
dpc-2912	240	2	clin	clin	PROPN
dpc-2912	240	3	.	.	PUNCT
dpc-2912	241	1	2021;39(4):653	2021;39(4):653	PROPN
dpc-2912	241	2	-	-	PUNCT
dpc-2912	241	3	673	673	NUM
dpc-2912	241	4	.	.	PUNCT
dpc-2912	242	1	doi	doi	NOUN
dpc-2912	242	2	:	:	PUNCT
dpc-2912	242	3	10.1016	10.1016	NUM
dpc-2912	242	4	/	/	SYM
dpc-2912	242	5	j.det.2021.05.016	j.det.2021.05.016	PROPN
dpc-2912	242	6	.	.	PUNCT
dpc-2912	243	1	pmid	pmid	NOUN
dpc-2912	243	2	:	:	PUNCT
dpc-2912	243	3	34556254	34556254	NUM
dpc-2912	243	4	.	.	PUNCT
dpc-2912	244	1	pmcid	pmcid	ADJ
dpc-2912	244	2	:	:	PUNCT
dpc-2912	244	3	pmc8165093	pmc8165093	ADJ
dpc-2912	244	4	.	.	PUNCT
dpc-2912	245	1	25	25	NUM
dpc-2912	245	2	.	.	PUNCT
dpc-2912	245	3	ayhan	ayhan	PROPN
dpc-2912	245	4	e	e	PROPN
dpc-2912	245	5	,	,	PUNCT
dpc-2912	245	6	öztürk	öztürk	PROPN
dpc-2912	245	7	m	m	PROPN
dpc-2912	245	8	,	,	PUNCT
dpc-2912	245	9	an	an	DET
dpc-2912	245	10	i̇	i̇	PROPN
dpc-2912	245	11	,	,	PUNCT
dpc-2912	245	12	bekçibaşi	bekçibaşi	PROPN
dpc-2912	245	13	m.	m.	NOUN
dpc-2912	245	14	covid-19	covid-19	PROPN
dpc-2912	245	15	infection	infection	NOUN
dpc-2912	245	16	under	under	ADP
dpc-2912	245	17	omalizumab	omalizumab	NOUN
dpc-2912	245	18	therapy	therapy	NOUN
dpc-2912	245	19	for	for	ADP
dpc-2912	245	20	chronic	chronic	ADJ
dpc-2912	245	21	spontaneous	spontaneous	ADJ
dpc-2912	245	22	urticaria	urticaria	NOUN
dpc-2912	245	23	:	:	PUNCT
dpc-2912	245	24	three	three	NUM
dpc-2912	245	25	cases	case	NOUN
dpc-2912	245	26	.	.	PUNCT
dpc-2912	246	1	int	int	NOUN
dpc-2912	246	2	j	j	PROPN
dpc-2912	246	3	dermatol	dermatol	NOUN
dpc-2912	246	4	.	.	PUNCT
dpc-2912	247	1	2021;60(2):253254	2021;60(2):253254	NUM
dpc-2912	247	2	.	.	PUNCT
dpc-2912	248	1	doi	doi	NOUN
dpc-2912	248	2	:	:	PUNCT
dpc-2912	248	3	10.1111	10.1111	NUM
dpc-2912	248	4	/ijd.15379	/ijd.15379	NOUN
dpc-2912	248	5	.	.	PUNCT
dpc-2912	249	1	pmid	pmid	NOUN
dpc-2912	249	2	:	:	PUNCT
dpc-2912	249	3	33332576	33332576	NUM
dpc-2912	249	4	.	.	PUNCT
dpc-2912	250	1	26	26	NUM
dpc-2912	250	2	.	.	PUNCT
dpc-2912	251	1	parohan	parohan	PROPN
dpc-2912	251	2	m	m	PROPN
dpc-2912	251	3	,	,	PUNCT
dpc-2912	251	4	yaghoubi	yaghoubi	NOUN
dpc-2912	251	5	s	s	NOUN
dpc-2912	251	6	,	,	PUNCT
dpc-2912	251	7	seraji	seraji	PROPN
dpc-2912	251	8	a	a	NOUN
dpc-2912	251	9	,	,	PUNCT
dpc-2912	251	10	javanbakht	javanbakht	PROPN
dpc-2912	251	11	mh	mh	PROPN
dpc-2912	251	12	,	,	PUNCT
dpc-2912	251	13	sarraf	sarraf	VERB
dpc-2912	251	14	p	p	PROPN
dpc-2912	251	15	,	,	PUNCT
dpc-2912	251	16	djalali	djalali	ADJ
dpc-2912	251	17	m.	m.	NOUN
dpc-2912	251	18	risk	risk	NOUN
dpc-2912	251	19	factors	factor	NOUN
dpc-2912	251	20	for	for	ADP
dpc-2912	251	21	mortality	mortality	NOUN
dpc-2912	251	22	in	in	ADP
dpc-2912	251	23	patients	patient	NOUN
dpc-2912	251	24	with	with	ADP
dpc-2912	251	25	coronavirus	coronavirus	NOUN
dpc-2912	251	26	disease	disease	NOUN
dpc-2912	251	27	2019	2019	NUM
dpc-2912	251	28	(	(	PUNCT
dpc-2912	251	29	covid-19	covid-19	PROPN
dpc-2912	251	30	)	)	PUNCT
dpc-2912	251	31	infection	infection	NOUN
dpc-2912	251	32	:	:	PUNCT
dpc-2912	251	33	a	a	DET
dpc-2912	251	34	systematic	systematic	ADJ
dpc-2912	251	35	review	review	NOUN
dpc-2912	251	36	and	and	CCONJ
dpc-2912	251	37	meta	meta	ADJ
dpc-2912	251	38	-	-	PUNCT
dpc-2912	251	39	analysis	analysis	NOUN
dpc-2912	251	40	of	of	ADP
dpc-2912	251	41	observational	observational	ADJ
dpc-2912	251	42	studies	study	NOUN
dpc-2912	251	43	.	.	PUNCT
dpc-2912	252	1	aging	age	VERB
dpc-2912	252	2	male	male	NOUN
dpc-2912	252	3	.	.	PUNCT
dpc-2912	253	1	2020;23(5):1416	2020;23(5):1416	NUM
dpc-2912	253	2	-	-	SYM
dpc-2912	253	3	1424	1424	NUM
dpc-2912	253	4	.	.	PUNCT
dpc-2912	254	1	doi	doi	NOUN
dpc-2912	254	2	:	:	PUNCT
dpc-2912	254	3	10.1080/13685538.2020.1774748	10.1080/13685538.2020.1774748	NUM
dpc-2912	254	4	.	.	PUNCT
dpc-2912	255	1	pmid	pmid	NOUN
dpc-2912	255	2	:	:	PUNCT
dpc-2912	255	3	32508193	32508193	NUM
dpc-2912	255	4	.	.	PUNCT
dpc-2912	256	1	.1080/08923973.2021.1925906	.1080/08923973.2021.1925906	PROPN
dpc-2912	256	2	.	.	PUNCT
dpc-2912	257	1	pmid	pmid	NOUN
dpc-2912	257	2	:	:	PUNCT
dpc-2912	257	3	34018464	34018464	NUM
dpc-2912	257	4	.	.	PUNCT
dpc-2912	258	1	pmcid	pmcid	ADJ
dpc-2912	258	2	:	:	PUNCT
dpc-2912	258	3	pmc8146297	pmc8146297	NOUN
dpc-2912	258	4	.	.	PUNCT
dpc-2912	259	1	13	13	NUM
dpc-2912	259	2	.	.	PUNCT
dpc-2912	260	1	passante	passante	PROPN
dpc-2912	260	2	m	m	PROPN
dpc-2912	260	3	,	,	PUNCT
dpc-2912	260	4	napolitano	napolitano	PROPN
dpc-2912	260	5	m	m	PROPN
dpc-2912	260	6	,	,	PUNCT
dpc-2912	260	7	dastoli	dastoli	PROPN
dpc-2912	260	8	s	s	PROPN
dpc-2912	260	9	,	,	PUNCT
dpc-2912	260	10	et	et	PROPN
dpc-2912	260	11	al	al	PROPN
dpc-2912	260	12	.	.	PUNCT
dpc-2912	260	13	safety	safety	NOUN
dpc-2912	260	14	of	of	ADP
dpc-2912	260	15	omalizumab	omalizumab	NOUN
dpc-2912	260	16	treatment	treatment	NOUN
dpc-2912	260	17	in	in	ADP
dpc-2912	260	18	patients	patient	NOUN
dpc-2912	260	19	with	with	ADP
dpc-2912	260	20	chronic	chronic	ADJ
dpc-2912	260	21	spontaneous	spontaneous	ADJ
dpc-2912	260	22	urticaria	urticaria	NOUN
dpc-2912	260	23	and	and	CCONJ
dpc-2912	260	24	covid-19	covid-19	PROPN
dpc-2912	260	25	.	.	PROPN
dpc-2912	260	26	dermatol	dermatol	NOUN
dpc-2912	260	27	ther	ther	ADV
dpc-2912	260	28	.	.	PUNCT
dpc-2912	261	1	2021;34(6):e15111	2021;34(6):e15111	X
dpc-2912	261	2	.	.	PUNCT
dpc-2912	261	3	doi	doi	NOUN
dpc-2912	261	4	:	:	PUNCT
dpc-2912	261	5	10.1111	10.1111	NUM
dpc-2912	261	6	/dth.15111	/dth.15111	PROPN
dpc-2912	261	7	.	.	PUNCT
dpc-2912	262	1	pmid	pmid	NOUN
dpc-2912	262	2	:	:	PUNCT
dpc-2912	262	3	34427028	34427028	NUM
dpc-2912	262	4	.	.	PUNCT
dpc-2912	263	1	pmcid	pmcid	NOUN
dpc-2912	263	2	:	:	PUNCT
dpc-2912	263	3	pmc8646731	pmc8646731	NOUN
dpc-2912	263	4	.	.	PUNCT
dpc-2912	264	1	14	14	NUM
dpc-2912	264	2	.	.	PUNCT
dpc-2912	265	1	lam	lam	PROPN
dpc-2912	265	2	hy	hy	PROPN
dpc-2912	265	3	,	,	PUNCT
dpc-2912	265	4	tergaonkar	tergaonkar	PROPN
dpc-2912	265	5	v	v	NOUN
dpc-2912	265	6	,	,	PUNCT
dpc-2912	265	7	kumar	kumar	PROPN
dpc-2912	265	8	ap	ap	PROPN
dpc-2912	265	9	,	,	PUNCT
dpc-2912	265	10	ahn	ahn	PROPN
dpc-2912	265	11	ks	ks	PROPN
dpc-2912	265	12	.	.	PROPN
dpc-2912	265	13	mast	mast	NOUN
dpc-2912	265	14	cells	cell	NOUN
dpc-2912	265	15	:	:	PUNCT
dpc-2912	265	16	therapeutic	therapeutic	ADJ
dpc-2912	265	17	targets	target	NOUN
dpc-2912	265	18	for	for	ADP
dpc-2912	265	19	covid-19	covid-19	PROPN
dpc-2912	265	20	and	and	CCONJ
dpc-2912	265	21	beyond	beyond	ADP
dpc-2912	265	22	.	.	PUNCT
dpc-2912	266	1	iubmb	iubmb	NOUN
dpc-2912	266	2	life	life	NOUN
dpc-2912	266	3	.	.	PUNCT
dpc-2912	267	1	2021;73(11):1278	2021;73(11):1278	NUM
dpc-2912	267	2	-	-	SYM
dpc-2912	267	3	1292	1292	NUM
dpc-2912	267	4	.	.	PUNCT
dpc-2912	268	1	doi	doi	NOUN
dpc-2912	268	2	:	:	PUNCT
dpc-2912	268	3	10.1002	10.1002	NUM
dpc-2912	268	4	/	/	SYM
dpc-2912	268	5	iub.2552	iub.2552	NOUN
dpc-2912	268	6	.	.	PUNCT
dpc-2912	269	1	pmid	pmid	NOUN
dpc-2912	269	2	:	:	PUNCT
dpc-2912	269	3	34467628	34467628	NUM
dpc-2912	269	4	.	.	PUNCT
dpc-2912	270	1	pmcid	pmcid	NOUN
dpc-2912	270	2	:	:	PUNCT
dpc-2912	270	3	pmc8652840	pmc8652840	ADJ
dpc-2912	270	4	.	.	PUNCT
dpc-2912	271	1	15	15	NUM
dpc-2912	271	2	.	.	X
dpc-2912	271	3	walls	wall	NOUN
dpc-2912	271	4	ac	ac	PROPN
dpc-2912	271	5	,	,	PUNCT
dpc-2912	271	6	park	park	PROPN
dpc-2912	271	7	yj	yj	PROPN
dpc-2912	271	8	,	,	PUNCT
dpc-2912	271	9	tortorici	tortorici	PROPN
dpc-2912	271	10	ma	ma	PROPN
dpc-2912	271	11	,	,	PUNCT
dpc-2912	271	12	wall	wall	PROPN
dpc-2912	271	13	a	a	PROPN
dpc-2912	271	14	,	,	PUNCT
dpc-2912	271	15	mcguire	mcguire	PROPN
dpc-2912	271	16	at	at	ADP
dpc-2912	271	17	,	,	PUNCT
dpc-2912	271	18	veesler	veesler	PROPN
dpc-2912	271	19	d.	d.	PROPN
dpc-2912	271	20	structure	structure	NOUN
dpc-2912	271	21	,	,	PUNCT
dpc-2912	271	22	function	function	NOUN
dpc-2912	271	23	,	,	PUNCT
dpc-2912	271	24	and	and	CCONJ
dpc-2912	271	25	antigenicity	antigenicity	NOUN
dpc-2912	271	26	of	of	ADP
dpc-2912	271	27	the	the	DET
dpc-2912	271	28	sarscov-2	sarscov-2	NUM
dpc-2912	271	29	spike	spike	ADJ
dpc-2912	271	30	glycoprotein	glycoprotein	NOUN
dpc-2912	271	31	cell	cell	NOUN
dpc-2912	271	32	.	.	PUNCT
dpc-2912	272	1	2020;181(2):281	2020;181(2):281	NUM
dpc-2912	272	2	-	-	PUNCT
dpc-2912	272	3	292.e6	292.e6	NUM
dpc-2912	272	4	.	.	PUNCT
dpc-2912	273	1	doi:10.1016	doi:10.1016	PROPN
dpc-2912	273	2	/	/	SYM
dpc-2912	273	3	j.cell.2020.02.058	j.cell.2020.02.058	PROPN
dpc-2912	273	4	.	.	PUNCT
dpc-2912	274	1	pmid	pmid	NOUN
dpc-2912	274	2	:	:	PUNCT
dpc-2912	274	3	32155444	32155444	NUM
dpc-2912	274	4	.	.	PUNCT
dpc-2912	275	1	pmcid	pmcid	NOUN
dpc-2912	275	2	:	:	PUNCT
dpc-2912	275	3	pmc7102599	pmc7102599	ADJ
dpc-2912	275	4	.	.	PUNCT
dpc-2912	276	1	16	16	NUM
dpc-2912	276	2	.	.	PUNCT
dpc-2912	277	1	zietkowski	zietkowski	PROPN
dpc-2912	277	2	z	z	PROPN
dpc-2912	277	3	,	,	PUNCT
dpc-2912	277	4	skiepko	skiepko	VERB
dpc-2912	277	5	r	r	NOUN
dpc-2912	277	6	,	,	PUNCT
dpc-2912	277	7	tomasiak	tomasiak	NOUN
dpc-2912	277	8	-	-	PUNCT
dpc-2912	277	9	lozowska	lozowska	NOUN
dpc-2912	277	10	mm	mm	NOUN
dpc-2912	277	11	,	,	PUNCT
dpc-2912	277	12	bodzenta	bodzenta	ADJ
dpc-2912	277	13	-	-	PUNCT
dpc-2912	277	14	lukaszyk	lukaszyk	NOUN
dpc-2912	277	15	a.	a.	NOUN
dpc-2912	277	16	anti	anti	ADJ
dpc-2912	277	17	-	-	ADJ
dpc-2912	277	18	ige	ige	ADJ
dpc-2912	277	19	therapy	therapy	NOUN
dpc-2912	277	20	with	with	ADP
dpc-2912	277	21	omalizumab	omalizumab	NOUN
dpc-2912	277	22	decreases	decrease	VERB
dpc-2912	277	23	endothelin-1	endothelin-1	NOUN
dpc-2912	277	24	in	in	ADP
dpc-2912	277	25	exhaled	exhale	VERB
dpc-2912	277	26	breath	breath	NOUN
dpc-2912	277	27	condensate	condensate	NOUN
dpc-2912	277	28	of	of	ADP
dpc-2912	277	29	patients	patient	NOUN
dpc-2912	277	30	with	with	ADP
dpc-2912	277	31	severe	severe	ADJ
dpc-2912	277	32	persistent	persistent	ADJ
dpc-2912	277	33	allergic	allergic	ADJ
dpc-2912	277	34	asthma	asthma	NOUN
dpc-2912	277	35	.	.	PUNCT
dpc-2912	278	1	respiration	respiration	NOUN
dpc-2912	278	2	.	.	PUNCT
dpc-2912	279	1	2010;80(6):534542	2010;80(6):534542	NUM
dpc-2912	279	2	.	.	PUNCT
dpc-2912	280	1	doi	doi	NOUN
dpc-2912	280	2	:	:	PUNCT
dpc-2912	280	3	10.1159/000317137	10.1159/000317137	NUM
dpc-2912	280	4	.	.	PUNCT
dpc-2912	281	1	pmid	pmid	NOUN
dpc-2912	281	2	:	:	PUNCT
dpc-2912	281	3	20588001	20588001	NUM
dpc-2912	281	4	.	.	PUNCT
dpc-2912	282	1	17	17	NUM
dpc-2912	282	2	.	.	PUNCT
dpc-2912	283	1	zhang	zhang	PROPN
dpc-2912	283	2	h	h	PROPN
dpc-2912	283	3	,	,	PUNCT
dpc-2912	283	4	li	li	PROPN
dpc-2912	283	5	y	y	PROPN
dpc-2912	283	6	,	,	PUNCT
dpc-2912	283	7	zeng	zeng	PROPN
dpc-2912	283	8	y	y	PROPN
dpc-2912	283	9	,	,	PUNCT
dpc-2912	283	10	wu	wu	PROPN
dpc-2912	283	11	r	r	PROPN
dpc-2912	283	12	,	,	PUNCT
dpc-2912	283	13	ou	ou	X
dpc-2912	283	14	j.	j.	PROPN
dpc-2912	283	15	endothelin-1	endothelin-1	PROPN
dpc-2912	283	16	downregulates	downregulate	VERB
dpc-2912	283	17	angiotensin	angiotensin	NOUN
dpc-2912	283	18	-	-	PUNCT
dpc-2912	283	19	converting	convert	VERB
dpc-2912	283	20	enzyme-2	enzyme-2	NUM
dpc-2912	283	21	expression	expression	NOUN
dpc-2912	283	22	in	in	ADP
dpc-2912	283	23	human	human	ADJ
dpc-2912	283	24	bronchial	bronchial	ADJ
dpc-2912	283	25	epithelial	epithelial	ADJ
dpc-2912	283	26	cells	cell	NOUN
dpc-2912	283	27	.	.	PUNCT
dpc-2912	284	1	pharmacology	pharmacology	NOUN
dpc-2912	284	2	.	.	PUNCT
dpc-2912	285	1	2013;91(5	2013;91(5	NUM
dpc-2912	285	2	-	-	PUNCT
dpc-2912	285	3	6):297	6):297	NUM
dpc-2912	285	4	-	-	PUNCT
dpc-2912	285	5	304	304	NUM
dpc-2912	285	6	.	.	PUNCT
dpc-2912	285	7	doi	doi	NOUN
dpc-2912	285	8	:	:	PUNCT
dpc-2912	285	9	10.1159/000350395	10.1159/000350395	NUM
dpc-2912	285	10	.	.	PUNCT
dpc-2912	286	1	pmid	pmid	NOUN
dpc-2912	286	2	:	:	PUNCT
dpc-2912	286	3	23751363	23751363	NUM
dpc-2912	286	4	.	.	PUNCT
dpc-2912	287	1	18	18	NUM
dpc-2912	287	2	.	.	PUNCT
dpc-2912	288	1	chen	chen	PROPN
dpc-2912	288	2	j	j	PROPN
dpc-2912	288	3	,	,	PUNCT
dpc-2912	288	4	jiang	jiang	PROPN
dpc-2912	288	5	q	q	PROPN
dpc-2912	288	6	,	,	PUNCT
dpc-2912	288	7	xia	xia	PROPN
dpc-2912	288	8	x	x	PROPN
dpc-2912	288	9	,	,	PUNCT
dpc-2912	288	10	et	et	PROPN
dpc-2912	288	11	al	al	PROPN
dpc-2912	288	12	.	.	PUNCT
dpc-2912	289	1	individual	individual	ADJ
dpc-2912	289	2	variation	variation	NOUN
dpc-2912	289	3	of	of	ADP
dpc-2912	289	4	the	the	DET
dpc-2912	289	5	sarscov-2	sarscov-2	NUM
dpc-2912	289	6	receptor	receptor	NOUN
dpc-2912	289	7	ace2	ace2	NOUN
dpc-2912	289	8	gene	gene	NOUN
dpc-2912	289	9	expression	expression	NOUN
dpc-2912	289	10	and	and	CCONJ
dpc-2912	289	11	regulation	regulation	NOUN
dpc-2912	289	12	.	.	PUNCT
dpc-2912	290	1	aging	age	VERB
dpc-2912	290	2	cell	cell	NOUN
dpc-2912	290	3	.	.	PUNCT
dpc-2912	291	1	2020;19(7):e13168	2020;19(7):e13168	X
dpc-2912	291	2	.	.	PUNCT
dpc-2912	291	3	doi:10.1111	doi:10.1111	NOUN
dpc-2912	291	4	/	/	SYM
dpc-2912	291	5	acel.13168	acel.13168	PROPN
dpc-2912	291	6	.	.	PUNCT
dpc-2912	292	1	pmid	pmid	NOUN
dpc-2912	292	2	:	:	PUNCT
dpc-2912	292	3	32558150	32558150	NUM
dpc-2912	292	4	.	.	PUNCT
dpc-2912	293	1	pmcid	pmcid	NOUN
dpc-2912	293	2	:	:	PUNCT
dpc-2912	293	3	pmc7323071	pmc7323071	NOUN
dpc-2912	293	4	.	.	PUNCT
dpc-2912	294	1	19	19	NUM
dpc-2912	294	2	.	.	X
dpc-2912	295	1	lindsley	lindsley	PROPN
dpc-2912	295	2	aw	aw	INTJ
dpc-2912	295	3	,	,	PUNCT
dpc-2912	295	4	schwartz	schwartz	PROPN
dpc-2912	295	5	jt	jt	PROPN
dpc-2912	295	6	,	,	PUNCT
dpc-2912	295	7	rothenberg	rothenberg	PROPN
dpc-2912	295	8	me	i	PRON
dpc-2912	295	9	.	.	PUNCT
dpc-2912	296	1	eosinophil	eosinophil	ADJ
dpc-2912	296	2	responses	response	NOUN
dpc-2912	296	3	during	during	ADP
dpc-2912	296	4	covid-19	covid-19	PROPN
dpc-2912	296	5	infections	infection	NOUN
dpc-2912	296	6	and	and	CCONJ
dpc-2912	296	7	coronavirus	coronavirus	NOUN
dpc-2912	296	8	vaccination	vaccination	NOUN
dpc-2912	296	9	.	.	PUNCT